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Abstract 
Intracellular signalling cascades are mediated by a plethora of receptors, enzymes, 
adaptors and small molecules. The Protein Tyrosine Phosphatase (PTP) Shp2 is a 
highly conserved enzyme involved in a myriad of cellular processes including growth, 
differentiation and apoptosis. Shp2 is multi-domain protein composed of two SH2 
domains in tandem, a PTP catalytic domain and a C-terminal tail containing multiple 
phosphorylation sites and a proline-rich region. The majority of biophysical research 
has utilised X-ray crystallography to study interactions and effects of mutations at the 
structural level. To gain a further understanding of Shp2 ligand binding and 
perturbations caused by disease relevant mutations, a structural investigation was 
performed with Nuclear Magnetic Resonance (NMR) spectroscopy and Small-angle 
X-ray Scattering (SAXS) in solution. The NMR signals from the backbone of both 
SH2 domains were assigned and residue-level interactions and differential SH2 
domain specificities with peptides from the novel receptor G6b-B were delineated. In 
addition, the E76K point mutation that causes Noonan Syndrome and leukaemia was 
found to have increased conformational dynamics, the first experimental evidence of 
this phenomenon at the structural level.
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Chapter I 
Introduction 
Phosphorylation 
Phosphorylation is the selective and reversible addition of a phosphate moiety onto a 
target substrate. The substrate may be a small molecule, such as a metabolite or a 
lipid, or part of a polypeptide. This phenomenon can be observed in all domains of 
life and as such is a ubiquitous cellular control mechanism (Cohen, 2002).  
Serine, threonine and tyrosine residues of proteins are most susceptible to 
phosphorylation and other post-translational modifications (PTMs), with landmark 
studies putting the relative Ser/Thr/Tyr phosphorylation levels at 90:10:0.05 (Hunter 
and Sefton, 1980). These relative levels can increase or decrease depending on 
signalling cues (Ubersax and Ferrell, 2007). However, histidine, arginine, lysine, 
cysteine and aspartic acid residues have also been discovered to undergo enzyme-
mediated phosphorylation (Matthews, 1995; Lewis et al. 1999).  
Phosphorylation can modify the function of a protein in a number of ways, by 
increasing or decreasing its biological activity, initiating or abolishing protein:ligand 
interactions, aiding or disrupting movement between different cellular compartments 
and by stabilizing or marking the protein for breakdown. The outlined changes in 
protein function due to phosphorylation occur as a result of local and/or remote 
structural changes, causing steric hindrance and charge-mediated attraction and 
repulsion (Johnson et al., 2001). However, it is possible for phosphorylation to have 
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no effect on protein structure and function. This is termed ‘silent phosphorylation’ 
(Huffine, 1996). 
It is thought that roughly 30% of the proteins encoded by the human genome are 
modified by phosphorylation at some point in their cellular existence (Cohen, 2002). 
Phosphorylation most likely became prevalent as a regulatory mechanism due to the 
relative abundance of adenosine triphosphate (ATP) as a phosphate donor, along 
with the simplicity and flexibility of the modification (Pearlman et al., 2011). 
 
Protein Tyrosine Kinases 
Protein tyrosine kinases (PTKs) are a family of enzymes able to phosphorylate the 
tyrosine residues of specific polypeptide substrates, of which there are receptor 
bound and cytosolic members. The former have the general domain architecture of 
an N-terminal extracellular domain, a single transmembrane (TM) domain and a C-
terminal cytoplasmic domain. There are 58 receptor PTKs in the human proteome 
and most of these are activated by a ligand binding to the extracellular domain. 
These ligands can be growth factors, cytokines, or extracellular domains of other 
proteins on the same or different cell. Activation causes oligomerization and 
activation of the cytoplasmic kinase domain by transphosphorylation of the tyrosine 
residue found in the activation loop (Bossemeyer, 1995).  Non-receptor tyrosine 
kinases (NRTKs) are involved in a myriad of growth factor and signalling cascades. 
Aside from acting as strict cytoplasmic enzymes, some NRTKs can act as catalytic 
modulators for membrane-bound receptors that require kinase binding after 
themselves undergoing phosphorylation (Lemmon & Schlessinger, 2010) . The 
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recruitment of NRTKs via PTM adds another layer of regulation to a complex highway 
of signalling networks (Deribe et al. 2010). 
Protein Tyrosine Phosphatases 
Protein Tyrosine Phosphatases (PTPs) are a highly conserved group of enzymes 
involved in the removal of a phosphate group from a polypeptide substrate. The 
various mammalian PTPs are important in the regulation of mammalian cell signalling 
and due their modular nature many PTPs can exert their functions in specific 
subcellular compartments at specific times, only being recruited when required and 
dephosphorylating substrates according to their intrinsic specificity (Zhang et al., 
1994). As will be explained later, the simple idea that PTKs switch on signalling 
pathways and PTPs switch them off is now known to be over simplistic and incorrect. 
There are 107 PTPs within the human genome, of which 38 make up the ‘classical 
PTPs’ which contain catalytic domains of high sequence and structural homology ( 
[Figure 1.1 A])  This is surprising as the number of protein phosphatases is vastly 
outnumbered by the number of protein kinases, of which there are 518 (Manning, 
2002). Clearly there are mechanisms in place to account for this disparity. The 
classical PTPs can be further separated into two groups, the receptor (rPTPs) and 
nonreceptor (nrPTPs) phosphatases.  
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Figure 1.1: The PTPome 
and Non-receptor PTPs. 
(i) The PTPome, classified 
based on sequence 
alignments (taken from 
Alonso et al. 2004). (ii) 
Schematic diagram 
showing the 17 non-
receptor PTPs in nine 
groups. Note that Shp1 
and Shp2 are the only 
members of group NT2. 
(taken from Andersen et al. 
2001 and Alonso et al. 
2004).  
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PTPs in Signalling 
PTPs are involved in most aspects of signalling where phosphorylation is concerned 
and like PTKs regulate many different aspects of cellular function (Stoker, 2005). 
PTPs have been found to regulate various intracellular kinase pathways such as 
mitogen-activated protein kinase (MAPK), extracellular signal-related kinase (ERK), 
Janus kinase-signal transducer and activator of transcription (JAK-STAT), 
phosphoinositide 3-kinase PI-3K/Akt and int/Wingless (WNT) signalling, as well as 
play a particularly crucial role in immune signalling (Pao et al. 2007). Their pivotal 
role in these pathways and the wider function they play in disease contexts is the 
topic of much research, especially in a therapeutic context (Scott et al., 2010; Tonks 
2006). 
 
Nonreceptor phosphatases 
As seen in Figure 1.1 B, the nrPTP subfamily contains 17 of the classical PTPs. 
Closer inspection of the 17 nrPTPs shows how diverse they are in modular 
architecture. It is these modular, independently foldable domains which, through 
subcellular localisation, increase the specificity of the PTPs they are attached to. 
PTPN1, now widely known as PTP1B, was the first tyrosine phosphatase catalytic 
domain to be purified (Tonks et al., 1988). The crystal structure of PTP1B’s catalytic 
domain was solved both free and in complex with a tungstate ion, the latter complex 
chosen for crystallisation due to sodium tungstate’s relatively high IC50 (10μM) for 
PTP1B (Barford et al., 1994). The tungstate ion was found within the catalytic cleft 
interacting with residues important in catalysis, explaining why it had inhibitory effects 
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on the enzyme. A crystal structure of PTP1B in complex with peptide substrates 
derived from the Epidermal Growth Factor Receptor (EGFR) intracellular tail was 
published a year later (Jia et al., 1995). 
Architecture of the PTP Domain 
The catalytic PTP domain is around 280 residues in length and made up of a mixed 
β-sheet of eight strands, flanked by six α-helices (Figure 1.2 A and B). The active site 
forms a deep pocket of around 9 Å in depth, located at the base of the catalytic cleft 
with the conserved “KNRY” motif ensuring selectivity for the side-chain of 
phosphotyrosine over phosphothreonine and phosphoserine. Selectivity is achieved 
by the side-chain phenol group of tyrosine within the motif engaging in π-stacking 
interactions with the aromatic ring of the incoming phosphotyrosine substrate. The 
loop regions of PTP domains are highly mobile and have been demonstrated to open 
and close independently of substrate engagement, especially for the WPD loop 
which has been crystallised as part of PTP domains in open and closed states (Yang 
et al., 2001). 
 
General Mechanism of Dephosphorylation by PTPs 
Catalysis is mediated by a number of highly conserved motifs within the phosphatase 
catalytic domain. These motifs have been identified by sequence alignments, 
mutagenesis and close inspection of available PTP structures (Alonso et al., 2004). 
The first motif is the catalytic signature motif, which has the consensus sequence 
CX5R, where C is the catalytic cysteine and X is any amino acid. In addition a 
tryptophan-proline-aspartic acid segment (known as the WPD loop) and a glutamine-
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containing region dubbed the Q-loop are all positioned near one another (Figure 1.2 
C for efficient phosphotyrosine dephosphorylation via the following steps:  
 
 
 
 
 
 
 
 
Figure 1.2: Architecture of the PTP Domain. 
PTP Domain overview, using archetype PTP1B (PDB ID: 2HNP) (A) 
Cartoon representation (grey) with regions and residues important for 
catalysis coloured as follows: orange, catalytic signature motif; blue, 
WPD loop; cyan, Q-loop and red, KNRY loop. (B) Surface 
representation, with catalytic pocket (orange) and WPD loop (blue 
highlighted for clarity. (C) Zoomed region of (A) better highlighting 
individual residues important for catalysis (labelled in black according to 
PTP1B numbering).  
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1) Initial phosphotyrosine binding, aided by specificity pocket adjacent to catalytic 
pocket. 
2) WPD loop transition from the open state to the closed state, bringing the 
protonated aspartate side-chain into close proximity of phosphate group. 
3) Arginine residue within catalytic sequence binds phosphotyrosine 
4) Cysteine thiolate ion acts as a nucleophile, attacking phosphate group and forming 
the phosphocysteine intermediate. 
5) Q-loop coordinates a bound water molecule to hydrolyse reaction intermediate 
6) Aspartate group of WPD loop acts as a general base to neutralize the leaving 
tyrosine side-chain.    
 For more information, see (Barford et al., 1998). 
 
Src Homology 2 (SH2) Domains 
It is estimated there are over 10,000 sites across the proteome that undergo tyrosine 
phosphorylation in the eukaryotic cell (Bernard A. Liu et al., 2012). Some of these 
phosphorylated sites serve as docking platforms for transient interactions of varying 
affinities. The specificity of protein:protein interactions is governed by a number of 
factors, including spatiotemporal regulation, tissue-specific protein and isoform 
expression, subcellular localization and degradation rates. However, this is an 
incomplete view of the complexities behind cell:cell and intracellular communication; 
the diverse roles observed in multiple signalling pathways are a result of the various 
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modular domains connected to enzyme effectors, fine-tuning all aspects of signal 
transduction. 
Modular domains have evolved and diverged in order to fulfil a specific function or set 
of functions in the cell and importantly, within the protein. Some modular domains 
have enzymatic activity whilst others serve as adaptor proteins capable of regulating 
cellular processes without explicitly harbouring catalytic activity. These adaptor 
proteins and domains are non-catalytic but modulate catalysis through their 
interactions with other domains, proteins and biological ligands as part of the same, 
or distinct polypeptide chain (Bhattacharyya et al., 2006). In the past 30 years there 
has been an explosion of research into molecular determinants of cell signalling 
pathways, accelerated further by the use of genome sequencing technologies. 
Through the boon of knowledge it has provided, as well as the discovery and 
improvements in sequence alignment algorithms, it has come to light that modular 
domains are widespread in the mammalian cell. One of these, the SH2 domain is of 
importance within phosphotyrosine signalling as a crucial regulatory domain involved 
in bringing numerous proteins together to initiate signalling cascades. 
 
After the initial discovery of the SH2 domain sequence in Fujinami Sarcoma Virus 
(Sadowski et al., 1986), highly conserved SH2 sequences were soon found in other 
proteins involved in signal transduction. It is now well established that the SH2 
domain is a eukaryotic, primarily metazoan protein domain, though some unicellular 
eukaryotes have been found to contain genes encoding SH2 domains; this being due 
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to a small number of proteins containing what is known as tandem SH2 domains- two 
SH2 domains in one polypeptide sequence (Bernard A Liu et al., 2012). 
SH2 domains are usually found as part of multidomain proteins that have a range of 
functions, spanning phosphorylation:dephosphorylation to ubiquitination, 
transcriptional regulation via STAT proteins (Reich & Liu, 2006) and guanine 
nucleotide exchange. The protein SH2D1A (also known as SAP) only consists of a 
single SH2 domain and a C-terminal 25 residue unstructured tail, (Cannons et al., 
2011) highlighting that SH2 domains are not just footnotes in multidomain proteins 
but can be self-contained functional proteins in their own right.  
SH2 domains are folded polypeptides around 100 amino acid residues in length with  
a  highly conserved molecular structure consisting of a central β-sheet formed from 
multiple antiparallel strands flanked by two α-helices; one on either side of the sheet 
(Figure 1.3). The helices are named αA and αB while the strands are named βA to 
βG according to the naming convention by Michael Eck and colleagues (Eck et al., 
1993). While the SH2 domain secondary structures are largely conserved, a few 
members of the SH2 family exhibit slight structural differences which relate to their 
role in signalling pathways (Kaneko et al., 2012). A number of conserved sequences 
within the SH2 domain polypeptide are involved in the recognition and binding of 
phosphorylated tyrosine motifs and are described below. It is worth mentioning that 
the SH2 domain is not the only domain capable of binding pY-peptides. 
Phosphotyrosine binding (PTB) domains (Uhlik et al., 2005) have also been shown to 
bind pY-containing peptides, as has the calcium ion binding (C2) domain of PKCδ 
(Benes et al., 2005) and the HYB domain of E3 ubiquitin ligase Hakai (Mukherjee et 
al., 2012). 
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Figure 1.3: Molecular structure of the SH2 Domain. 
The SH2 domain (PDB ID: 1AYD, white and black cartoon) is an independently 
folded modular polypeptide capable of binding pY-containing peptides and is 
composed of two α-helices flanking a central set of antiparallel β-sheets (βB, βC and 
βD) with various loop regions playing structural or functional (BC and BG) roles. 
Secondary structure naming convention as in Eck et al. (1993).  
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The phosphotyrosine binding pocket contains an invariant arginine residue that forms 
a bi-dentate salt-bridge with the phosphate group of phosphotyrosine in the bound 
state (Figure 1.4 C). Mutation of this critical residue abrogates phosphopeptide 
binding (Bibbins et al., 1993). This conserved Arg is part of the  flavor motif, or FLVR 
(residues Phe-Leu-Val-Arg, invariant Arg underlined). This sequence makes up most 
of the βB sheet, with the phosphopeptide binding perpendicular to the entire β-sheet 
in an extended conformation. 
Immediately C-terminal to the flavor motif is the BC loop which acts as a hinge. In the 
“open” state it is available to bind phosphopeptide, adopting a “closed” state upon 
interaction with pY phosphate oxygens, its main binding partner in the 
SH2:phosphopeptide interaction (Figure 1.4 A). An overall positive charge within the 
pY binding pocket is maintained by various residues. The side-chains of the 
conserved histidine βD4, lysine βD6 and arginine αA2 also help maintain the charged 
state for phosphotyrosine docking, though the latter two also interact with the 
aromatic ring of phosphotyrosine. Thermodynamic studies of SH2:phosphopeptide 
interactions posit that the phosphotyrosine binding pocket provides around half the 
binding energy during complex formation (Bradshaw et al., 1998), with the remainder 
driven by burial of hydrophobic phosphopeptide residues into the SH2 domain 
specificity pocket as well as liberation of bound water from the SH2 pocket into the 
bulk water.  
The EF and BG loops are located in the second half of the SH2 domain sequence 
and both form portions of the +3 specificity pocket. This pocket is important in 
defining the specificity for SH2 domains toward certain ligands by the shape and 
charge of the pocket (Figure 1.4 B and C).  
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Figure 1.4: A Closer Look at SH2:Phosphopeptide Interactions. 
The N-terminal SH2 domain of Shp2 in complex with the 11-mer PDGFR 
pY-1009 phosphopeptide (PDB ID: 1AYA). (A) Surface representation of 
the SH2 domain (grey), with peptide depicted as purple sticks. In general, 
the pY pocket (right side of line) binds pY whilst the specificity pocket (left 
side of line) binds residues C-terminal to pY. Numbers depict peptide 
residue positions in relation to pY. (B) Cartoon and stick form of the SH2 
domain (grey) with peptide (purple ribbon) bound. Space-filling spheres 
depict either pY (0) or V (+3). The invariant Argβ5 (32R) is coloured cyan. 
Black dashes indicate polar contacts with 32R. (C) and (D) show zoomed 
specificity and pY pockets respectively. For (D), red text represents SH2 
residues forming salt bridges with 32R.  
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The residues of the hydrophobic pocket are less conserved than those that make up 
the positively-charged pocket for phosphotyrosine-docking and have classically been 
thought to recognise hydrophobic residues at the +3 position, with respect to 
phosphotyrosine. This has since been studied extensively using combinatorial 
peptide arrays, which have shown that SH2 domains can sense phosphopeptide 
residues as far as the +4 and +6 positions (Imhof et al., 2006). Mutation of residues 
within the C-terminal hydrophobic pocket alter peptide binding specificity and affinity 
(Bradshaw et al., 1998), further demonstrating that this pocket plays a critical role in 
determining the domain’s role in signalling pathways. Based on a study by Huang et 
al (Huang et al. 2008) using a novel peptide-array approach, the specificity space of 
the SH2 domain was heavily investigated, leading to new insights regarding the 
preferences of SH2 domains for amino acids at all positions of a phosphopeptide. 
The end result of this study was the reordering of the entire SH2 family into new 
groups based on theses binding preferences. Herein the +3 pocket will be referred to 
as the “specificity pocket”.  
The amino acid at position βD5 of the SH2 domain interacts with amino acids at the 
+1 and +3 position of the phosphopeptide, playing a critical role in determining 
peptide specificity.  
The binding affinity between SH2 domains and their ligands vary considerably; 
equilibrium dissociation constants between the nanomolar and low micromolar range 
(Ladbury et al., 1995). This allows for the formation of transient complexes of various 
residence times, controlling signalling cascades with exquisite temporal precision. 
However, SH2 domains are capable of binding non-optimal phosphopeptide 
sequences (Lee et al., 1994). 
15 
 
Modifying the on/off rates of SH2:ligand complexes by mutation can lead to changes 
in normal signalling function (Kaneko et al., 2010). In other experiments, it was 
demonstrated that substituting key residues in an SH2 domain to that of another SH2 
domain can alter the phosphopeptide binding preferences of the former to resemble 
that of the latter (Songyang et al., 1995). 
Despite the high sequence and structural conservation of SH2 domain family 
members, it is of note that a few still manage to exert novel functions. The JAK1 SH2 
domain exhibits characteristics atypical for SH2 domains. A loss-of-function mutant 
did not affect subcellular localization, nor did it affect downstream signalling 
pathways (Rui et al., 1997). JAK1 instead plays a structural role with binding partners 
(Radtke et al., 2005). It has also been observed that the SH2-only adaptor protein 
SAP is capable of binding unphosphorphorylated tyrosine-containing motifs (Poy et 
al., 1999) and the Vav1 SH2 is able to bind two closely spaced pY residues at once; 
engaging both the pY and specificity pockets (Chen et al., 2013). In addition, the c-
Abl SH2 domain can bind phosphoinositide 4,5 bisphosphate-containing liposomes 
(Tokonzaba et al., 2006). Clearly, SH2 domain interactions are numerous and 
versatile in binding partners, deviating from the classical view of the domain in the 
1990s. 
Mutations in the SH2 domains of certain proteins can lead to certain disease states. 
For example, deletion or mutation of the SAP SH2 domain causes X-linked 
lymphoproliferative (XLP) syndrome (Nichols et al., 1998) and many mutations within 
the SH2 domains of Shp2 lead to cancer, with germline mutations causing two 
related childhood syndromes (Bentires-Alj et al., 2004a). 
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Tandem SH2 domains 
A minority of proteins encoded in the human genome contain two SH2 domains: 
spleen tyrosine kinase (Syk), zeta-chain associated protein kinase 70kDa (Zap-70), 
SH2-containing Phosphatases 1 and 2 (Shp1 and Shp2, respectively) and the p85α 
subunit of PI-3K, playing an important role in modulating protein function 
(Filippakopoulos et al., 2009). The yeast genome encodes Spt6, a transcription 
elongation factor which harbours a tandem SH2 domain containing both a canonical 
SH2 and noncanonical SH2 domain with novel binding properties (Diebold et al. 
2010).  
For Syk and Zap-70, which make up the Syk family of PTKs, both SH2 domains are 
separated by a large coiled coil linker region and exhibit conformational flexibility 
when bound to dually-phosphorylated peptide. Interestingly for Zap-70, the C-
terminal SH2 cannot effectively bind phosphopeptide without forming an interface 
with the N-terminal SH2 (Hatada et al., 1995). The same is not true for the Syk 
tandem SH2 when binding dual phosphopeptides, though there is still an interface 
between both SH2 domains present (Fütterer et al., 1998).  
Shp1 and Shp2 tandem SH2 domains lack a long inter-SH2 linker, instead the two 
SH2 domains are separated by a 6-8 amino acid linker with significant contacts 
between it and both SH2s (Yang et al., 2003a; Hof et al., 1998).  
The presence of two SH2 domains in proteins is thought to not only increase overall 
binding affinity between them and cognate ligands in signalling pathways, but 
contribute additional specificity for ligands whose pY residues are spaced at an 
optimal distance for binding the SH2 domain-containing proteins of choice. Another 
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study by Eck et al. demonstrated that varying the linker length between two 
phosphorylated peptides modulates the relative affinity of tandem SH2 domain 
toward them (Eck et al., 1996). The individual SH2 domains within a tandem domain 
demonstrate different peptide binding specificities, fine-tuning interactions where 
many potential binding partners are available (Isakov et al., 1995; Imhof et al., 2006). 
Phosphopeptide binding orientations of either SH2 domain within a tandem domain 
can also modulate affinities, only permitting binding where it is spatially favourable 
(Cowburn, 1996).  
Although structures of the Syk and ZAP-70 tandem SH2 domains in complex with 
dually phosphorylated peptides exist, no such structures have been solved of Shp1 
and Shp2 tandem domains. 
 
Shp2  
Initial Discovery and Characterisation 
The PTP Shp2 was first cloned in and purified the early 1990s (Adachi et al., 1992; 
Freeman et al., 1992; Sugimoto et al., 1993; Zhao et al., 1994) and since then a 
plethora of studies spanning many fields of biology have been conducted to 
investigate various aspects of its structure and function (Neel et al., 2003; Poole & 
Jones, 2005). Shp2 is ubiquitously expressed, with high levels observed in the brain, 
skeletal muscle, heart and testis (Ahmad et al., 1993). Homozygous knockout of the 
PTPN11gene leads to embryonic lethality in mice, demonstrating the important role 
Shp2 plays in development.  Knockout mouse studies further established the role of 
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Shp2 in development, supported by many in vitro cell studies of wild-type (WT) and 
mutant forms of Shp2 (Yang et al., 2006). 
 
Gene and Isoforms 
Shp2 is encoded by the PTPN11 gene, situated on the long arm of chromosome 12 
at position 24 (Ch12q24) (Isobe et al., 1994). There are three known isoforms, of 
which the most well characterised is the 593 amino acid form. The slightly longer, 
597 amino acid form is a result of ribonucleic acid (RNA) splicing and contains a 
tetrapeptide sequence in the PTP domain capable of reducing catalytic activity (Mei 
et al., 1994), though this study was performed in rats and not repeated in human cell 
lines. 
 
Similarity to Shp1 
Shp1 is another member of the SH2-containing PTP family. The Shp1 and Shp2 
protein sequences exhibit 61% overall identity (Figure 1.5) (Stein-Gerlach et al., 
1998) and the folds of their individual domains are also very similar (Figure 1.6). 
However, a notable structural deviation resides within the Shp1 C-terminal SH2 
(cSH2) domain, which takes an alternative domain orientation to the Shp2 cSH2 
domain with respect to the N-terminal SH2 (nSH2) and PTP domains. The overall 
structures of both cSH2 domains are nearly identical however. Whilst Shp2 is 
ubiquitously expressed (Adachi et al., 1997), Shp1 expression is confined to certain 
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Figure 1.5: Sequence Identity of Shp1 and Shp2 Phosphatases. 
 
Shp1 and Shp2 possess 61% sequence identity overall. Black filled 
triangles represent important phosphorylation sites in Shp2. Figure adapted 
from Stein-Gerlach et al., 1998.  
 
blood cells and plays a largely inhibitory role in cell signalling, in contrast to the 
activatory nature of Shp2 (Haque et al., 1998). 
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Figure 1.6: Structural Comparison of Current Shp1 and Shp2 Crystal 
Structures. 
Shp1 (PDB ID: 2B3O, purple) and Shp2 (PDB ID: 4DGP, grey) were 
superimposedusing PyMol v1.6. An RMSD of 1.67 Å was observed, with the 
nSH2 and PTP domains of both phosphatases aligning well. However, the 
cSH2 domain orientation is highly divergent, with the Shp1 cSH2 tilting ≈50° 
toward the nSH2. Shp1 and Shp2 ArgβB5 residues are highlighted in blue 
and red, respectively.  
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Shp2 in Cell Signalling 
Being a bonafide PTP, Shp2 would be expected to play a generally inhibitory role in 
cell signalling pathways by remove phosphate groups from ligands that were 
previously phosphorylated and possible activated by one of many cellular and 
membrane-bound tyrosine kinases (Lemmon & Schlessinger, 2010). However, many 
cell-based studies of Shp2 have consistently demonstrated that this is not the case. 
For example, deletion of Shp2 in mesenchymal cells leads to growth retardation due 
to downregulated MAPK (Lapinski et al., 2013) . Knockout of Shp2 catalytic activity 
via the well characterised C459S substrate-trapping mutant has also shown largely 
inhibitory consequences in downstream growth factor pathways (Ren et al., 2010). It 
was later discovered that Shp2 dephosphorylates proteins inhibited by the presence 
of phosphotyrosine; removal of the phosphate groups serve to activate the inactive 
substrates and cause the activation and upregulation of downstream effectors 
(Figure 1.7) (da Silva et al., 2013). Shp2 catalytic activity is also not a prerequisite for 
signalling function, as catalytic-dead Shp2 knockouts still maintain partial function 
(Yu et al. 2003). In addition to MAPK/ERK pathway activation, Shp2 plays a role in 
regulating JAK-STAT signalling, a pathway important in modulating interferon 
receptor function (You et al., 1999). 
Most research has found that Shp2 is localised to the cytosol and inner leaflet of the 
plasma membrane where cognate ligands and substrates co-localise (Incoronato et 
al., 2004). Shp-2 has also been found to co-localise with lipid rafts (Kim et al., 2006). 
However, roles for Shp2 in the nucleus (Jakob et al., 2008) and mitochondria 
(Büchner et al., 2010) have revealed Shp2 function is pivotal to normal cell function. 
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Not only is signalling activity mediated by the PTP domain of Shp2, but by the C-
terminal tail. In particular, two well-studied tyrosines, Y542 and Y580, can be  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Shp2 Signalling. 
Phosphorylation of growth factor tyrosine residues (yellow circles, P) causes 
recruitment of Shp2, in turn recruiting Gab1 and Grb2 adapter proteins which 
can bind and activate downstream signalling molecules leading to changes in 
gene expression. Figure taken from de Silva et al., 2013.  
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reversibly phosphorylated and are even required for normal ERK activation (Araki et 
al., 2003).  
In addition to phosphorylation-dependent signalling activity, the Shp2 C-terminal tail 
contains a proline-rich motif of sequence PLPPCTPTPP which could bind Src 
Homology 3 (SH3) domains of a variety of signalling proteins such as Src (Walter et 
al., 1999), a central protein in phosphotyrosine signalling. Shp1 however, only 
contains two consecutive proline residues in its C-terminal tail.  
Shp2 can therefore not only act as an enzyme but have functional roles as an 
adapter protein, since it can bind specific pY-peptides via its two SH2 domains or be 
bound to by other proteins via their SH2 and SH3 domains. It has also been shown 
previously that C-terminal residues Y542 and Y580 can be phosphorylated and 
activate Shp2 catalytic activity (Lu et al., 2001; Lu et al., 2003), adding another level 
of complexity, as spatiotemporally separated phosphorylation could fine tune Shp2 
function in vivo.  
 
Shp2 Structure 
At the time of writing there are 22 crystal structures in the protein databank (PDB) of 
various domains of Shp2 and its homologues, and one additional published crystal 
structure which has not been submitted to the PDB (Eck et al., 1996). These can be 
summarised in Table 1. 
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PDB ID Domain(s) Ligand Reference 
1AYA nSH2 PDGFR 1005-1015 
 
Lee, CH. 
 1AYB nSH2 IRS-1 887-898 (SPGEpYVNIDFGS) Lee, CH. 
 1AYC nSH2 PDGFR 736-744 (DGGpYMDMSKGS) Lee, CH. 
 1AYD nSH2 N/A (WT Syp) Lee, CH. 
 N/A tSH2 PDGFR 1005-1015 
 
Eck, MJ. 
 2SHP tSH2, PTP Dodecane-Trimethylamine Hof, P. 
 3B7O PTP Malate ion Barr, AJ. 
 3O5X PTP 3-{1-[3-(biphenyl-4-ylamino)-3-
  
Zhang, X. 
 3MOW PTP (2Z)-2-[(1R)-3-
     
   
Liu, S. 
 3TKZ nSH2 Synthetic peptide RVIpYFVPLNR  Zhang, Y. 
 3TL0 nSH2 Synthetic peptide RLNpYAQLWHR  Zhang, Y. 
 4DGP tSH2, PTP N/A (WT) Yu, ZH. 
 4DGX tSH2, PTP N/A (Y279C mutant) Yu, ZH. 
 4H34 tSH2, PTP N/A (Q506P mutant) Qiu, W. 
 4GWF tSH2, PTP N/A (Y279C mutant) Qiu, W. 
 4H1O tSH2, PTP N/A  (D61G mutant) Qiu, W. 
 4JE4 nSH2 N/A (monobody) Sha, F. 
 4JEG cSH2 N/A (monobody) Sha, F. 
 3ZM0 PTP N/A (to be published) Bohm, K. 
 3ZM1 PTP N/A (to be published) Bohm, K. 
 3ZM2 PTP N/A (to be published) Bohm, K. 
 3ZM3 PTP N/A (to be published) Bohm, K. 
 4JMG C-terminal “Clamp Ptpn11_pY580” modified Grb2 
  
Yasui, N. 
 Table 1: Details all current crystal structures of various Shp2 domains and their 
bound ligands, if any, and reference.  
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 Crystal structure of the Syp-nSH2 domain  
The mouse homologue of Shp2, Syp, is 99.5% conserved in primary sequence when 
compared to the human homologue, amounting to three conservative amino acid 
substitutions: one of which is close to the PTP signature motif, the other two residing 
in the C-terminal tail. The SH2 domains of mouse Syp and human Shp2 are 100% 
identical in sequence, of which the nSH2 domain has been subject to successful 
crystallisation and structure determination of the unbound, non-specific peptide-
bound and two high-affinity peptide bound forms (Lee et al., 1994) .The peptides 
were derived from known tyrosine phosphorylation sites that Syp-SH2 and other SH2 
domains bind; these are pY895 of IRS-1 and pY740 and pY1009 of PDGFR.  
The crystal structures show a typical SH2 domain fold reminiscent of others 
previously solved by other groups, even with the low sequence identity, although 
there are a few differences (Waksman et al., 1992; Overduin et al., 1992). There is a 
small insertion within the BG loop that forms an anti-parallel β-strand, which interacts 
with the phosphopeptide, but this insertion is not only present in the Syp-nSH2 
domain. The loops that make up the hydrophobic patch are less conserved in the 
features they present on the surface, which as discussed earlier plays a critical role 
in determining peptide specificity.  
Another marked difference is the lack of an arginine in the αA2 position; the side-
chain of which forms an amino-aromatic interaction with the pY ring as well as other 
hydrogen bonds with parts of the phosphopeptide. In nSH2-Syp’s case the 
conserved arginine is replaced by a glycine which does not interact with the 
phosphopeptide and is not compensated by the presence of another basic residue 
26 
 
nearby interacting with the pY. Interestingly, the cSH2 domain of Shp2, as well as 
both the nSH2 and cSH2 domains of Shp1 also harbour glycine residues at this 
position instead of Arg at position αA2 (Hof et al., 1998; Yang et al., 2003b). The 
presence of a non-basic residue at this point could have an influence on the 
phosphopeptide binding activity of Shp phosphatases toward their substrate. 
However, the highly conserved ArgβB5 is present and positioned in a similar fashion 
to previous pY bound-states solved for SH2 domains, though the absence of ArgαA2 
causes a re-orientation of the pY side-chain in order to form the equivalent number of 
hydrogen bonds to Syp-nSH2 (Machida & Mayer, 2005). 
LysβB6 and HisβD4 side-chains wedged with one edge of the pY ring, the histidine 
being well conserved and critical throughout most SH2 domains, as mutations 
abolish interactions and normal signalling (Marengere & Pawson, 1992). LysβB6 
itself does not interact with phosphopeptide. The LysβB6 conformation is not well 
conserved, though it is ordered in the structure, hydrogen bonding with two side 
chains in BC loop, stabilizing loop conformation for phosphate docking. The Syp-
nSH2 crystal structures provided more evidence that SH2 domains are well 
conserved structurally and bind phosphopeptides in a very similar way to each other. 
 
Crystal structure of the Tandem SH2 domain of Shp2 
The tandem SH2 domain (TanSH2) of human Shp2 in complex with two mono-
phosphopeptides revealed a canonical SH2:ligand interaction between the nSH2 and 
cSH2 domains connected in tandem by their wild-type linker region. Whilst the 
TanSH2 of Shp1 also has a short linker between its SH2 domains, it is worth noting 
27 
 
that other TanSH2 domain-containing proteins have much longer linkers, forming 
stable secondary structure elements (Described in Tandem SH2 Domains section 
above). In the present TanSH2 structure, the linker is well-ordered and forms part of 
the interface between the two domains and their pY-binding clefts are far apart, 
almost perpendicular to one another. Cys104 and Cys174 form a disulphide bridge, 
which is peculiar since Shp2 is a cytosolic protein and thus expected to be in a 
reducing environment, making disulphide bridge formation difficult.  
Phosphopeptide binding is near enough identical to previously determined 
SH2:ligand structures; between the two SH2 domains that make up the tandem there 
is an root-mean-square deviation (RMSD) of 0.56 Å when comparing the 44 Cα that 
make up the helix A and the β-sheet. The interaction between helix B and the β-sheet 
is altered due to the presence of an alanine in the βB FLVR sequence, instead of the 
conserved valine. The βD loops between both SH2 domains also occupy divergent 
positions. 
Interestingly, it was found that changing the length of the linker between two 
monophosphopeptides connected together altered the rate of phosphatase activity, 
with four-five amino hexanoic acid molecules being optimal and anything more or 
less diminishing activation rates. In addition, when testing peptides of known higher 
affinity toward one SH2 domain over another, single peptides weren’t sufficient to 
fully activate Shp2, nor was a bisphosphorylated peptide where the peptide positions 
were switched so that the C-terminal peptide would be N-terminal and vice versa. 
Only a bisphosphorylated peptide in the correct orientation with four aminohexanoic 
acid molecules separating them was sufficient for full activation (Eck et al., 1996). 
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Crystal structure of Shp2: TanSH2 and PTP Combined 
The crystal structure of human Shp2 lacking the last 66 amino acids of the C-
terminus showed with no ambiguity how the TanSH2 domains played an important 
role in regulating phosphatase activity (Hof et al., 1998). The nSH2 domain sits on 
one face of the classical PTP domain (Figure 1.8), forming many intramolecular, 
polar contacts, amounting to a surface area of 1208 Å2 on each participating subunit. 
In contrast, the cSH2 domain lies on the opposite side, maintaining a few contacts 
with the PTP domain. A portion of the nSH2 domain, in particular the DE loop, makes 
extensive contacts with the catalytic cleft (Figure 1.9 A). The DE loop, made up of 
residues 58-63, is unique within the SH2 family, only being present in Shp1 and is 
conserved within Shp-type proteins of other species. This loop, and the β-strands on 
either side of it, bind deep into the phosphotyrosine binding site of the PTP domain, 
mimicking substrate interaction and preventing closure of the WPD loop, ensuring an 
inactive form of the enzyme. 
Outside of this region, a number of interactions are formed between the nSH2 and 
PTP domain, further stabilizing the interdomain closed conformation. (Figure 1.9 B) 
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Figure 1.8: Cartoon Representation of Shp2.  
(PDB ID:2SHP) Dark blue: nSH2, Yellow: cSH2, Orange: PTP domain, Cyan: 
catalytic cleft, Red sticks: conserved Arginine βB5 residues, Grey: loops connecting 
domains, dashed lines show missing loop regions.  
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Figure 1.9: Mechanism of Shp2 Inhibition. 
(A) Cartoon representation of Shp2 (PDB ID: 4DGP) in the autoinhibited 
state (cyan sticks: DE loop residues 60G, 61G and 62Y; orange signature 
catalytic motif 458-466, residues 462-465 shown as sticks; mid-blue: 
WPD loop; black dashed lines: polar interactions).  (B) Zoomed region of 
(A) showing interactions between nSH2-DE loop and PTP-catalytic cleft 
residues via bound water (red bunched lines).  
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More recent crystal structures of Shp2, both WT and mutant, have yielded a greater 
insight into the consequence of disease-relevant mutations (Qiu et al., 2014). These 
are discussed further below. 
 
Shp2 in Disease 
Pathogens employ a plethora of strategies to enable successful infection to occur. 
For many species of bacteria, this involves the secretion of certain virulent effectors 
that affect host-cell machinery. The gram-negative bacterium Heliobacter pylori in 
particular, using a type IV secretion system, injects many of these effectors into 
gastric epithelial cells, one of which is called CagA. The strain of H. pylori determines 
the virulence of CagA, Western CagA being far less virulent than Eastern CagA 
strains. This is due to the presence of certain protein sequences termed EPIYA 
motifs in Eastern CagA which can become phosphorylated on tyrosine residues by 
host-cell protein kinases and bind to the cell membrane. Once this has occurred, 
binding of these motifs by Shp2 occurs, increasing PTP activity and activating 
RAS/MAPK signalling pathways, leading to growth and proliferation of the host cells. 
This leads to the initiation of tumours that can lead to gastric cancer (Hatakeyama, 
2004; Lochhead & El-Omar, 2007). 
 
There are a large number of germline mutations within the Shp2 gene that have 
biochemical consequences during development, ultimately leading to a disease 
phenotype from birth (Huang et al., 2014). Interestingly, two syndromes have been 
linked to mutations in Shp2, both of which present with similar symptoms but may 
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have different underlying pathogenesis. These are the Noonan and LEOPARD 
syndromes. These syndromes fall under the umbrella term ‘RASopathies’, since their 
pathogenesis can be traced back to mutations in components of the RAS/MAPK 
signalling cascade. Both syndromes are discussed below, with further analysis of the 
genetic, biochemical and structural features of mutated Shp2. 
 
Noonan Syndrome  
Noonan syndrome is a disorder apparent from birth characterised by congenital heart 
defects such as pulmonary valve stenosis, short stature, underdeveloped bones and 
a characteristic facial dysmorphology. Partial deafness and blood disorders are also 
fairly common (van der Burgt, 2007). It affects between 1:1000 and 1:2500 children 
born and currently has no cure; some patients go onto develop a rare blood cancer 
called Juvenile Myelomonocytic Leukaemia (JMML), though this is dependent on the 
nature of the germline mutation behind Noonan syndrome (Jongmans et al., 2011). 
The molecular basis of Noonan syndrome causation has been elucidated and will be 
discussed below. 
 
LEOPARD Syndrome 
LEOPARD syndrome, as mentioned earlier, has a similar phenotype to Noonan 
syndrome. LEOPARD is an acronym which stands for Lentigines, 
Electrocardiographic conduction abnormalities, Ocular Hypertolerism, Pulmonary 
stenosis, Abnormal genitalia, Retarded growth and Deafness, after some of the 
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symptoms that patients presented. These are not the only symptoms however, with 
palpebral ptosis, hypertrophic cardiomyopathy and other heart defects distinct from 
pulmonary stenosis also concurrent in the syndrome. Phenotype-genotype 
correlations are difficult for LEOPARD syndrome as there many symptoms and many 
different amino acid substitutions within the same amino acid position. 
 
Shp2 in Cancer 
As well as gastric cancers developing due to Eastern strain H. pylori infection, Shp2 
has also been implicated in the formation of other cancers. As mentioned previously 
a subset of JMML patients harbour mutations in their PTPN11 gene. Sporadic solid 
tumours of the colon and stomach, as well as the brain have all been found to 
contain PTPN11 mutations (Bentires-Alj et al., 2004b). Shp2 overexpression has also 
recently been linked to breast cancer progression (Aceto et al., 2012). As breast 
cancer is the most common cancer in people, efforts are being made to understand 
the role of enzymes, particularly PTPs, in breast cancer initiation, progression and 
metastasis (Aceto et al., 2012). 
 
Functional Consequences of Shp2 Mutation in Disease 
Through genetic analysis of Noonan syndrome patients it was discovered that 
missense mutations were present in the PTPN11gene (Tartaglia et al., 2003; Gelb 
and Tartaglia, 2006). Mutations in Shp2 account for approximately 50% of Noonan 
syndrome cases, with mutations in other RAS pathway members such as the 
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proteins KRAS, son of sevenless-1 (SOS1)  and RAF1 being responsible for other 
incidences. 
Structural mapping of Noonan syndrome mutations onto the Shp2 structure revealed 
the majority were localised to the nSH2:PTP interface (Tartaglia et al., 2002), with 
one mutation situated in the interSH2-linker region: D106A. Few mutations are found 
in the cSH2 domain; these localise to a residues within the conserved FLVR motif: 
E139D and affect pY-peptide binding properties (Keilhack et al., 2005). Biochemical 
analyses of Noonan syndrome Shp2 mutants demonstrate a gain-of-function effect 
where catalytic activity is markedly increased close to fully-activated levels. Ligand 
binding is disrupted in some cases (Martinelli et al., 2008), causing downstream 
signalling consequences such as mistargeting of Shp2 to non-canonical binding 
partners in a mutation-dependent manner (Müller et al., 2013). One of the most 
active mutants observed is E76K, a charge switch which is posited to disrupt 
nSH2:PTP binding (Darian et al., 2011).  
The pathogenesis of LEOPARD syndrome with regards to Shp2 mutation is less 
understood than its Noonan syndrome counterpart. Whilst the latter disorder 
harbours mutations that increase enzyme activity and alter SH2 domain binding 
properties, the former seems to manifest from a catalytically inactive phenotype. The 
majority of LEOPARD syndrome amino acid substitutions in Shp2 are localized to the 
PTP domain.  
There is speculation as to how two syndromes harbouring mutations within the same 
gene lead to similar phenotypes through different biochemical pathways (Edouard et 
al. 2007). Since Shp2 has both enzymatic and adaptor functions, having a 
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catalytically deficient PTP domain whilst maintaining phosphopeptide binding 
capacity via its SH2 domains (and perhaps the PTP active site) could mean 
LEOPARD syndrome mutants only partially knockout function (Kontaridis et al., 
2006). The presence of the C-terminal tail also means signalling proteins are still able 
to phosphorylate residues and bind Shp2 via pSer/pThr/pTyr residues or its proline-
rich motif.  
Structural Insights into Shp2 Dysregulation 
Earlier in 2014, a number of crystal structures of Shp2 were solved characterising 
Noonan and LEOPARD syndrome mutants at the atomic level (Qiu et al., 2014). The 
authors found that depending on the mutation, different mechanisms leading to the 
same effect were observed. For D61G, the electrostatic surface of the DE loop where 
D61 is normally located changes from highly negative to neutral. D61 is said to act as 
a phosphate mimic and the removal of the negatively charged side chain by genetic 
mutation ultimately leads to a diminished interaction between the nSH2 domain DE 
loop and PTP catalytic cleft. For the mutation E139D, no charge removal or reversal 
is observed, but shortening of the side-chain by one methylene group is enough to 
cause the BC loop of cSH2-Shp2 to become more ordered than in the WT structure 
and have higher basal activity. Y279C not only disrupts nSH2:PTP binding but also 
perturbs the pTyr binding site within the PTP domain, impairing efficient catalysis. 
Interestingly, although the aforementioned structures were solved and presented, no 
structural data are available for the E76K mutant which causes JMML and Noonan 
syndrome. 
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A molecular dynamics study predicted that E76K mutation would cause the nSH2 
domain to release from the PTP domain (Darian et al., 2011). Interestingly the 
authors found that mutation of D61 may cause reorientation of the connected EF and 
BG loops into a conformation more amenable to pY-binding or closely resemble the 
“open” state of the nSH2 domain during uncoupling of the nSH2:PTP domain 
interaction.   
 
Final remarks 
Though much work has characterised Shp2 in various aspects of its biology, 
including its roles in signalling pathways, biochemical perturbations upon mutation, 
clinical symptoms in a genetic disorder context, and many crystallographic studies, 
there has been little biophysical and high-resolution solution structural research 
dedicated to studying Shp2 and its interactions. 
 
Immunoreceptor Signalling and Protein G6b-B 
Membrane bound receptors can receive signals by the interaction of one or more of 
their extracellular domains with its cognate ligand. The induced conformational 
change upon ligand binding causes transmission of information through the 
transmembrane helix resulting in further conformational changes resulting in the 
exposure of one or more potential binding and/or phosphorylation sites essential for 
signalling.  
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A large number of receptors are expressed on the cell surface and the expression of 
these is often cell-specific. Signalling is invariably a complex process involving 
hundreds of interactions which together induce a concerted change in gene 
expression. Delineation of these pathways will allow a wider understanding of 
signalling in general as well as knowledge of the specific system of interest. This 
knowledge is essential in understanding those pathways of therapeutic potential. The 
modulation of immune signalling is a heavily researched field in an industrial context, 
as many human diseases and ailments have an immune component. For example, 
immunomodulation during chemotherapy treatment or after organ transplants are 
important in increasing survival and success rates in these therapies (Kandalaft et 
al., 2010). 
Immunoreceptors are a subset of membrane receptors found mainly on the surface 
of cells such as B-cells, T-cells and platelets, the latter of which has been found to 
play a role in immune regulation (Smyth et al., 2009). As these cells are responsible 
for processes such as immune memory, antimicrobial defence and blood clotting, 
careful regulation of the signalling systems is needed to ensure minimal aberrant 
signalling as they may have serious consequences for health. 
Within immunoreceptors there are a number of consensus peptide motifs which when 
phosphorylated can recruit adaptor proteins and enzymes in a specific manner to 
initiate a specific signalling cascade. These peptide motifs are termed ITIM 
(Immunoreceptor Tyrosine-based Inhibitory Motif), ITAM (Immunoreceptor Tyrosine-
based Activation Motif) and ITSM (Immunoreceptor Tyrosine-based Switch Motif) and 
will be discussed further below. 
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ITIMs 
ITIMs are characterised by the consensus sequence: (S/I/V/L)-X-pY-X-X-(I/V/L), 
containing either a branched chain amino acid or a serine residues at the -2 position, 
a single phosphotyrosine and a hydrophobic branched chain amino acid at the +3 
position. ITIMs inhibit various processes and exert function by binding Shp1, a 
generally inhibitory phosphatase (Billadeau & Leibson, 2002). 
 
ITAMs 
ITAMs are characterised by the consensus sequence: pY-X-X-(L/I)-X6–12-pY-X-X-
(L/I). The presence of the longer spacer region and dual pY residues could mean that 
an ITAM could bind two independent proteins each with a single SH2 domain, or 
binding a single protein with two SH2 domains. ITAMs bind proteins that upregulate 
signalling cascades leading to activation of downstream cellular processes. ITAMs 
are thought to bind Syk and/or ZAP-70, tandem SH2 domain containing tyrosine 
kinases (Barrow & Trowsdale, 2006). 
 
ITSMs 
ITSMs are characterised by the consensus sequence T-X-pY-X-X-(V/I) and are able 
to activate signalling pathways depending on the binding partner they recruit  
(Chemnitz et al., 2004). 
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Noncanonical ITIMs/ITAMs 
Another class of peptide sequences involved in immune regulation, the so-called 
hemITAMs, are essentially half an ITAM motif i.e they only have one pY and lack the 
6-12 amino acid linker followed by another pY that would normally be part of an ITAM 
sequence. In addition, hemITAMs contain an upstream triacidic amino acid stretch 
required for signalling (Hughes et al., 2013). 
There also exist ITAM sequences with ITIM-like function in specific cellular context, 
these are dubbed inhibitory ITAM or ITAMi sequences (Blank et al., 2009).  
 
G6b-B  
The G6b protein is encoded by C6ORF25 (Chromosome 6 Open Reading Frame 
25), located in the MHC III cluster region. G6b belongs to the Ig (Immunoglobulin) 
superfamily and is expressed as seven distinct alternative transcripts – some of 
which are soluble Research regarding the precise mechanisms of function has 
focussed on G6b’s novel role in blood signalling, specifically on the cell surface of 
platelets and megakaryocytes (Mori et al., 2008). Human G6b-B, a 241 amino acid 
protein, contains a predicted single extracellular Ig domain followed by a single-pass 
transmembrane (TM) region and an intracellular tail containing a membrane proximal 
proline rich region and a number of Tyr, Thr and Ser residues further C-terminal (de 
Vet et al. 2001a). The most well characterised phosphorylation sites at the time of 
writing are Y211 and Y237. Both are constitutively phosphorylated at these positions 
(Mazharian et al. 2013). Site Y211 is an ITIM whilst Y237 is an ITSM. However, for 
simplicity they will be referred to as ITIM1 and ITIM2 respectively. The sequence of 
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ITIM1 is EPSLL(pY)ADLD whilst the sequence of ITIM2 is DASTI(pY)AVVV. Both pY 
residues are separated by 26 residues and interestingly, there is basic region 
(RPRR) which could interact with negatively charged species. 
G6b-B has been shown by co-immunoprecipitation experiments to bind Shp1 and 
Shp2 (de Vet et al. 2001b). Furthermore, it was recently demonstrated that the ITIMs 
of G6b-B have varying affinities for Shp1 and Shp2 (Coxon et al., 2012). It was also 
demonstrated that the SH2 domains of Shp1 and Shp2, apart from nSH2-Shp1, had 
varying affinities for the various ITIM sequences. More recently, conditional mouse 
knockout experiments by our collaborators found that mice lacking G6b-B showed 
bleeding defects as a consequence of diminished platelet function (Mazharian et al. 
2012). Further experiments demonstrated that Shp1, Shp2 and G6b-B have 
overlapping and functionally distinct signalling pathways in megakaryocytes and 
platelets important for function of these cell  types (Mazharian et al. 2013). 
 
Concluding Remarks 
Clearly there is much to be learnt about the interplay of Shp1 and Shp2 in immune 
signalling pathways. The novel immunoreceptor G6b-B has many unanswered 
questions associated with it: what are the molecular determinants of Shp1 and Shp2 
interaction? Based on the C-terminal tail sequence and structure, can we predict 
other potential binding partners? On a side note, it has been shown in the 
prototypical ITIM-containing receptor PECAM-1 is able to bind phospholipid 
membranes (Paddock et al., 2011) and this leads to functional consequences in 
downstream signalling pathways. As G6b-B contains ITIM sequences and other 
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similarities with PECAM-1, it would be interesting to see whether phospholipid 
binding plays a role in G6b-B regulation.  
Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy, is a powerful technique capable 
of characterising the structure, dynamics and motions of molecules ranging from 
small compounds (including water) to megadalton macromolecular complexes 
(Marion 2013; Yee et al. 2006). At the heart of the method is the physical 
phenomenon known as nuclear magnetic resonance. Exploitation of the so-called 
NMR has been successful in answering many pertinent biological questions 
(Grzesiek & Sass, 2009) and has been pivotal in exploring the realms of 
“Unstructural biology” where proteins with little to no structure can be characterised at 
the atomic level (Tompa, 2011). In this section the physical basis for the NMR signal 
is discussed, moving onto chemical shift and chemical exchange phenomena and 
thereafter an overview of protein NMR techniques used in the present study. 
 
Origin of NMR Signal  
For any given atomic nucleus there are a number of intrinsic properties one can use 
to describe it. One of these properties is the spin quantum number, denoted I, and is 
dependent on the number of unpaired neutrons and protons such that having an odd 
number of either will usually result in a non-zero non-integer I value while having odd 
numbers of both translate to an integer I. Nuclei with an even number of neutrons 
and protons have an I value of 0 (Hore, 1995). Nuclei with I=0 are unable to produce 
an NMR signal as they do not have a magnetic moment; common isotopes with I=0 
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include 12C and 14N. However, 1H, 13C and 15N all have quantum spin numbers of ½ 
and are NMR-active since the quantum spin number of a nucleus has an associated 
magnetic moment µ which is proportional to its gyromagnetic ratio γ by the equation: 
µ= γI 
Nuclei are able to populate a number of orientations when placed in an externally 
applied magnetic field (B0, the direction of which is the z-axis, by convention) equal to 
2I+1, meaning for I=½ nuclei this is two states, dubbed the α and β-states. This is 
possible due to interaction of the nuclear magnetic moment with B0. In the absence of 
of B0, a degenerate state of equal energy is populated by the nuclei. In the presence 
B0 spin ½ nuclei can orient themselves either parallel (α-state) or antiparallel (β-state) 
to B0 and as a consequence they populate one of two discrete energy levels, where 
α-state is lower and β-state is higher, as it requires more energy to align against B0. 
However, nuclei can transition between these two states as they are in thermal 
equilibrium. States are populated thermally according to the Boltzmann distribution: 
Nα/Nβ= ΔE/2kT 
Where N denotes the number of nuclei in either α or β-state, k is the Boltzmann 
Constant, ΔE is energy difference and T is thermodynamic temperature. 
The populations of nuclei in α and β-states in B0 is roughly 50:50, but with slightly 
more nuclei in the lower (α) state. This energy state anisotropy is miniscule; but it is 
exactly this that can be exploited in NMR. The presence of a slight net magnetic 
moment of bulk nuclei in the α-state can be termed a longitudinal magnetic moment. 
In spectroscopy  ΔE is calculated by way of the Planck Relation (ΔE=hv, where h is 
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the Planck constant and v is frequency), and ΔE in the context of NMR is the energy 
difference between the two energy states.  
The frequency at which a given nucleus precesses perpendicular to an external 
magnetic field can be described by the equation: 
v= γB0 
This is also known as the Larmor frequency and is dependent on the gyromagnetic 
ratio of the nucleus of interest and the externally applied magnetic field. Due to this 
relationship, increasing B0 field strength also increases ΔE between α and β-states 
(Figure 1.10). 
This means the application of energy at a frequency corresponding to ΔE between 
nuclei in α and β-states causes energy transitions of magnetic nuclei between the 
two adjacent states. Radiofrequency (RF) pulses are used as they happen to match 
the frequency at which magnetic nuclei can undergo energy transitions. When 
applied at 90° to B0, nuclear magnetisation “flips” from the +z-axis (B0) to the –y-axis 
(i.e perpendicular). As the magnetic moment of the nucleus is rotating, a current is 
induced in a coil surrounding the container in which the nuclei are situated. This 
current is induced for as long as there is magnetic moment transverse to the z-axis. 
Transverse relaxation (T2) occurs, where the nuclear magnetisation gradually returns 
to the +z-axis; the changes in coil current over time from the end of RF pulsing to the 
end of transverse relaxation shows a decrease in current induction, this is the NMR 
signal and is known as Free Induction Decay (FID). 
Fourier transformation of the FID results in conversion of the FID from the time-
domain to the frequency domain.  
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Figure 1.10: Relation Between Field Strength and Nuclear Energy 
State. 
As external magnetic field strength increases (B0), so does the energy 
difference (ΔE) between two adjacent energy states of a magnetic 
nucleus. Adapted from: 
http://www.cryst.bbk.ac.uk/PPS2/projects/schirra/images/evonb_1.gif.  
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Chemical Shift  
Since the frequency at which an NMR-active nucleus undergoes energy transitions is 
B0-dependent, converting the frequencies into dimensionless values independent of 
B0 is performed by use of a reference standard such as tetramethylsilane (TMS) or, 
as is commonly used in protein NMR, the strong water peak. The conversion 
equation is: 
δ= 106 [(v-vref)/vref] 
Where V is the frequency and Vref is the reference frequency. The unit for δ is parts 
per million, or ppm and is deemed the chemical shift. 
In practice, the chemical shift of a nucleus is affected by the induced magnetic field 
caused by the electron cloud that surrounds itself as well as electrons from 
neighbouring nuclei in a chemical. The electron cloud itself is affected by bond 
geometry, chemical groups nearby, binding partners and transient interactions. This 
induced magnetic field effectively “shields” the nucleus from the full extent of the 
external magnetic field such that the local magnetic field experienced is slightly less 
than the actual B0 value. It is this subtle effect that allows one to characterise various 
chemicals by NMR through knowledge of the chemical shift values certain functional 
groups yield. For example, the region of a 1H NMR spectrum one would normally find 
amide groups (-NH2) is around 7-10 ppm.  
Though it is nuclei-dependent, in general the chemical shift of a nucleus is sensitive 
to its surrounding, its so-called “chemical environment”. For example, if a nucleus is 
exposed to the solvent, transient dipoles and interactions may occur, affecting 
nuclear shielding caused by the changes in electron density distribution. The same 
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effects caused by the solvent may not apply in a different solvent, where different 
interactions may occur. Thus the chemical shift of a nucleus is dependent on its 
surroundings. Motional processes within a molecule may cause its nuclei to 
experience slightly different chemical environments during its normal internal motions 
by modulating the extent of shielding processes. 
 
Chemical Exchange Processes 
Chemical exchange is the process whereby conformational changes occur around a 
relatively rigid chemical i.e. a protein backbone, causing fluctuations in local 
electronic environments.  
In the context of proteins, a multitude of exchange processes are known of, ranging 
from very slow conformational changes on the minutes to seconds timescale, to fast 
processes such as molecular rotation (ranging milliseconds to nanoseconds), to 
ultrafast motions such as molecular vibrations on the pico- to femto-second 
timescale. These processes may have a wider function in protein stability and 
function and are thus important to understand. NMR is well suited to this challenge 
as it can be used to observe such processes spanning multiple timescales (Kleckner 
& Foster, 2011). 
Two-site exchange is the process whereby a certain nuclear spin within a molecule 
experiences two distinct chemical environments, leading to different chemical shift 
values between the two states. Within this there is symmetrical and asymmetrical 
two-site exchange. In the former, both states are equally probable whereas in the 
latter, the probability of one state being populated is higher than the other. With two-
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site exchange comes three exchange regimes whereby two-site exchange occurs on 
different timescales. These are slow, intermediate and fast two-site exchange. In 
practice the terms do not necessarily mean a transition from one state to another 
happens slowly, rather that it does not happen often. The actual transition between 
chemical environments might indeed be fast (µs-ns) but the residence times, i.e the 
time spent in a given chemical environment, might range s-ns.  
Crucially, two-site exchange can be observed by NMR, meaning its effects are 
observable and even quantifiable. The effects of a two-site exchange process on an 
NMR spectrum are dependent on the chemical shift difference frequency between 
the two states (A and B) being sampled by the nuclear spin. This is defined as: 
ΩΔ= Ω0A – Ω0B 
where Ω0A and Ω0B are the chemical shift frequencies in Hertz between states A and 
B. If the exchange rate (k) between states A and B ~ ΩΔ, the process is said to be in 
intermediate exchange. Within this are slow intermediate and fast intermediate 
exchange where k is < or > | ΩΔ/2| respectively. k can also equal | ΩΔ/2| i.e the 
“cross-over point” (Levitt, 2007). Collectively, these three exchange phenomena are 
within the spectral timescale of ms-µs. Figure 1.11 outlines the effect of two-site 
exchange processes on NMR lineshape. 
In the contexts of protein:ligand interactions and secondary conformations, the two-
site exchange phenomenon can be observed and can yield information regarding 
their nature. For example, it is generally accepted that a protein:ligand interaction in 
slow exchange has an estimated dissociation constant (KD) of < 3 µM (Williamson, 
2013). This makes it fairly straightforward to characterize the binding affinity of a 
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protein:ligand interaction qualitatively. For a KD > 3 µM, unbound:bound peaks are 
likely in fast exchange.  In intermediate exchange, the KD  rests somewhere between 
the aforementioned values; in the high nanomolar to micromolar range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Schematic of Two-site Exchange Processes 
Visualised by NMR. 
Range of two-site exchange processes and their effects on an NMR 
lineshapes. Adapted from 
http://web.nmsu.edu/~snsm/classes/chem435/Lab8/exchange.gif  
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Pulse Sequences 
NMR experiments are composed of a set of specific pulses for magnetisation transfer 
and decoupling as well as chemical shift evolution periods, with the acquisition period 
at the end of an experiment, followed by a recycle delay period (d1, giving the system 
enough time to reach thermal equilibrium, allowing the restoration of longitudinal 
magnetisation in time for the beginning of the next set of pulses. Put together, the 
various components are known as a pulse sequence, of which many exist for breadth 
of NMR experiments, ranging simple 1D acquisition experiments of 1H NMR data, to 
highly complex multidimensional experiments for backbone assignment (Reynolds, 
2010).   
 
1D-NMR 
The first spectrum collected of most protein NMR samples is a 1D 1H spectrum and 
can quickly tell the user whether the sample is folded or not by checking the 
dispersion of peaks across the range (1-10 ppm usually) and for a small group of 
peaks < 0.5 ppm corresponding to high field methyl groups, suggestive of a packed 
hydrophobic core of a protein. Solvent suppression is performed to reduce the 
contribution of the water signal to the NMR spectrum, as it dominates the 1H 
spectrum if left unsuppressed. There are a number of strategies that can be used to 
achieve good solvent suppression (Price, 1999).  
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15N,1H Heteronuclear Single Quantum Coherence Experiment (HSQC) 
The 15N- HSQC is a mainstay of protein solution studies. Within a matter of hours or 
less (depending on protein concentration and behaviour) one can record, analyse 
and draw a number of conclusions from a HSQC.    
The HSQC depends on sensitivity enhancement using an Insensitive Nuclei 
Enhanced by Polarization Transfer (INEPT) pulse sequence which pairs sensitive 
nuclei (such as protons) with insensitive nuclei such as 13C or 15N. The ratio of 
gyromagnetic ratios between the sensitive and insensitive nuclei partly determines 
the signal enhancement factor by transferring magnetisation from the sensitive 
nucleus to the insensitive one via scalar coupling. The basic architecture of an HSQC 
pulse sequence is an INEPT pulse followed by chemical shift evolution during t1 and 
a reverse-INEPT thereafter, ending with acquisition of the proton FID whilst 
decoupling of the indirect nuclei (15N) acquisition via a decoupling pulse 
(Bodenhausen & Ruben, 1980).   
 
15N-HSQC Data: What Can it Tell us? 
A 15N-HSQC experiment can provide much information regarding the protein(s) of 
interest in solution. The basic output of a 15N-HSQC is a spectrum with two 
dimensions, 1H (direct dimension) and 15N (indirect dimension). Cross-peaks within 
the spectrum correspond to amino acid main-chain amide groups, one for each 
amino acid, as well as the side-chain amide groups of Asn, Gln and Trp side chain 
groups. Proline does not give a cross-peak due to the lack of an amide proton. One 
can then use this information to assess protein foldedness by inspection of amide 
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peak dispersion throughout the spectrum. Sharp, poorly dispersed cross-peaks in 
8.0-8.5 ppm region of the spectrum likely correspond to amide protons of disordered 
loops exposed to solvent. Proteins with helical and/or stranded secondary structure 
character usually show more dispersed cross-peaks. In addition, uniform peak 
intensities are suggestive of a stably structured protein in long-lived states. Partially 
unfolded proteins and molten globules give rise to a range of peak intensities across 
the spectrum. Peak intensities can also hint at dynamic processes, such as 
conformational changes, monomer:multimer equilibria and aggregative status; 
comparison of observed and expected peak count (from the equation: No. of amino 
acids + No. Trp – No. Pro + 2[No. Gln+ No. Asn], where letters represent amino acid 
three letter codes) can aid such analyses (Kwan et al., 2011). 
 
SOFAST-HMQC Experiments for Fast Data Acquisition 
In recent years much development has gone into speeding up data acquisition in a 
protein NMR context (Felli & Brutscher, 2009). The “band-Selective Optimized Flip-
Angle Short-Transient”, or SOFAST-HMQC method, was developed to acquire 2D 
15N/13C-1H correlation spectra in shorter lengths of time yet maintain sensitivity and 
use on standard commercial spectrometers (Schanda & Brutscher, 2005). The 
SOFAST-HMQC experiment works by using a polychromatic pulse shape (PC9) for 
band-selective excitation of amide protons, leading to faster 1H spin-lattice relaxation 
times, allowing for shorter recycle delay periods (Schanda et al., 2005). 
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TROSY-HSQC for Large Proteins 
Use of a Transverse Relaxation Optimized Spectroscopy (TROSY) pulse allows the 
size limit of protein NMR to be extended and is generally recommended for 
polypeptides larger than 25 kDa. TROSY makes use of the different relaxation 
mechanisms present in an NMR sample during an experiment, exploiting it to select 
for sharp signals, raising the signal to noise ratio. (Pervushin et al., 1997). 
Three Dimensional NMR Experiment for Backbone Assignment 
A number of experiments are available to permit unambiguous assignment of 
backbone amide (HN) peaks of 15N HSQC protein spectra. Other information derived 
from these experiments include carbon alpha (CA) and beta (CB), as well as 
carbonyl (CO) chemical shifts. Assignment of these chemical shifts allows for 
secondary structure prediction, discussed later. These experiments require 13C 
labelling. 
The most widely used are the standard set of backbone assignment spectra, named 
after the order of nuclei that magnetization is transferred from, starting with the 
backbone amide proton HN. These are HNCO, HNCACO, HNCA, HNCOCA, 
HNCACB and HNCOCACB. These will be discussed in more detail below. 
 
HNCO and HNCACO 
The HNCO is the most sensitive standard protein backbone experiment and for this 
reason is usually the first 3D experiment performed when assessing the feasibility of 
a protein for backbone assignment (Kay et al., 2011). The high sensitivity is due to 
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the large J-coupling constant between CO (i-1) and N (i). The spectrum yields 
chemical shift data of the preceding (i-1) carbonyl C to the originally magnetized HN 
(Figure 1.12 A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Overview of 3D Backbone Assignment Magnetisation Transfer 
Pathways. Schematic representation of magnetisation transfer pathways of 
standard 3D protein backbone assignment spectra. Two residues are depicted with 
atom names in circles. (i) denotes a residue whilst (i-1) denotes the preceding 
residue to (i). Circles highlighted pink denote atoms where magnetisation is 
transferred and data indirectly collected, whereas circles highlighted blue denote 
atoms where magnetisation is transferred but data is not collected. (A) HNCO (B) 
HN(CA)CO (C) HNCA (D) HN(CO)CA (E) (HB)CB(HA)CA(CO)NH  and (F) 
(HB)CB(HA)CANH. Note that magnetisation begins at atom HN for (A-D) but at the 
Hα and Hβ for (E-F), depending on whether the experiments are out-and-back or 
not. Figure taken from protein-nmr.org.uk, Higman V. 
54 
 
The HN(CA)CO, in addition to providing the same information as the HNCO, also 
provides chemical shift data of the carbonyl C of the originally magnetized HN 
(Figure 1.12 B). However, due to the much smaller J-coupling between the 15N and 
13Cα, sensitivity is markedly reduced.  
Taken together, the HNCO and HN(CA)CO can be used to sequentially assign the 
backbone HN of the protein(s) in question. As Asn and Gln side-chains include a 
terminal CONH group, chemical shift information of these regions are usually present 
in HNCO spectra. These correspond to the carbon gamma (Cg) of Asn and carbon 
delta (Cd) of Gln and can be assigned too, along with their corresponding H-
delta/epsilon (HD and HE) chemical shifts. As a 15N HSQC contains a pair of side-
chain amide peaks for each Asn/Gln, assignment of both is possible, though this will 
be ambiguous. 
 
HNCA and HNCOCA 
The HNCA experiment provides chemical shift information between HN and the CA 
of (i) and (i-1) (Bax & Ikura 1991) (Figure 1.12 C).. This is presented as two peaks on 
a HNCA spectrum, with (i) usually displaying higher intensity than (i-1).  
The HN(CO)CA experiment, much like the HNCO, provides chemical shift information 
between HN and the CA of (i-1) (Figure 1.12 D). When the HN(CO)CA and HNCA 
spectra are superimposed, unambiguous determination of HNCA (i) and (i-1) peaks 
are possible. This pair of experiments allows for CA-based backbone assignment. 
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HNCACB and CBCACONH 
The HNCACB experiment provides chemical shift information between HN and the 
CA and CB of (i) and (i-1). A spectrum will usually contain four peaks: two positive 
peaks for the CA (i) and (i-1) and two negative peaks for the CB (i) and (i-1) (Figure 
1.12 E). The more intense positive and negative peak are likely to be (i), and vice 
versa for (i-1). The exceptions to this rule are where either (i) or (i-1) are Gly, in which 
case only 3 three peaks are expected since Gly does not have a CB. In addition, the 
N-terminal (i) residue will not have an (i-1) peak and thus should only give a 
maximum of two peaks (one if Gly). However, in most cases the N-terminal residue is 
unobserved in spectra due to motional dynamics and exchange processes causing 
broadening of signals. 
The HN(CO)CACB experiment provides chemical shift information between HN and 
the (i-1) CB (Figure 1.12 F) (Grzesiek & Bax, 1992). Depending on how the 
experiment is set up, Gly residues which do not contain a CB, will be displayed as 
(often very intense) peaks of opposite phase to other CA peaks, and thus very easy 
to identify. Superimposition of HN(CO)CACB with HNCACB allows for unambiguous 
determination of (i-1) CB peaks within the latter spectrum. In addition, both HNCACB 
and HN(CO)CACB (but particularly the latter) spectra can also provide chemical shift 
information on side-chain Asn/Gln carbons. 
The HNCACB and HN(CO)CACB spectra are the most information rich but may not 
be enough for unambiguous backbone assignment. For example, a suspected set of 
weak peaks in the HNCACB can be validated by the HNCA and HNCOCA 
experiments which have greater sensitivity and better resolution of the Cα. For this 
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reason, recording and analysing all six backbone experiments mentioned in this 
section allows for ease of chemical shift assignment by complimenting one another. If 
most of these spectra, when superimposed, corroborate one another, there is an 
increased likelihood of present peaks being real.  
Whilst the HNCACB and HNCOCACB experiments are “out-and-back” experiments 
meaning magnetisation begins at the main-chain amide, is transferred all the way to 
CB and brought all the way back to HN for detection, versions of the experiments 
exist which begin magnetisation at the HB/HA protons and transfer magnetisation to 
HN for detection. These are dubbed (HB)CB(HA)CACONH and (HB)CB(HA)CANH 
and are useful for smaller proteins; larger proteins may be deuterated, preventing 
magnetisation of HB since they are replaced with non-exchangeable deuterons. 
 
Fast Acquisition of Backbone Assignment Data 
Recent advances in multidimensional pulse sequences for protein NMR have 
permitted collection of entire backbone datasets in > 3 days, instead of 2 weeks 
when utilising standard pulse sequences. This is achieved by use of a Band-selective 
Excitation Short Transient pulse, also known as BEST (Lescop et al., 2007; Schanda 
et al., 2006) and uses a shaped pulse which reduces the non-specific excitation of 
water and aliphatic 1H resonances, as well as reduction of signal loss via 
heterogeneous B0  and transverse relaxation using broadband 1H inversion pulses. 
These measures result in dramatic reduction of the recycle delay period of a scan 
from 1s to ~0.3s. By combining this regime with standard backbone assignment 
pulse sequences data can be quickly recorded. . 
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Small-angle X-ray Scattering 
SAXS (Small Angle X-ray Scattering) is a structural technique that has undergone 
significant improvements in the last 20 years. It does not require any prior labelling or 
tag-inclusion and typically yields data for molecules from the nanometer to sub-
micrometer range (Schnablegger & Singh, 2011). Data collection is rapid, ranging 
from seconds to milliseconds depending on the X-ray source. Whilst laboratory scale 
SAXS instrumentation exists, higher intensity beams can be taken advantage of at 
synchrotron sources, providing higher quality data and requiring lower protein 
concentrations. 
Almost all matter large enough will cause X-rays to scatter. There are therefore a 
number of important steps the SAXS experimenter must take to ensure high quality 
data which do not contain scattering information from anything but the matter of 
interest. Specifically, good sample preparation and characterization beforehand will 
increase the likelihood of quality data. One of the most vital steps is correct solvent 
matching. In order for a meaningful dataset representing the X-ray scattering of only 
the particles of interest in the solution, the scattering contribution from the solvent (as 
well as the sample holder, which may be a tube or cuvette) must be subtracted. This 
is why solvent blanks are run in between every experimental sample. Samples must 
be dialysed in the same physical buffer being used for solvent matching, though 
buffer used in the last purification step, such as size exclusion chromatography 
(SEC), is generally acceptable. 
Samples appropriate for SAXS analysis should be monodisperse, as demonstrated 
by native polyacrylamide gel electrophoresis (PAGE) and solution-based biophysical 
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methods such as analytical ultracentrifugation (AUC), dynamic light scattering (DLS), 
analytical SEC and/or NMR spectroscopy. Samples must also be of high purity, 
typically above 95% and have no higher molecular weight contaminants which could 
affect the data.  Hence these assays were performed on all the SHP2 constructs 
studies here. 
It is recommended to test samples for aggregation across a range of concentrations.. 
Soluble aggregates in samples can be minimized by performing SEC purification or 
high-speed centrifugation immediately prior to SAXS data collection.  
SAXS has found use in the physical and material sciences as a technique capable of 
acquiring size and shape information of matter in almost all forms. Since the 1950s, 
SAXS has been also been used to probe the structure of biological material at low 
resolution. Biological SAXS (often abbreviated to BioSAXS) is usually applied to the 
study of various biomolecules, commonly proteins, DNA/RNA and complexes thereof. 
 
Theory 
The spatial resolution of scattered X-rays is dependent on the wavelength of 
electromagnetic radiation used to study the material of interest. In SAXS, X-rays are 
utilised; primary (or incident) beam wavelengths between 0.1-0.2 nm are normal and 
refer to the unscattered, collimated and monochromatic beam needed for SAXS. The 
dependent variable measured in a SAXS experiment is the intensity (arbitrary units, 
AU) across the scattering vector q, which is in this study defined as:  
q= (4πsinθ)/λ 
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2θ is the scattering angle (<3°) and λ is the wavelength of radiation.  q usually ranges 
from 0.04-6 nm-1, where the lower limit is dependent on the beamstop. 
 
Data collection 
The primary beam is passed through a molecule-containing sample causing a 
fraction of the X-rays to scatter due to interaction with any matter in its path. The 
scattered X-rays eventually hit a detector, where it is converted into a digital signal 
and processed further. Any unscattered radiation are absorbed by a beamstop to 
prevent damage to the detector. This is summarised in Figure 1.13. Since the fraction 
of scattered X-rays is usually very small in a SAXS experiment, intense X-rays are 
usually required and provided by synchrotron sources, though in-house sources are 
available.  SAXS experiments are performed in the solution state and data can be 
acquired in a variety of different buffers, usually containing glycerol and/or a free-
radical scavenging reducing agent such as dithiothreitol (DTT) or tris-(2-carboxyethyl) 
phosphine (TCEP).  
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Figure 1.13: Schematic representation of a typical SAXS experiment.  
The incident beam (black arrow) passes through the protein-containing 
sample. A portion of the incident beam scatters (dashed black line) and hits 
the detector, registering a signal. The remainder of unscattered incident 
beam hits the beamstop. Detector image adapted from 
http://www.rigaku.com/en/products/saxs/smax3000/app012 and depicts 
SAXS pattern of silver behenate. 
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Post-Data Collection 
Radial averaging of the raw data is performed almost immediately after in a step 
often referred to as data reduction. This increases the signal:noise ratio. Normally 10 
frames are collected per sample (for both buffer and macromolecule samples) and 
inspected automatically by software to assess radiation damage state. After merging 
of good quality frames, the two buffer-only datasets are then averaged to further 
increase the signal to noise ratio. After, in a process called buffer subtraction, the 
scattering data of the buffer is subtracted from the macromolecule-containing 
sample, yielding a dataset representative of only the macromolecules of interest in 
solution. 
 
Initial Inspection of SAXS Data 
Aggregation can be observed in solvent-subtracted SAXS data as steep slopes in the 
low-q area of the Guinier plot (explained in below). Using a concentration series one 
can ameliorate the data by extrapolating it to zero concentration, also known as 
infinite dilution. Concentration series can also be utilised to rule out interparticle 
interference of scattering particles, of which there are repulsive and attractive forces, 
again observable at low-q regions of the Guiner plot. Data indicative of concentration 
effects can be removed from the low-q region but care must be taken to avoid 
removing valuable points required for invariant parameter derivation. 
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Determination of Invariant Parameters 
Basic information tractable from SAXS experiments are the radius of gyration (Rg), 
maximum particle dimension (Dmax) and intensity at zero angle (I(0)). André Guinier 
pioneered analysis of SAXS data to determine the Rg to reasonable accuracy by 
plotting of the data with x-axis as the square of the magnitude of momentum transfer 
(q2) and y-axis as the natural logarithm of I(q). This came to be known as the Guinier 
Law and results in an estimation of the second moment of inertia, or, as put by 
Konarev P (EMBO SAXS Lecture Series), the “quadratic mean of distances to the 
centre of mass weighted by the contrast of electron density”.  
 
Estimation of the molecular mass (MM) can also be achieved through use of protein 
standards. SAXS data collection of a protein of known MM such as bovine serum 
albumin (BSA, ~66 kDa) and subsequent I(0) estimation. Thereafter, MMsample can be 
determined via the following equation: 
MMsample = I(0)sample * (MMreference/I(0)reference) 
MM estimation in this manner has an accuracy of around +/- 10% (Mylonas & 
Svergun, 2007).  
Fourier transform of the experimental SAXS profile generates a pair distance 
distribution function (PDDF). This describes the likely frequency of vector lengths 
between pairs of atoms within a studied macromolecule and can provide information 
on shape and excluded volume. For multidomain proteins the PDDF, which is also 
known as a P(r) function, can be used to investigate subtle conformational changes 
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upon a change in local environment, such as during a binding event. Changes in 
domain orientation, and even the spatial distribution of a few amino acid residues, 
can alter the PDDF and hint toward the nature of structural changes occurring. 
AUTOGNOM is commonly used to calculate a PDDF for subsequent analysis, 
including as input into ab initio structure determination programs such as 
DAMMIN/DAMMIF and GASBOR. The online data-driven homology modelling 
program SAXSTER has an option to submit SAXS data as a PDDF. 
 
Data Analysis 
 
PRIMUS  
PRIMUS is an interactive suite of programs and modules for the processing and 
manipulation of SAXS data (Konarev et al., 2003). From here data can be visualised, 
inspected, subtracted, averaged, merged and extrapolation to zero concentration. 
 
AUTORG and AUTOGNOM 
AUTORG  and AUTOGNOM are programs developed to approximate invariant 
parameters such as Rg and Dmax respectively (Petoukhov et al., 2007). Both 
programs can be accessed via PRIMUS.  AUTORG estimates Rg using the Guinier 
Law, which relates particle size and intensity of scattered radiation (Koch et al., 
2003). AUTOGNOM is an automated version of the program GNOM which calculates 
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the PDDF via indirect Fourier transformation of the data. This effectively converts the 
reciprocal space data into real space. Data processed in this manner can be used as 
input for ab initio shape reconstruction and data-driven modelling.  
 
SUPCOMB 
The program SUPCOMB allows one to superimpose (by automatic fitting) and 
quantify the similarity between atomic and/or bead models (Kozin & Svergun, 2001). 
SUPCOMB minimizes input structures into an ensemble of points and attempts to 
find the superimposition that yields the lowest Normalized Spatial Discrepancy (NSD) 
value. An NSD close to 0 indicates two well superimposed models, above 1 suggests 
models that consistently differ from one another.  
 
DAMMIF 
Ab initio shape reconstruction of SAXS data is achieved using the program DAMMIF 
and produces a 3D model based on dummy atom beads (Franke & Svergun, 2009b). 
DAMMIF works by filling a search volume with densely packed space-filling spheres 
and computing the theoretical scattering amplitude, after which point a simulated 
annealing algorithm is implemented to generate a model that best fits the data. 
Usually 10-20 models are generated with DAMMIF and further manipulated with the 
DAMAVER suite of programs in the following order: damsel, damsup, damaver and 
damfilt. Damsel compares all the input models, chooses the most likely one and 
provides NSD values for all others. Models with high NSD values were designated as 
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outliers. Damsup then superimposed all models to the reference (i.e. most likely) 
model and damaver aligns all models. Damfilt then filters the averaged model, 
removing outlier beads to yield a final envelope. 
 
CRYSOL 
Existing atomic models, experimental, comparative or otherwise, can be converted 
into simulated SAXS data using the program CRYSOL (Svergun et al., 1995). 
CRYSOL works by back-calculating a theoretical SAXS intensity curve and also 
provides an option to fit an experimental data set against it, providing a means to 
compare atomic models. χ² values are usually given as output, allowing quantification 
of the goodness of fit between theoretical and experimental datasets. 
 
BUNCH 
SAXS data can be used to assist rigid-body modelling of multidomain proteins. 
BUNCH is a program capable of using multiple experimental and CRYSOL-derived 
theoretical datasets to model whole or part of a protein utilising a simulated annealing 
algorithm (Petoukhov & Svergun, 2005). BUNCH is also capable of modelling 
missing linkers and loop regions of high-resolution structures. Amino acid residues 
are modelled as dummy residues centered on the approximate Cα position and 
commonly visualised as spheres.  
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BUNCH works by global minimization of a target function. Penalties to the score are 
introduced when steric clashes occur. Additional restraints from high-resolution data 
also assist in reducing the discrepancy between the model and experimental data. 
 
SAXSTER 
SAXS-assisted MUSTER fold-recognition, or SAXSTER, is a web server based 
program developed for the template-based modelling of proteins using SAXS data as 
a restraint. Data can be provided in real (as PDDF) or reciprocal space, along with 
the protein sequence (i.e. query) of the protein construct, the latter passed through 
MUSTER (MUlti-Sources ThreadER), a protein structure prediction algorithm, to find 
structures deposited in the PDB with sequence similarity to the query sequence (Wu 
& Zhang 2008). Highest scoring hits are then used to generate homology models via 
MODELLER (Eswar et al., 2007). Model theoretical SAXS data are computed then 
compared to experimental SAXS data and ranked.  
 
EOM 
The Ensemble Optimization Method (EOM) was developed to better characterize 
intrinsically disordered proteins (IDPs) and multidomain proteins with flexible linkers 
in solution by SAXS. It is composed of two programs run consecutively, the first of 
which is RanCh (Random Chains) which generates a large number of random 
(usually 10,000) models based on the number of domains, primary protein sequence 
and regions of flexibility introduced within the protein of interest. These random 
67 
 
models are collectively referred to as the pool. Thereafter a Genetic Algorithm 
Judging Optimization of Ensembles (GAJOE) is performed, selecting models from the 
RanCH-generated pool that best fit the experimental SAXS data. The averaged 
theoretical scattering profiles of the selected ensemble should, in theory, fit the data 
better than a single profile. Rg and Dmax values for the pool and ensemble structures 
are calculated and plotted as frequency diagrams, allowing visual inspection and 
comparison of the ensemble to the pool. If the frequency plots of both pool and 
ensemble are similar, this suggests the ensemble samples a broad range of 
conformations and is either disordered (for IDPs) or very mobile for multidomain 
proteins. The proteins can also be more compact or extended on average, if the 
frequency plots for the ensemble lies to the left or right of the pool frequency, 
respectively (Bernadó et al., 2007). 
 
Analytical Ultracentrifugation 
Analytical ultracentrifugation (AUC) is a biophysical technique capable of providing 
information relating to the size distribution and shape of particles in solution. It is 
performed in an analytical ultracentrifuge fitted with specialised optics adapted to the 
type of experiment: boundary sedimentation velocity (SV) measures the rate of 
sedimentation whereas sedimentation equilibrium (SE) measures the concentration 
distribution achieved when diffusion and sedimentation are balanced. The SV 
experiment will be discussed further below. 
SV experiments are used to measure sedimentation coefficients expressed in 
Svedbergs (S). The sedimentation of a particle over time whilst under the influence of 
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a strong centrifugal force is detected by optical techniques: absorbance in the UV-
visible domain, fluorescence or interferometry. Many factors affect S, including the 
shape and mass of the particles in solution. The technique is used in structural 
biology to assess the formation of complexes, their association constants or the 
solution state of particles.    
Analysis of AUC data is performed using the software package Sedfit (Schuck, 
2000). The Lamm equation used to calculate S from the radial concentration 
distribution. The analysis of AUC data describes the particle and solvent as it is 
experiencing centrifugal force (Laue & Stafford, 1999). 
 
Circular Dichroism Spectroscopy 
The secondary structure content of proteins can be reliably quantified by the 
collection and analysis of data obtained from circular dichroism spectroscopy, 
otherwise known as CD. The technique relies on passing circularly polarised light 
(left and right circularly polarised light are in equal proportions) at wavelengths 
between 190-260 nm through an aqueous sample containing the molecules of 
interest. Free passage of left and right forms of light through the sample recombine 
and result in plane polarised light detected by a photomultiplier. However, the 
presence of optically active molecules and secondary structural elements leads to 
the non-equal absorption of left and right circularly polarised light, producing 
elliptically polarised light. Information regarding the chirality or secondary content of 
the molecules (Kelly et al., 2005) can then be assessed by analysis of the resultant 
absorption spectrum.  
69 
 
It is normal practice to collect a control sample containing the exact buffer the 
molecules of interest are dissolved in. For high quality CD data, buffers should 
contain as few chemical components as possible. Chloride ion (Cl-) concentration 
should either be minimal or omitted completely as they strongly absorb at low UV 
wavelengths (Kelly & Price, 2000). After collecting CD data of the molecules of 
interest dissolved in buffer, a step known as solvent subtraction is performed where 
the solvent contribution to the CD spectrum is removed, leaving only information 
concerning the secondary structure of your molecules of interest. CD spectra are 
normally presented as molar ellipticity (θ) in millidegrees (mdeg) as a function of 
wavelength. CD data can be analysed using a variety of available stand-alone 
software and online web servers; for the present study DICHROWEB 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml) was utilised (Whitmore & Wallace, 
2004). 
 
Aims of Study 
The aims of this study are to overexpress, purify and investigate various Shp2 
constructs (i.e. the individual and Tandem SH2 and PTP domains) by solution NMR 
and SAXS. In addition, ligand interactions of Shp2 with the novel immunoreceptor 
G6b-B doubly phosphorylated ITIM will be studied using NMR/SAXS and other 
biophysical methods in solution. The Noonan syndrome/leukaemia mutant (E76K) full 
length Shp2 as well as the wild-type, as yet uncharacterized structurally, will be 
studied by SAXS and molecular modelling.    
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CHAPTER II 
 MATERIALS AND METHODS 
 
Full-length Shp2 
The gene encoding full length Shp2 (PTPN11) was codon-optimized for heterologous 
expression in E.coli, synthesised  and inserted into the pUC57 vector by ECORV 
blunt ended ligation (Genscript USA Inc., see Appendix 1 for gene sequence).  
The PTPN11 gene was then subcloned by ligation independent cloning (LIC) into a 
custom-made bacterial expression vector (kindly provided by Dr. Stefan Knapp, 
Structural Genomics Consortium, Oxford) named pNIC28-BSa4, containing an N-
terminal histidine tag sequence and Tobacco Etch Virus (TEV) protease cleavage 
site (MHHHHHHSSGVDLGTENLYFQS). The pNIC28-Bsa4 vector allows efficient 
and fast generation of expression constructs. First the vector is linearized and treated 
with T4 DNA polymerase in the presence of dinucleotide guanine triphosphate 
(dGTP) to generate 10-15 basepair overhangs. Next specially designed primers with 
complementary bases to the T4-treated vector are used to amplify your gene of 
interest. Incubation of both vector and amplified insert allows base-pairing to occur, 
producing an intact construct ready for bacterial transformation (Savitsky et al., 
2010). 
 An amplification step was carried out using a thermal cycler to produce a DNA 
fragment with the additional complementary bases required at the 5’ and 3’ ends to 
mediate ligation.  
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Forward primer: Full length Shp2: 
5’-TACTTCCAATCCATGACCAGCCGTCG-3’ 
Reverse primer: Full length Shp2: 
5’- TATCCACCTTTACTGTTAACGAAAAGATTTCTGC-3’  
N.B: The underlined bases indicate where ligation occurs  
The KOD polymerase (Merck Chemicals)was used according to standard protocol. 
Thermal cycler steps were as follows: 1) 94°C for 2 min, 2) 94°C for 15 sec,  3) 44°C 
for 30 sec,  4) 68°C for 1 min and 5) 68°C for 2 min. Repeat steps 2-4 20 times. 
Agarose gel electrophoresis (AGE) confirmed presence of a band in correct size 
range (Between 1500-2000 bp; Full length Shp2 insert ~1800bp). Briefly, samples 
were run in a 1% agarose gel in Tris-base/acetic acid/EDTA buffer containing 0.5 
µg/ml ethidium bromide for 30 min at 100 V, then visualised with an ultraviolet 
transilluminator. Purification of polymerase chain reaction (PCR) amplification 
products was carried out using a PCR purification kit (Invitrogen), followed by 
treatment of 5 μl of the PCR product with T4 polymerase to generate sticky ends. 
AGEof the full length Shp2 insert and pNIC28-Bsa4 vector was performed to 
estimate concentration based on a marker (DNA Hyperladder; Bioline). Insert and 
vector concentration were determined to be 5-6 ng/μl. 1 μl insert was added to 2 μl 
vector and incubated at room temperature for 10 min before using 2 μl for a bacterial 
transformation (DH5α, standard protocol) and plated out onto 30 μg/ml kanamycin LB 
agar plates followed by incubation at 37°C overnight. 7 colonies appeared, of which 2 
were used for plasmid amplification/purification (Qiagen Miniprep kit) and sequence 
confirmation (Functional Genomics, School of Biosciences, University of 
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Birmingham). (Additional primer required for sequencing: 5’- 
GATCTGGTGGAACACTATAA-3’). 
 
Tandem SH2 domain of Shp2 
The LIC subcloning method was also applied to produce a construct containing both 
the N and C-SH2 domains of Shp2 (residues 4-216 of wild-type) as well as an N-
terminal Histidine tag followed by a TEV protease cleavage site. 
Primers used to amplify Tandem SH2 of Shp2 DNA:  
Tandem SH2 Forward: 5’- TACTTCCAATCCATGCGTCGCTGGTTTCAT-3’ 
Tandem SH2 Reverse: 5’- TATCCACCTTTACTGTTACAGCGGCTGTTTCA-3’   
Tandem SH2 of Shp1 and nSH2 and cSH2s of Shp1 and Shp2 
The modified pET28a vectors containing  individual nSH2(residues 1-104) and cSH2 
(residues 101-222) domains of Shp-1 and Shp2 were a kind gift from Tony Pawson 
(University of Toronto). The pET28a vector is under T7 promoter control and is thus 
compatible with lacO-based expression systems. Both constructs feature an N-
terminal Histidine tag followed by a TEV protease cleavage site and a C-terminal 
Leu-Ile-Asn-Glu-Phe (also referred to as LINEF) pentapeptide sequence. 
A summary of constructs used in this study can be found in Table 1.2. For a 
graphical schematic of Table 1.2 see Appendix 4.
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Table 1.2. Summary of constructs used. 
Construct 
Name 
Vector Antibiotic 
Resistance 
Affinity Tag Cleavage 
Tag 
WT FL-Shp2 pNIC28-
Bsa4 
50 μg/ml Kanamycin Hexahistidine TEV 
Protease 
TanSH2-Shp2 pNIC28-
Bsa4 
50 μg/ml Kanamycin Hexahistidine TEV 
Protease 
nSH2-Shp2 pET28a 50 μg/ml Kanamycin Hexahistidine TEV 
Protease 
cSH2-Shp2 pET28a 50 μg/ml Kanamycin Hexahistidine TEV 
Protease 
nSH2-Shp1 pET28a 50 μg/ml Kanamycin Hexahistidine TEV 
Protease 
cSH2-Shp1 pET28a 50 μg/ml Kanamycin Hexahistidine TEV 
Protease 
TanSH2-Shp1 pET28a 50 μg/ml Kanamycin Hexahistidine TEV 
Protease 
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Expression trials 
Expression trials were conducted to optimize the yield of protein produced after 
overexpression in E. coli. Three lots of 10-20 ml LB media containing kanamycin at a 
final concentration of 30 μg/ml in 50 ml falcon tubes were inoculated with single 
colonies grown on LB-agar-kanamycin plates. Cultures were grown at 37°C and 220 
revolutions per minute (rpm) in an Ecotron shaker incubator (Infors-HT). Optical 
density at 600 nm (OD600) values were measured every hour until values between 
0.4-0.6 were reached, at which point the cultures were transferred to incubators set 
at different temperatures: 18°C, 25°C and 37°C. Cultures were left to acclimatise for 
15 min, after which another OD600 measurement was recorded. 1 ml of each culture 
were then removed and transferred to a 1.5 ml microfuge tube. These pre-induction 
samples were centrifuged at 20000 xg for 1 min, the pellet stored at -20°C and the 
supernatant discarded. Isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 1 mM were added to all the main cultures and incubated at their 
respective temperatures overnight (16 h) whilst shaking at 220 rpm. The next 
morning, OD600 measurements were recorded for all bacterial growths and 1 ml 
samples were removed and treated in the same way as pre-induction samples. 
Thereafter, pre-induction pellets were resuspended in 100 μl Laemmli buffer and kept 
on ice. Post-induction pellets were resuspended in a similar manner except higher 
volumes of Laemmli buffer were used in resuspension so as to normalise the cell 
density between pre- and post-induction samples. Volumes for each TanSH2-Shp2 
expression trial sample are summarised in Table 1.3 as a typical example. 
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Table 1.3. Values measured and calculated for expression trials of TanSH2-
Shp2. 
Sample OD600 at 
pre-
induction 
OD600 16 h 
post-
induction 
Ratio of pre- and 
post- induction 
OD600 values  
Volume of 
Laemmli 
buffer added 
(μl) 
18°C 1 0.976 1.751 1.79 179 
18°C 2 0.773 1.656 2.14 214 
25°C 1 0.621 1.111 1.79 179 
25°C 2 0.731 1.217 1.66 166 
37°C 1 0.79 1.543 1.95 195 
37°C 2 0.705 1.642 2.33 233 
 
All samples were lysed by sonication for 20 sec at 5 microns amplitude in a Soniprep 
150 fitted with an exponential probe (MSE). Samples were then loaded onto a pre-
cast sodium dodecyl sulphate-PAGE (SDS-PAGE) gel (Criterion Tris HCl 15% 
resolving/4% stacking gel BioRad) with a molecular weight standard (Precision Plus 
Protein™ All Blue Standards, Bio-Rad) and run for 40 min at 180 V (~21 V/cm), after 
which the gel was stained at room temperature and gentle shaking with 30 ml 
InstantBlue (Expedeon) for 20 min. 
 
Protein expression 
A single colony from an agar plate was picked with a disposable inoculating loop and 
agitated in a 50 ml Falcon tube containing 5-10 ml LB and kanamycin at a final 
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concentration of 30 μg/ml and left overnight at 37°C in a shaker incubator running at 
225 rpm. 
The following morning the 5 ml cultures were transferred into a 2 L flask containing 
1L of autoclaved LB liquid media at a final kanamycin concentration of 30 μg/ml. 
Cultures were grown at 37 °C in either unbaffled flasks at 180 rpm or baffled flasks at 
150 rpm until an OD600 between 0.4-0.6 was reached, at which point the temperature 
was dropped to 18°C and cultures induced with the addition of IPTG to a final 
concentration of 1 mM. Cultures were left overnight for approximately 16 h.  
 
Labelled expression 
In order to produce isotopically labelled recombinant proteins for solution NMR 
studies, use of minimal M9 media with NMR-active isotopes (given as 15NH4Cl for 15N 
label incorporation, 13C-glucose for 13C incorporation and deuterium oxide, otherwise 
known as D2O, for deuteron incorporation). A standard M9 recipe was followed and 
the same bacterial cell lines and growth protocol were used. 
 
Protein Purification 
Buffers used: 
• Resuspension buffer: HEPES pH 7.5, 500 mM NaCl, 5 mM imidazole, 0.5 mM 
TCEP and 1 Complete EDTA-free protease inhibitor cocktail (Roche) 
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• Equilibration buffer: 50 mM HEPES pH 7.5, 500 mM NaCl, 5 mM imidazole, 
0.5 mM TCEP 
• Wash buffer: 50 mM HEPES pH 7.5, 500 mM NaCl, 25mM imidazole, 0.5 mM 
TCEP 
• Elution buffer: : 50 mM HEPES pH 7.5, 500 mM NaCl, 250 mM imidazole, 0.5 
mM TCEP 
• Dialysis buffer: 50 mM HEPES pH 7.5, 300 mM NaCl, 0.5 mM TCEP 
• SEC buffer: 50 mM HEPES pH 7.5, 300 mM NaCl 0.5 mM TCEP 
• NMR buffer: 50 mM sodium phosphate pH 7.0, 50 mM NaCl, 0.5 mM TCEP, 
0.01% NaN3.  
 
Cells were transferred to 1 L centrifuge pots and spun at 6000 xg for 20 min at 4 °C. 
After media were decanted, cell pellets were resuspended in 25 ml/l equilibration 
buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES] pH 7.5, 
500 mM NaCl, 5 mM imidazole, 0.5 mM TCEP and 1 Complete 
ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail (Roche)). Cell 
suspension was then homogenised and lysed with three passes using Emulsiflex. 
Lysate was centrifuged immediately afterward at 75000 xg for 45 min at 4°C. 
Supernatant decanted and passed through 0.45 μm filter (Sartorius) before loading 
onto a 5 ml Nickel-NTA affinity column (HisTrap, GE Healthcare) pre-equilibrated with 
five column volumes of equilibration buffer free from protease inhibitors. Supernatant 
was loaded at 1.5 ml/min and the flow-through collected for SDS-PAGE analysis. 7 
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column volumes of wash buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 25 mM 
imidazole, 0.5 mM TCEP) were then passed through at 2.5 ml/min, with the flow-
through collected. Thereafter, elution buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 
250 mM imidazole, 0.5 mM TCEP) was passed through at 2 ml/min with 1.5 ml 
fractions collected in microfuge tubes and qualitatively tested for protein 
concentration using Bradford reagent (Bio-Rad)  until no protein eluted. Fractions 
were prepared for SDS-PAGE analysis by mixing equal parts sample and 2x Laemmli 
sample buffer prior to being loaded into an 18 or 26 –well SDS-PAGE gel and run 
and stained in a similar manner as described earlier. 
Fractions of the highest purity were then pooled for diafiltration prior to SEC or for tag 
removal depending on the construct.  
 
His-tag cleavage with TEV protease 
500 μl 1.5 mg/ml TEV protease in 50 mM HEPES pH 7.5, 100 mM NaCl and 0.5 mM 
TCEP in 50% glycerol are added to the pooled fractions, lightly agitated and 
transferred to Snakeskin dialysis tubing (3 or 10 kDa molecular weight cut-off 
[MWCO]) and placed in 1 L dialysis buffer overnight at 4°C with mild agitation.  
Contents of the dialysis tubing were filtered with a 0.45 μm filter device and syringe, 
then passed through an equilibrated 5 ml HisTrap Ni-NTA affinity column, with flow-
through collected. 5 column-volumes of equilibration, wash and elution buffer were 
sequentially passed through the column, with flow-through collected. SDS-PAGE 
analysis of flow-through samples immediately followed. 
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Ion Exchange Chromatography (IEX) 
Supernatant was loaded onto a GE 16/60 HiPrep Q XL column pre-equilibrated with 
two column volumes of 50 mM HEPES pH7.5, 50 mM NaCl, 0.5 mM TCEP and 
EDTA-free protease inhibitor cocktail (Roche). Flow-through was collected and kept 
on ice. Two column volumes of elution buffer (50 mM HEPES pH 7.5, 1M NaCl, 0.5 
mM TCEP, EDTA-free protease inhibitor cocktail) was applied to the column, flow-
through collected and stored on ice. 
 
Size Exclusion Chromatography (SEC) 
Protein-containing fractions were concentrated in Amicon concentrators (3 or 10KDa 
MWCO) to <5 ml and centrifuged at 17,000 g for 10 min. The concentrated sample 
was then taken up into a Hamilton syringe pre-washed with SEC buffer and injected 
into the 5 ml sample loop of an AKTA Purifier. A Superdex 75 prep grade 26/60 gel 
filtration column was equilibrated with 1.2 column volumes of SEC buffer and injected 
with sample, followed by 1 column volume elution collected in 4 ml fractions. For FL-
Shp2 WT and E76K the SEC was performed at 4°C. For TanSH2, nSH2 and cSH2 
domains this was performed at room temperature. 
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Peptides 
ITIM1, ITIM1_s, ITIM2 and dITIM peptides were synthesised (Fmoc method) by 
Genscript (U.S) or Alta Bioscience (Birmingham UK). Properties of the peptides are 
briefly summarised in Table 1.4 (See Appendix 2 for full G6b-B amino acid 
sequence). 
 
Peptide 
Name 
Number 
of 
residues 
Amino acid sequence Modifications 
ITIM1 12 EPSLLYADLDHL N-acetylation; 
C-amidation; 
ITIM1_s 10 EPSLLYADLD N-acetylation; 
C-amidation 
ITIM2 12 DASTIYAVVV N-acetylation 
dITIM 36 EPSLLYADLDHLALSRPRRLSTADPADAST
IYAVVV  
N-acetylation 
 
Table 1.4. Summary of phosphorylated peptides used. Tyrosine residues with 
added phosphate groups are highlighted in bold and underlined.  
 
Mass Spectrometry 
Matrix-assisted laser desorption ionisation time of flight (MALDI-TOF) and liquid 
chromatography tandem mass spectrometry (LC-MS/MS) was performed in 
collaboration with Dr. Douglas Ward (University of Birmingham, UK) with a ultraflex 
MALDI-TOF Mass Spectrometer in linear mode (Bruker Daltonics). Samples were 
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either dialyzed into dilute hydrochloric acid (HCl) overnight prior to MS analysis to 
remove buffer salts or by use of a zip-tip fitted with a mini desalting medium. Samples 
were mixed with either sinapinic acid or 2, 6-dihydroxyacetophenone (DHAP) and air-
dried on sample plates at room temperature before loading into the mass 
spectrometer. This was done in collaboration with Dr. D. Ward (School of Cancer 
Sciences, University of Birmingham) 
 
Phosphatase Activity Assay 
The p-nitrophenyl phosphate (pNPP) activity assay is a colourimetric technique used 
to quantify PTP desphosphorylation rates. As pNPP is a non-natural surrogate 
substrate, not all PTPs show the same magnitude of catalytic activity towards it as 
they would toward their natural substrates (pY-containing peptides). However, the 
assay can yield data rapidly and to good quality (Montalibet et al. 2005). The pNPP 
assay is also cheap and straightforward. The assay works by allowing pNPP to be 
dephosphorylated by the PTP(s) of interest, producing p-nitrophenol, a chromogenic 
product. Addition of highly alkaline solution (usually between 1-3 M sodium 
hydroxide) deprotonates the product and in turn produces an intense yellow colour 
which absorbs optimally at 405 nm. This can be quantified using a 
spectrophotometer (Lorenz 2011). 
 
Phosphatase activity of Shp2 was determined using previously described protocols 
(Montalibet et al. 2005). Briefly, both PTP-Shp2 and WT and mutant forms of FL-
Shp2 were expressed and purified as above and concentrated to act as stock 
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solutions. Proteins were stored in 25% glycerol at -20 °C when not in use. A 10x 
assay buffer stock solution was prepared (500 mM HEPES pH 7.5, 5 mM DTT and 
20mM EDTA) and filter sterilised. 5 μM assay stock solutions of proteins were diluted 
to the concentrations required in enzyme dilution buffer (1x assay buffer, 20% 
glycerol, 0.1% Triton X-100) to make a working buffer of 50 mM HEPES pH 7.5, 2mM 
EDTA, 0.5 mM DTT, 20% glycerol and 0.1% Triton X-100. p-nitrophenol phosphate 
(PNPP, Sigma Aldrich) was dissolved in enzyme dilution buffer to a stock 
concentration of 150 mM, filter sterilised ( 0.45 µm cut-off) and aliquoted into 1 ml 
fractions in 1.5 ml microfuge tubes and stored at -20°C when not in use. Assays were 
performed in 96-well flat bottomed polypropylene microplates (Corning) at room 
temperature. 10 μl of stock PNPP solution was added and quickly pipetted repeatedly 
into 90 μl of reaction mix to ensure proper mixing, containing no enzyme (negative 
control) or enzyme of differing concentrations, in the presence or absence of G6B-b 
peptides mentioned above. The total reaction volume was 100 μl and was left to run 
for at least 5 min before being quenched with 25 μl 3M NaOH and analysed using a 
Bio-Rad iMark Microplate Reader at 415 nm single wavelength. ‘No enzyme’-
containing wells were used as buffer subtraction blanks post data collection. 
 
AUC 
Sedimentation velocity experiments were performed in collaboration with Rosemary 
Parslow (School of Biosciences, University of Birmingham, UK) using a Beckman XL-
I Ultracentrifuge. Free and dITIM-bound TanSH2-Shp2 were prepared via SEC and 
dialyzed into 50 mM sodium phosphate buffer, pH 7.0, 50 mM NaCl and 0.5 mM 
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TCEP. Two concentrations were made of each sample (500 μl total volume) so as to 
give an absorbance reading (A280) of 0.15 and 0.5 AU.  
 
CD 
Anhydrous dITIM peptide was dissolved in 50 mM sodium phosphate (pH 7.4) buffer 
to final concentrations of 1 and 10 mg/ml and loaded into Starna® 20/C Demountable 
cells of path lengths 0.1 mm and 0.01 mm respectively. CD data were collected using 
a Jasco J-810 Spectropolarimeter at 25°C and analysed with DICHROWEB. 
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NMR  
NMR data were collected on various Varian spectrometers at the Henry Wellcome 
Building for Biomolecular NMR and performed at 298°K unless stated otherwise. 
VNMRJ was used in all data collection procedures. All data were processed with 
NMRPipe (Delaglio, Grzesiek et al., 1995) and analysed with CCPNMR Analysis 
versions 1.5-2.2 (Vranken, Boucher et al., 2005). 
 
1D 1H-NMR 
Acquisition of 1D 1H NMR spectra were performed before higher dimensional 
experiments to verify the presence of protein in solution. Water suppression was 
achieved using a presat pulse sequence Optimisation of transmitter offset and 90° 
pulse calibration was performed. The 1H NMR spectrum was inspected in order to 
identify possible problems with the experimental set up as well as qualitatively decide 
whether to carry on with the NMR experiment. 
 
2D 15N-HSQC and SOFAST-HMQC  
1H, 15N-HSQC and 15N-SOFAST HMQC experiments (gNfhsqc  and sofastNhmqcA in 
VNMRJ, respectively) from the software Biopack were used. Optimised 90° 1H pulse 
width (approx 7-11 µs) and transmitter offset (tof) values were copied over from the 
1D 1H water experiment. Optimisation of 15N 90° pulse width was performed using 
the first increment of the 2D experiment and usually fell between 35-40 µs. The ‘half 
dwell time’ box was checked and after a final inspection of pulse sequence 
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parameters, the experiment was initiated. Observation of the probe temperature and 
program interface for the first minute ensured the experiment was running correctly. 
HSQCs were performed for all protein constructs apart from E76K FL-Shp2.  
 
Triple resonance assignment data acquisition for nSH2 and cSH2 -Shp2 
Acquisition of backbone resonance assignment data for the nSH2 and cSH2 domains 
of Shp2 were carried out on a Varian DirectDrive 600 MHz spectrometer fitted with z-
axis pulse field gradients and a 3-channel cryogenic probe. The samples were 
prepared as previously stated and dialysed into a buffer containing 50 mM sodium 
phosphate pH 7.0, 50 mM NaCl, 0.5 mM TCEP and 0.01% NaN3, made up to a final 
D2O concentration of 10% for locking. Final sample concentrations were 1.8 and 2.8 
mM for nSH2 and cSH2 Shp2 respectively, at a final volume of 600 μl. Samples were 
transferred to cleaned NMR tubes via NMR pipettes and lightly centrifuged to migrate 
all liquid to the bottom of the tube. After an initial 1H,15N-HSQC to confirm presence 
of labelled protein, gauge signal intensity and act as a reference spectrum onto which 
all resonance assignments will be matched to, BEST (Lescop et al. 2007)versions of 
backbone assignment experiments were performed: HNCO, HNCACO, HNCA, 
HNCOCA, HNCACB and HNCOCACB (Wittekund & Mueller, 1993; Bax & Ikura, 
1991); these were obtained from VNMRJ biopack. 
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Triple resonance assignment data acquisition for TanSH2-Shp2 
Acquisition of triple resonance assignment data were performed on a Varian INOVA 
800 MHz spectrometer fitted with z-axis pulse field gradients and 4-channel 
cryoprobe. TROSY versions of HNCO, HNCACO, HNCA, HNCOCA, HNCACB and 
HNCOCACB experiments were performed after an initial 15N HSQC, using a ~2 mM 
triple-labelled TanSH2-Shp2 sample with affinity tag left intact at a final volume of 
600 μl in 50 mM sodium phosphate buffer pH 7.0, 50 mM NaCl, 0.5 mM TCEP, 
0.01% NaN3 and 10% D2O. Backbone pulse sequences were obtained from VNMRJ 
Biopack. Backbone resonance assignments of the individual SH2 domains of Shp2 
aided in the assignment of the TanSH2-Shp2 triple resonance data. 
 
NMR Peptide Titrations 
NMR peptide titration data were collected on Varian DirectDrive 600 MHz and INOVA 
800 MHz spectrometers with 15N-labelled nSH2, cSH2 and TanSH2 domains of Shp2 
and cSH2 domains of Shp1 at concentrations ranging from 100-400 μM. All 
experiments were performed in buffer containing 50 mM sodium phosphate pH 7.0, 
50 mM NaCl, 0.5 mM TCEP, 0.01% NaN3 and 10% D2O at sample volumes between 
550-600 μl in standard NMR tubes. ITIM Peptides were dissolved before each NMR 
experiment in the same buffer and re-adjusted to pH 7.0. Peptides were added in 
equal increments up to 2.5-fold excess, 15N-HSQC or SO-FAST HMQC spectra were 
collected at each ligand concentration. Residue-level interactions can be obtained by 
calculating chemical shift differences between 1H and 15N using CCPN Analysis 
software and further statistical analysis in Microsoft Excel 2007. 
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SAXS 
SAXS data were collected on three sites, the X33 Beamline, part of the DORIS III 
storage ring at DESY (Deutsches Elektronen-Synchrotron), EMBL Hamburg, the P12 
beamline on PETRA III, part of the same organisation as the previously mentioned 
beamline and the BM29 Beamline in ESRF, Grenoble. All measurements were 
conducted at room temperature using a programmable automated sample changer.  
At X33, data were recorded using a single photon counting pixel detector system, 2D 
Pilatus 1M-W pixel X-ray detector within a momentum transfer range of 0.06 nm-1 to 
6 nm-1 at a distance of 2700 mm and X-ray wavelength of 0.15 nm.  
Data collection at P12 utilised a 2D photon counting Pilatus 2M pixel DECTRIS X-ray 
detector within a momentum transfer range of 0.05-1 to 0.35 nm-1 at a distance of 3.1 
m and X-ray wavelength of 0.124 nm. 
At BM29, data were recorded using a single photon counting pixel detector system, 
PILATUS 1M pixel X-ray detector within a momentum transfer range of 0.01 nm-1 to 5 
nm-1 at a distance of 2841mm and X-ray wavelength of 0.099 nm. 
Protein samples were measured between 1 and 10 mg /ml in 50 mM sodium 
phosphate buffer ranging from pH 7.0-7.4 and 100-200 mM NaCl, with either 1 mM 
DTT or 0.5 mM TCEP. Automated data processing on-site allowed for fast 
optimisation of conditions if need be, with further processing and analysis performed 
using modules from the ATSAS suite of programs (Konarev et al., 2006) and Scatter 
(Classen et al., 2013) . RG and I(0) values for each protein construct or complex were 
estimated using the AUTORG and AUTOGNOM modules, part of the PRIMUS 
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program (Konarev et al., 2003), with Porod Volume, P(r) distance distribution 
functions and DMax values estimated using the latter module.  
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Ab Initio Modelling 
DAMMIF and GASBOR were used to produce bead models using only SAXS data. 
GNOM files generated using AUTOGNOM served as input files for both programs. 10 
independent runs of DAMMIF (Franke and Svergun, 2009) in slow mode were 
performed for each SAXS construct. SUPCOMB (Kozin and Svergun, 2001) was 
performed on each set of 10 models to align them in 3D space and generate NSD 
values. DAMSUP, DAMAVER and DAMFILT (Volkov and Svergun, 2003) were then 
applied sequentially to generate a single, averaged bead model. Models were 
visualised with PyMol v1.3 (DeLano and Lam, 2005) and Chimera v1.6 (Pettersen et 
al., 2004). 
 
Homology Modelling 
Online versions of I-TASSER (Zhang, 2008) and SWISS-MODEL (Arnold et al., 2006; 
Bordoli et al., 2009) were utilised to produce homology models of various constructs 
of Shp1 and Shp2. For both programs, construct protein sequences were uploaded 
onto the server and a PDB code specified or uploaded as a template for modelling 
against. In the majority of cases this was carried out in order to model missing atoms 
and loop regions into already existing crystal structures.   
 
Rigid-body Modelling  
SAXS data were used to refine and assist in producing homology models;  the 
programs BUNCH (Petoukhov and Svergun, 2005) and SAXSTER (dos Reis et al., 
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2011) computed such structures for various constructs used in this study. 10 
independent models were generated for each construct and averaged.   
 
Ensemble Optimisation Method 
 The Ensemble Optimisation Method (EOM) was employed to generate models 
based on the SAXS data collected in this study and existing atomic coordinates. 
Unlike rigid-body modelling, EOM allows for flexibility to be accounted, producing 
models that best represent flexible particles in solution. EOM is split into two distinct 
parts, RANCH and GAJOE, the former to generate a pool of10,000 random models 
and their simulated SAXS curves, and the latter to apply a genetic algorithm to select 
an ensemble of structures from the pool that, when averaged, produce the best-fitting 
simulated curve when compared to the experimental data (Bernado et al., 2007). 
 
CRYSOL 
Simulated SAXS curves were generated from calculated high resolution structures, 
homology models and ab initio models were performed using CRYSOL (Svergun et 
al., 1995). 
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CHAPTER III 
CONSTRUCT GENERATION, 
EXPRESSION AND PURIFICATION 
 
Subcloning  
 The codon-optimized PTPN11 gene was synthesised by Genscript and inserted into 
pUC57. Subcloning TanSH2-Shp2 from the PTPN11 followed the same protocol as 
that of subcloning WT FL-Shp2. Sequencing the TanSH2-Shp2 containing plasmid 
only required two primers (T7 forward and reverse) as the insert was 639 bp in 
length, permitting full sequence coverage of both 5’ and 3’ ends of the gene. 
TanSH2-Shp2 gene insert and vector was digested by the BamH1 restriction enzyme 
and analysed by AGE (Figure 3.1), as was FL-PTPN11 (Figure 3.2). FL-PTPN11 
required both T7 primers and a specific primer for the middle of the gene. 
 
 
 
 
 
 
Figure 3.1: DNA AGE Analysis of TanSH2-
PTPN11 and Vector. 
Analysis of TanSH2-PTPN11 insert and pNIC28- 
BSa4 vector produced via restriction enzyme 
digestion by AGE. 1: TanSH2-PTPN11 band is 
located by †; pNIC28-BSa4 is located by *. Insert is 
~660 bp and vector is ~5.2 kbps L: DNA basepair 
ladder, BP: Basepairs  
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Figure 3.2: DNA AGE Analysis of FL-PTPN11 Plasmid Minipreps. 
Analysis of Plasmid Minipreps of four FL-PTPN11 clones by AGE. 1-4: Plasmid 
clones. Plasmids are estimated to be ~7 kBp. L: DNA basepair ladder, BP: 
Basepairs. NB: All four plasmids are circular (i.e. not linearized by single 
digestion).  
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Expression Trials of WT FL-Shp2 and TanSH2-Shp2 
Expression trials were performed for TanSH2-Shp2 in order to maximize the protein 
yield. These were carried out in BL21 DE3 cells (Agilent). Temperature variation was 
tested to quickly assess growth conditions for preparation of TanSH2-Shp2.  
Expression trials of TanSH2-Shp2 yielded a positive result; the protein was 
overexpressed in large quantities (Figure 3.3). An overnight incubation temperature 
of 18°C was selected for TanSH2-Shp2 overexpression. 
 
 
 
 
 
 
 
 
Figure 3.3: Expression trials of TanSH2-Shp2: SDS-PAGE Analysis. 
SDS-PAGE analysis of TanSH2-Shp2. The expected mass was estimated 
by Protparam (Expasy) to be 26.6 kDa. Each induction temperature (18, 25 
and 37°C) was tested in duplicate. Odd and even numbers are Pre- and 
post-induction respectively. kDa: kiloDaltons, L: MW marker, Pre: Pre- 
induction, Post: Post-induction. Red arrow indicates bands of interest. 
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Expression trials were also performed for the WT FL-Shp2 construct, indicating that 
good levels of expression were possible at the three induction temperatures tested 
(Figure 3.4). 
 
 
 
Figure 3.4: Expression trials of WT FL-Shp2: SDS-PAGE Analysis. 
SDS-PAGE analysis of WT FL-Shp2. The expected mass was estimated 
by Protparam (Expasy) to be 70.5 kDa. Each induction temperature (18, 
25 and 37°C) was tested in duplicate. Odd and even numbers are Pre- 
and post-induction respectively. kDa: kiloDaltons, L: MW marker, Pre: 
Pre-induction, Post: Post-induction.  
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In this study, no further optimization of expression conditions were performed. 
Quantities of WT FL-Shp2 were near-identical across all induction temperatures 
tested; 18°C was chosen as a precaution to decrease the probability of degradation 
during overexpression. Yields of FL-Shp2 were too low at higher temperatures to 
warrant induction at 25 or 37 °C for a few hours then harvesting  TanSH2-Shp2 
concentration seemed highest at 18°C and lowest at 25 °C; this led to an induction 
temperature of 18°C to be chosen. Protein stability was not assessed post-
expression but despite this, at the selected temperatures, protein synthesis in 
mesophilic bacterial cells would occur at a slower rate than would otherwise result at 
25°C or 37°C, decreasing the likelihood of protein misfolding and aggregation. After 
expression, proteins are at reduced risk of degradation due to bacterial proteases, 
since these enzymes would be operating at sub-optimal temperatures.  
 
Expression and Purification of FL-Shp2 Constructs 
WT FL-Shp2 
Scaling up overexpression from 10 ml to litres of growth was not an issue, however, 
purification of WT FL-Shp2 was problematic. Whilst WT FL-Shp2 was adequately 
overexpressed, SDS-PAGE analysis of fractions eluted from Ni2+- affinity 
chromatography (Figure 3.5) indicated a second gel band lower in size to the 
estimated size of the full length construct (~70.5 kDa). This indicated the presence of 
either a degradation product or bacterial contaminant. After pooling of fractions for 
overnight dialysis in the presence of TEV protease and second-pass Ni2+ affinity 
chromatography step, the low-molecular weight band was still present, and in higher 
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quantities than the previous gel, indicating the band likely corresponds to a 
degradation product. This band was still present after size-exclusion 
chromatography, as well as a number of faint bands ranging from 26-50 kDa (Figure 
3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: SDS-PAGE of WT FL-Shp2 Post-HisTrap Affinity 
Chromatography. 
A 5 ml HisTrap was loaded with the flowthrough of the previous anion 
exchange chromatography step, containing WT FL-Shp2. Bound protein was 
then eluted with 250 mM imidazole in 50 mM HEPES pH 7.5, 500 mM NaCl 
and 0.5 mM TCEP into 1.5 ml fractions (1-16). 17: pre-load sample. 18: Post-
load sample. WT FL-Shp2 is observed as a strong band around 75 kDa in 
size.  kDa: kiloDaltons, L: MW marker. 
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Since both bands were present after affinity chromatography, the degradation 
product could be a C-terminal truncation, as N-terminal degradation would cleave the 
Hexahistidine tag, decreasing the fusion protein’s affinity for the Nickel-NTA resin of 
a HisTrap. 
To decrease the likelihood of degradation, protease inhibitor cocktail tablets (EDTA-
free so as not to interfere with Ni2+ affinity purification) were added to each buffer. In 
addition, buffers were kept on ice and measures were taken to minimize exposure of 
the supernatant and eluted fractions to room temperature. This included performing 
Ni2+ affinity and size exclusion chromatography steps at 4°C. This however, did not 
suffice to dramatically reduce degradation (results not shown). 
Figure 3.6: Initial SEC Purification of WT FL-Shp2: SDS-PAGE 
Analysis. 
SDS-PAGE analysis of fractions from highest mAU intensity 
collected post-SEC of WT FL-Shp2. High MW contaminants ~150 
kDa are observed in fractions 3-10. Low MW contaminants are 
observed in nearly all fractions, particularly fractions 15-21. Fractions 
23 and 24 contain unpurified supernatant in low and high volumes, 
respectively. kDa: kiloDaltons, L: MW marker.  
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An anion exchange chromatography step (a type of ion exchange chromatography) 
was applied before the first Ni2+ affinity chromatography step. This was performed 
using a HiPrep Q XL 16/10 column. Filtered supernatant was kept on ice throughout 
and flowthrough was collected during purification (Figure 3.6). After Ni2+ affinity 
purification little to no double bands were observed, indicating that at least some of 
the proteases were removed. However, subsequent overnight TEV protease 
cleavage during dialysis increased the proportion of degraded WT FL-Shp2. In 
addition, incomplete cleavage of the Hexahistidine tag was noted. This led to the 
removal of the dialysis/tag cleavage step from the purification protocol. Little to no 
lower molecular weight bands were observed upon SDS-PAGE analysis (Figure 3.7). 
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Figure 3.7: Optimized SEC Purification of WT FL-Shp2: SDS-PAGE 
Analysis. 
(A) Elution Profile of WT FL-Shp2 Post-SEC. WT FL-Shp2 was purified at 
RT on a prep grade S75 column. Fractions of highest UV AU intensities 
(~180-210 ml) were collected and analysed by SDS-PAGE. (B) SDS-PAGE 
analysis of fractions (1-10) from highest mAU intensity collected post-SEC 
of WT FL-Shp2. 10-12: Low to high concentrations of pre-purification 
supernatant. 13: Post-Ni2+ affinity chromatography supernatant, with 
unbound WT FL-Shp2 present Low MW contaminants are observed in 
nearly all fractions, particularly fractions 1 and 2. Fractions 1-6 were pooled 
and concentrated for downstream analysis (not shown in gel). kDa: 
kiloDaltons, L: MW marker.  
A 
B 
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Expression and Purification of TanSH2-Shp2 
Like WT FL-Shp2, scaling up the bacterial overexpression was not an issue, and 
large quantities of TanSH2-Shp2 were produced. The initial Ni2+ affinity 
chromatography step (Figure 3.8) indicated a high amount of TanSH2-Shp2 had 
bound to the column, as indicated by the flowthrough post-loading sample. Tag-
removal was inefficient; SDS-PAGE analysis of the second Ni2+ affinity 
chromatography step revealed large amounts of protein left after elution with 250 mM 
imidazole, indicating that the Hexahistidine tag was still present. Optimisation of TEV 
protease cleavage conditions, such as increasing protease concentration and/or 
temperature, as well as decreasing NaCl concentration, had little to no effect. To this 
extent, downstream experiments were conducted with the tag left on, unless 
specified. 
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TanSH2-Shp2 eluted as a monomer during SEC; this step was performed as a 
polishing step (Figure 3.9), and early elution fractions (2-7) were pooled and 
concentrated for use in structural studies. Interestingly, the remaining elution 
fractions (8-12, Figure 3.9) are contaminated with low molecular weight proteins. 
 
 
 
 
Figure 3.8: SDS-PAGE Analysis of TanSH2-Shp2 Post-Ni2+ affinity 
Chromatography. 
A 5 ml HisTrap column was loaded with supernatant containing 
TanSH2-Shp2 and eluted with 250 mM imidazole in 50 mM HEPES 
pH 7.5, 500 mM NaCl and 0.5 mM TCEP into 1.5 ml fractions (1-17) 
Lanes 4-10 contain large quantities of protein at the expected size 
(~26 kDa), leading to gel overloading. kDa: kiloDaltons, L: MW 
marker.  
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Figure 3.9: SEC Purification of TanSH2-Shp2: SDS-PAGE 
Analysis. 
(A) Elution Profile of TanSH2-Shp2 Post-Size Exclusion 
Chromatography. TanSH2-Shp2 was purified at RT on a prep grade 
S75 column. Fractions of highest UV AU intensities (~160-190 ml) 
were collected and analysed by SDS-PAGE. (B) SDS-PAGE 
analysis of fractions from highest AU intensity collected post-SEC of 
TanSH2 Shp2. Elution fractions 2-7 were pooled and concentrated 
for further high-resolution structural studies. Remaining samples 
were discarded. kDa: kiloDaltons, L: MW marker.  
 
A 
B 
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Expression and Purification of Individual SH2 domains of Shp1 and Shp2 
Expression trials were performed for these constructs, and expression levels at all 
temperatures tested were near-identical, leading to the default induction temperature 
of 18°C to be used for all subsequent growths (Figure 3.10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.10: Expression trials of n and cSH2-Shp2: SDS-PAGE 
Analysis. 
SDS-PAGE analysis of nSH2 and cSH2 domains of Shp2. The 
expected mass of the uncleaved proteins was estimated (Protparam, 
Expasy) to be 15.6 and 17.6 kDa for cSH2 and nSH2 domains 
respectively. Each induction temperature (18, 25 and 37°C) was tested 
in duplicate, though only duplicate of 37°C is shown. Odd and even 
numbers are Pre- and post-induction respectively. kDa: kiloDaltons, L: 
MW marker, Pre: Pre-induction, Post: Post-induction.  
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Purification of nSH2 and cSH2-Shp2 by Ni2+ affinity chromatography was resulted in 
all SH2 protein binding the column (Figure 3.11), as was overnight tag-removal by 
TEV protease and subsequent second step Ni2+ affinity chromatography (Figure 
3.12), which resulted in a >95% pure sample. However, SEC was performed as a 
final polishing step so as to remove any higher order soluble aggregates; elution 
fractions analysed by SDS-PAGE gel. (Figure 3.13 and 3.14). Similar results were 
obtained for cSH2-Shp1 (Figure 3.15). 
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Figure 3.11: SDS-PAGE Analysis of nSH2-Shp2 Post-Ni2+ affinity 
Chromatography. 
A 5 ml HisTrap was loaded with supernatant containing nSH2-Shp2 and 
eluted with 250 mM imidazole in 50 mM HEPES pH 7.5, 500 mM NaCl and 
0.5 mM TCEP into 1.5 ml fractions (1-24). nSH2-Shp2 elutes from fractions 
5-24, just under the 20 kDa mass marker (computed mass: 15.6 kDa). 
Elution fractions 1-5 contain no nSH2-Shp2 protein. kDa: kiloDaltons, L: 
MW marker 
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Figure 3.12: SDS-PAGE Analysis of cSH2-Shp2 Post-HisTrap 
Chromatography. 
A 5 ml HisTrap was loaded with supernatant containing cSH2-Shp2 
and eluted with 250 mM imidazole in 50 mM HEPES pH 7.5, 500 mM 
NaCl and 0.5 mM TCEP into 1.5 ml fractions (1-12). cSH2-Shp2 
elutes from fractions 5-12, just under the 20 kDa mass marker 
(computed mass: 17.6 kDa).13: Flowthrough of supernatant post-
loading to HisTrap, 14: Flowthrough post-wash step with 25 mM 
imidazole-containing buffer.  kDa: kiloDaltons, L: MW marker 
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Figure 3.13: Elution Profile of nSH2 and cSH2-Shp2 Post-Size 
Exclusion Chromatography. 
(A) nSH2-Shp2 was purified at RT on a prep grade S75 column. 
Fractions of highest intensities (~250-275 ml) were collected and 
analysed by SDS-PAGE. (B) cSH2-Shp2 was purified at RT on a prep 
grade S75 column. Fractions of highest intensities (~195-220 ml) were 
collected and analysed by SDS-PAGE.  
A 
B 
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Figure 3.14: Purified nSH2 and cSH2 Shp2: SDS-PAGE Analysis. 
SDS-PAGE analysis of nSH2 and cSH2-Shp2 post-purification, prepared 
for downstream experiments. 1. nSH2-Shp2 , 2. cSH2-Shp2, 3. 250 mM 
imidazole elution fraction for nSH2-Shp2 HisTrap purification (no nSH2-
Shp2 present), 4. 250 mM imidazole elution fraction for nSH2-Shp2 
HisTrap purification (no cSH2-Shp2 present) kDa: kiloDaltons, L: MW 
marker.  
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The nSH2-Shp1 construct, which was expected to behave in a similar fashion to the 
other three SH2 domains that were purified successfully, yielded an unexpected 
result. Despite adopting similar expression and purification protocols, little to no 
protein was identified in eluted fractions post-Ni2+ affinity chromatography (results not 
shown). It was later found to form inclusion bodies and although attempts were made 
to purify them, the methods employed were not successful This is unusual as the 
nSH2 domain of Shp2 and cSH2 domains of Shp1 and Shp2 express and purify to 
adequate levels and purity.  
Figure 3.15: Elution Profile of cSH2-Shp1 Post-Size Exclusion 
Chromatography. 
cSH2-Shp1 was purified at RT on a prep grade S75 column. 
Fractions of highest intensities (~200-220 ml) were collected and 
analysed by SDS-PAGE.  
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Expression and Purification of PTP-Shp2 
The catalytic domain construct of Shp2, PTP-Shp2, was expressed and purified as 
previously described (Barr et al. 2009) excluding the anion exchange step (Figure 
3.16). No issues were noted with purification apart from precipitation during 
diafiltration in preparation for SEC.  Any precipitate was removed by centrifugation of 
the mixture followed by separation of supernatant and pellet by decanting. Highly 
pure, adequate quantities were produced for NMR and SAXS studies (Figure 3.17). 
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Figure 3.16: SDS-PAGE Analysis of PTP-Shp2 Post-HisTrap 
Chromatography. 
A 5 ml HisTrap was loaded with supernatant containing PTP-Shp2 and eluted 
with 250 mM imidazole in 50 mM HEPES pH 7.5, 500 mM NaCl and 0.5 mM 
TCEP into 1.5 ml fractions (1-21). PTP-Shp2 elutes from fractions 5-16, just 
under the 37 kDa mass marker. 22: supernatant pre-purification, 23: 
supernatant post-HisTrap purification, 24: flowthrough post-wash with 25 mM-
containing buffer as described in Materials and Methods. Fractions 5-16 were 
pooled for overnight cleavage with TEV protease. (computed mass: 36.8 
kDa). kDa: kiloDaltons, L: MW marker. 
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Figure 3.17: SEC Purification of PTP-Shp2: SDS-PAGE Analysis. 
(A) Elution Profile of PTP-Shp2 Post-Size Exclusion Chromatography. PTP-
Shp2 was purified at 4°C on a prep grade S75 column. Fractions of highest 
intensities (~160-200 mL) were collected and analysed by SDS-PAGE. (B) 
SDS-PAGE analysis of fractions (1-13) collected post-SEC of PTP-Shp2. All 
fractions were pooled and concentrated for downstream analysis. kDa: 
kiloDaltons, L: MW marker.  
A 
B 
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Mass Spectrometry 
Mass spectrometry (MS) was utilised as an accurate polypeptide size determination 
method for 1) the detection of degradation products for susceptible proteins and 2) to 
verify the presence of phosphorylation sites.  
The mass of WT FL-Shp2 prior to SAXS analysis was assessed by MALDI-TOF MS 
(Appendix Figure 5) and calculated to be consistent with the mass predicted by 
sequence analysis to be 70563.5 Da (Artimo et al., 2012).  
 
Conclusions 
Milligram quantities of pure, stable protein are required for high-resolution structural 
studies and biochemical analyses. In this chapter, the expression and purification 
results have been presented.  WT FL-Shp2 was subcloned into the pNIC28-Bsa4 
vector utilising the LIC protocol provided by the SGC (Gileadi et al., 2008) and 
transformed into high copy number, competent E. coli cells. Screening of individual 
colonies by agarose gel electrophoresis and PCR confirmed the presence of a 
plasmid around the estimated base-pair size and the correct, in-frame insert 
sequence. The same was performed with TanSH2-Shp2, with similar results.  
As previously mentioned in Chapter II, constructs for nSH2- and cSH2- Shp1 and 
Shp2, as well as Tan-SH2 Shp1, were kindly donated by Tony Pawson. No further 
molecular biology steps were required as they were already in-frame within T7-based 
expression vectors. 
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CHAPTER IV 
NMR ASSIGNMENTS OF THE SHP2 
SH2 DOMAINS 
 
The structure of Shp2 in solution has not been investigated extensively. Considering 
the importance of this PTP in cancer and developmental syndromes, an 
understanding of Shp2 in solution at the structural level may yield insights into the 
mechanisms of its biological function and various interactions, as well as providing 
future drug discovery efforts with data required to design and implement screening 
programmes effectively.  
For the present study various constructs of Shp2 were assessed by solution NMR 
and potential candidates were taken forward for further investigation. In addition, the 
cSH2 domain of Shp1 was assessed by solution NMR for comparative purposes. 
 
2D 15N HSQC of WT FL-Shp2 
At a mass of 70.5 kDa, FL-Shp2 is too large for conventional NMR experiments. 
However, as 15N-labelling is relatively inexpensive and straightforward, an attempt 
was made to collect and analyse a spectrum of this construct. Due to problems with 
protein solubility, a final FL-Shp2 concentration of 200 μM was used. A 15N TROSY-
HSQC spectrum was collected for the WT FL-Shp2 on a 900 MHz Agilent 
spectrometer; the use of a TROSY pulse sequence as well as a high-field magnet 
increase the likelihood of acquiring meaningful data with large proteins.  
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Processing of the data yielded a sparse spectrum (Figure 4.1) containing 47 peaks 
out of an expected 717. Four peaks lie in the side-chain amide region, with the 
remainder dispersed along the 15N axis and localised in the random-coil region of the 
1H axis, suggesting the peaks represent amino acids within loops segments of FL-
Shp2. These peaks could also correspond to amino acids within helices but crucially 
there is nothing in the NMR spectrum that suggests strands are present. The non-
uniform peak intensity throughout the spectrum suggests multiple timescales of 
motion within FL-Shp2. No further construct or buffer optimization, or additional 
isotopic labelling (i.e deuteration) was performed for WT FL-Shp2 as the percentage 
of visible peaks (6.5%) would not be significantly improved to the extent that 
backbone assignment becomes feasible. At a mass of 70.5 kDa, FL-Shp2 likely 
tumbles slowly in solution, causing fast T2 relaxation and thus leading to poor signal. 
The C-terminal tail may have more independent motion in solution than the other 
domains of Shp2, which is why sharp peaks in the spectrum are observed. For this 
reason a “divide and conquer” approach was taken, separating individual domains of 
WT FL-Shp2 for further study by NMR. 
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Figure 4.1: 15N-1H TROSY HSQC Spectrum of 15N-Labelled FL-
Shp2 WT. 
A 2D spectrum was recorded of 200 μM [U-15N]-FL-Shp2 WT in NMR 
buffer at 25°C on a 900 MHz (21.2 T) Varian Spectrometer. Around 
47 peaks are observed of an expected 717. Four peaks lie in the side-
chain amide region (6.8-7.5 ppm); the remainder in the random coil/α-
helical main-chain amide region (7.7-8.5 ppm). Peaks vary in intensity 
suggesting multiple timescales of motion are present. 
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2D 15N HSQC of nSH2-Shp2 
The 15N HSQC spectrum of nSH2-Shp2 is well dispersed and indicates the presence 
of folded protein (Figure 4.2). A total of 132 peaks are present out of a possible 133 
(>99%), taking into account dual Asparagine/Glutamine side-chain amide and 
tryptophan side-chain Hε1 resonances present, as well as the absence of proline 
resonances. The peaks are near-uniform in intensity, with a few possessing stronger 
intensities, suggesting variable exchange rates and therefore variable timescale 
motions in nSH2-Shp2. The two peaks around 10.5ppm in the 1H dimension are in 
the region Trp Hε1 resonances are commonly found. Since there is only one 
tryptophan (6W) in the nSH2-Shp2 sequence, it is reasonable to assume one of the 
peaks corresponds to 6W-Nε1. Another scenario is the peak belongs to a main chain 
amide residue involved in a strongly H-bonded region of β-sheet. 
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Figure 4.2: 15N-1H HSQC Spectrum of 15N-Labelled nSH2-Shp2. 
A 2D spectrum was recorded of 400 μM [U-15N]-nSH2-Shp2 in NMR 
buffer at 25°C on a 600DD MHz (14.1 T) Varian Spectrometer. 132 
peaks are observed of an expected 133. Peaks are well dispersed and 
mostly uniform, indicating a stable globular structure of mixed 
secondary structure character.  
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2D 15N HSQC of cSH2-Shp2 
Like nSH2-Shp2, the 15N-HSQC of cSH2-Shp2 is also well dispersed, indicating the 
presence of folded protein (Figure 4.3). 153 peaks out of an expected 149 are 
present in the spectrum, suggesting cSH2-Shp2 samples multiple conformational 
states at a slow exchange rate on the NMR timescale. The alpha-helical/unfolded 
region of the spectrum exhibits more peak overlap then nSH2-Shp2 and this may 
partly be due to the cSH2 construct being 20 amino acids larger than nSH2-Shp2. 
Other similarities with the nSH2-Shp2 spectrum include the different peak intensities 
observed and interestingly, two peaks of which at least one corresponds to 112W Hε1 
resonance.  
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Figure 4.3: 15N-1H HSQC Spectrum of 15N-Labelled cSH2-Shp2. 
A 2D spectrum was recorded of 400 μM [U-15N]-cSH2-Shp2 in NMR 
buffer at 25°C on a 600DD MHz (14.1 T) Varian Spectrometer. Peaks 
are well dispersed and mostly uniform, indicating a stable globular 
structure of mixed secondary structure character.  
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2D 15N HSQC of TanSH2-Shp2 
His-TanSH2-Shp2 
A 400 μM [U-15N]-His-TanSH2-Shp2 sample was prepared and a 15N HSQC 
spectrum acquired thereafter on an 800 MHz Varian spectrometer, Figure 4.4 shows 
the processed spectrum. 244 out of 266 peaks appear in the spectrum. Peaks are 
well dispersed, indicative of a folded protein with mixed secondary structure 
character. Peak intensities vary, suggesting multiple timescales of motion within His-
TanSH2-Shp2. With >92% of the expected peak count visible, backbone assignment 
was deemed to be feasible. However, around 35 peaks were overlapped between 
7.5-8.5 ppm in the 1H axis, which complicated the assignment process. Deuteration 
was used to improve the signal-to-noise ratio and the protein concentration was 
increased for the collection of assignment spectra. His-TanSH2-Shp2 is 26.2 kDa in 
size, meaning use of a TROSY-HSQC pulse sequence in the future may enhance 
peak resolution and signal-to-noise. 
The HSQC recorded and analysed in this study resembled that of a previously 
recorded 15N HSQC (Wu & Guo 2009) though due to differences in spectrometer field 
strength (600 Vs. 800 MHz) and temperature (17 vs. 25 °C), the HSQC from the 
current study is higher in resolution and signal-to-noise.  
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Figure 4.4: 15N-1H HSQC Spectrum of 15N-Labelled His-TanSH2-
Shp2. 
A 2D spectrum was recorded of 400 μM [U-15N]-His-TanSH2-Shp2 in 
NMR buffer at 25°C on an 800 MHz (18.8 T) Varian Spectrometer. 
Peaks are well dispersed and mostly uniform, indicating a stable 
globular structure of mixed secondary structure character.  
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Differences Exist Between Isolated and Tandem SH2 Domains 
Superimposition of HSQC spectra of either nSH2 or cSH2-Shp2 with TanSH2-Shp2 
revealed a degree of peak overlap: 53 and 34% of n and cSH2 domain peaks with 
TanSH2-Shp2, respectively (Figure 4.5). 
However, the fact there is limited peak overlap present suggests conformational 
differences existed between the TanSH2 domain and the isolated SH2 domains, 
especially the cSH2 domain as the HSQC peaks overlapped less with TanSH2-Shp2 
than does the nSH2 domain. Inspection of available crystal structures suggested an 
interface exists between the SH2 domains when part of the same polypeptide chain. 
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Figure 4.5: Superimposition of nSH2, cSH2 and TanSH2-Shp2 15N-1H HSQC 
Spectra. 
A 2D HSQC spectrum of His-TanSH2-Shp2 (black) is superimposed with (A) nSH2-
Shp2 (magenta) (B) cSH2-Shp2 (green) and (C) both nSH2 and cSH2-Shp2, 
indicating the chemical shift changes between the individual and continuous SH2 
domains, suggesting an intradomain interface may be present.  
125 
 
2D 15N HSQC of cSH2-Shp1 
The 15N HSQC of cSH2-Shp1 was well resolved and dispersed, indicative of a folded, 
mixed secondary structure protein (Figure 4.6). This is consistent with the known 
structure of SH2 domains. A total of 126 peaks out of 127 are visible (>99%). Around 
30 peaks in the spectrum are partially overlapped but easily distinguishable as 
separate peaks. Interestingly, even though there are two Trp residues within cSH2-
Shp1, there seemed to be only one peak in the Trp Nε1 region, located around 11.2 
ppm in the 1H axis, The nSH2 andcSH2 constructs of Shp2 all seem to have two Trp 
Nε1 peaks in this region, while TanSH2 demonstrates a possible four Trp side chain 
peaks. The solution NMR structure of cSH2-Shp1 has been solved both free and in 
complex with an ITIM peptide (PDB ID: 2YU7; Kasai et al., unpublished data), so 
backbone assignment is not a priority for this construct, though NMR titrations 
experiments were performed with ITIM peptides. Surface plasmon resonance (SPR) 
experiments suggested the SH2 domains of Shp1 and Shp2 were able to bind dITIM-
G6b-B. Due to the high sequence identity between the two tandem SH2 domains, 
one might expect this to be the case (Coxon et al., 2012). Observation of chemical 
shift perturbations (CSP) may yield more information regarding the interactions 
posited. 
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Figure 4.6: 15N-1H HSQC Spectrum of 15N-Labelled cSH2-Shp1. 
A 2D spectrum was recorded of 400 μM [U-15N]-cSH2-Shp1 in NMR 
buffer at 25°C on a 600DD MHz (14.1 T) Varian Spectrometer. 126 
peaks are observed of an expected 127. Peaks are well dispersed 
and mostly uniform, indicating a stable globular structure of mixed 
secondary structure character.  
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Backbone Assignments of Shp2 SH2 Domains 
Isolated SH2 Domains of Shp2 
Expression and purification of 15N, 13C-labelled nSH2 and cSH2-Shp2 was 
straightforward and produced final concentrations of 1.8 and 2.8 mM in 1 ml 
quantities each, respectively. As the Shp2 SH2 domains are > 15 kDa in mass and 
stable in solution they did not require deuteration. The small size, high concentration 
and stability all assist in the fast acquisition of backbone datasets using BEST pulse 
sequences. For each construct the acquisition of a full set of assignment spectra took 
3 days. 
 
92% Sequence-Specific Backbone Assignment of nSH2-Shp2 
All six BEST backbone datasets were processed and analysed in order to complete 
backbone assignment, establishing connectivities between (i) and (i-1) resonances 
for CA, CB and CO. A C(CO)NH dataset was used to validate backbone assignments 
by providing additional side-chain carbon chemical shift data for the (i-1) residue 
(data not shown). Figure 4.7 shows the sequential links between HNCA and 
HN(CO)CA resonances of residues 46-51 inclusive of nSH2-Shp2. This sequence 
makes up portions of sheets βC and βD as well as the entire CD loop. 
Almost full backbone assignments (H, N, Ca, Cb, C’) for 101 out of 110 residues 
were assigned and are displayed in Figure 4.8. In addition, all 11 Asn/Gln side-chain 
amides were assigned, one of which (107N) comprises the non-WT C-terminal 
region, of which full assignments pentapeptide sequence (LINEF) were established.  
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Figure 4.7: Sequential Backbone Assignment of nSH2-Shp2 
Using HNCA and HNCOCA Spectra. 
Strips of 3D NMR assignment spectra showing connectivities 
between HNCA (blue peaks) and HNCOCA (red peaks) 
established using a semi-automated assignment method within 
CCPN Analysis 2.1.5. Black solid lines show sequential 
connectivities between HNCA and HNCOCA peaks 
corresponding to residues at (i) and (i-1) positions for residues 
46-51 inclusively for WT nSH2-Shp2, corresponding to the 
protein sequence RRNGAV. A similar assignment approach was 
done for HNCO/HNCACO and HNCACB/HNCOCACB spectra in 
parallel. 
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Figure 4.8: Assigned 15N HSQC of 15N, 13C-labelled nSH2-Shp2. 
92% nSH2-Shp2 backbone amide signals were assigned using a 1.8 
mM sample of uniformly 15N and 13C-labelled protein in NMR buffer at 
RT using a 600 MHz magnet. The crowded region of the spectrum 
(boxed, middle) is expanded for clarity (bottom right). “sc” denotes side-
chain assignments. Assigned side-chain HN peaks of Asn/Gln are 
connected via single horizontal black solid lines.  
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Discounting non-WT residues, a total WT assignment of 94% was reached. Aside 
from four proline residues, a total of 9 residues remain unassigned, three of which 
form part of the non-WT N-terminal sequence: -4G, -3S and -2G, 1M marking the 
beginning of the WT nSH2-Shp2 sequence. The remaining unassigned WT residues 
are: 3S, 4R, 5R, 35K, 85H and 86G. These residues are highlighted in Figure 4.9 and 
show the three regions where assignments were unobtainable: 3S-5R are located at 
the N-terminus, 35K within the BC loop and 85H-86G form part of the loop C-terminal 
to helix αB.  Lack of assignments for peaks in the HSQC were due to the absence of 
CO, CA or CB (i and i-1) peaks in the 3D data. 
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Figure 4.9: Unassigned Regions of nSH2-Shp2. 
Six non-Pro residues remain unassigned: 3Ser, 4Arg, 5Arg, 35Lys, 
85His and 86Gly (red). All reside within loop regions. Four proline 
residues (9, 33, 38 and 101Pro) are highlighted in blue. (PDB ID: 
4DGP)  
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95% Sequence-Specific Backbone Assignment of cSH2-Shp2 
Assignment of the resonances from cSH2-Shp2 backbone was performed identically 
to the nSH2-Shp2 assignment. Figure 4.10 shows the connectivities between (i) and 
(i-1) resonances for the HNCA and HN(CO)CA spanning residues 145-150, which 
correspond to the sequence GDFVLS. This sequence makes up the portions of the 
cSH2-Shp2 BC loop and sheet βC. 
Backbone resonances for 122 out of 128 WT cSH2-Shp2 residues were assigned 
(Figure 4.11). Not including the five prolines, five residues remained unassigned. Of 
these, two are non-WT residues at the N-terminal, the other three being 115G, 141Q 
and 161N. Discounting non-WT residues, over 97% of the backbone amide signals 
were assigned unambiguously. These are summarised in Figure 4.12. 115G is 
located within the N-terminal loop preceding helix αA, 141Gln forms part of the BC 
loop and 161N is located within the CD loop. These regions are likely disordered and 
undergoing motions and/or chemical exchange in the intermediate timescale, leading 
to the lack of assignment. However, side-chain amide assignments for 141Q and 
161N were obtained. Of 10 Asn/Gln residues, two lack side-chain amide 
assignments, these are: 103N and 222N, which are located at the N and C termini of 
cSH2-Shp2 respectively. 
Much as was the case with nSH2-Shp2 a number of peaks within the HSQC were not 
assigned using 3D data due to the absence of CO, CA or CB (i and i-1) peaks or NH 
peaks with no apparent connectivities to 3D datasets.  
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Figure 4.10: Sequential Backbone Assignment of cSH2-Shp2 
Using HNCA and HNCOCA Spectra. 
Strips of 3D NMR assignment spectra showing connectivities 
between HNCA (blue peaks) and HNCOCA (red peaks) established 
using a semi-automated assignment method within CCPN Analysis 
2.1.5. Black solid lines show sequential connectivities between 
HNCA and HNCOCA peaks corresponding to residues at (i) and (i-1) 
positions for residues 145-150 inclusively for WT cSH2-Shp2, 
corresponding to the protein sequence GDFVLS. A similar 
assignment approach was done for HNCO/HNCACO and 
HNCACB/HNCOCACB spectra in parallel.  
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Figure 4.11: Assigned 15N HSQC of 15N, 13C-labelled cSH2-Shp2. 
Around 95% cSH2-Shp2 backbone amide signals were assigned using 
a 2.8 mM sample of uniformly 15N and 13C-labelled protein in NMR 
buffer at RT using a 600 MHz magnet. The crowded region of the 
spectrum (boxed, near middle) is expanded for clarity (bottom right). 
“sc” denotes side-chain assignments. Assigned side-chain HN peaks 
of Asn/Gln are connected via single horizontal black solid lines. “*” 
indicates assignment of alternate conformation(s) of residues.  
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Figure 4.12: Unassigned Regions of cSH2-Shp2. 
Three non-Pro residues remain unassigned: 115Gly, 141Gln and 
161Asn (red). Both 141Gln and 161Asn reside within loop regions, while 
115Gly forms the terminus for sheet βA. Five proline residues (101, 107, 
144, 201 and 215Pro) are highlighted in blue. (PDB ID: 4DGP)  
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Secondary Structure Prediction of Individual SH2 Constructs 
Chemical shift data derived from backbone assignment can be used to predict 
secondary structure elements and were used in the case of nSH2 and cSH2-Shp2 to 
further validate assignments. Data were analysed using the TALOS+ system and the 
results are summarised in Figure 4.13 and Figure 4.14 for nSH2 and cSH2 domains 
of Shp2, respectively. From this we can conclude that the overall fold of both SH2 
domains in solution are consistent with available crystallographic data, with minor 
variations in helix/strand length. 
 
Alternative Conformational States of nSH2 and cSH2-Shp2 Exist 
A number of weak peaks in the nSH2-Shp2 HSQC were identified which had 
corresponding carbon shifts at positions identical to previously assigned residues. 
These are for 24Gly and 25Val of the AB loop and 48Asn, 49Gly, 50Ala and 51Val of 
the CD loop and part of sheet βD. Interestingly, these residues are clustered to one 
side of nSH2 (Figure 4.15). From this data alone it is not possible to draw 
conclusions on the precise nature of residue motions or whether the clustering of 
residues with secondary HSQC peaks is coincidental; NMR-based dynamics 
experiments can however, shed light on any potential mobility. No significant 
biological role is apparent for these residues as they are not directly involved in 
phosphopeptide binding or stabilisation. However, SH2 domains have been 
demonstrated to have noncanonical roles and functions so this cannot be ruled out 
entirely (Bernard A. Liu et al., 2012). 
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Alternative conformational states were also observed for residues 102Leu-105Ala, 
which form the interSH2 linker but are located in the N-terminal of the cSH2-Shp2 
construct. This region would presumably display high mobility in the absence of the 
nSH2 domain, but may become more rigid in the tandem SH2 domain. 
 
 
 
 
 
Figure 4.13: Secondary Structure Predictions of nSH2-Shp2 using 
NMR Data. 
(A) Secondary structure via DSSP of available crystal structure (1AYD) 
and prediction using TALOS+. Structural elements are depicted as 
loops (green solid line), helices (cyan) and sheets (pink). Differences 
between the crystal and solution structure are apparent, mainly as 
shortened helices and more β-sheets. (B) TALOS+ secondary structure 
probability histogram, helical propensity is positive, sheet propensity is 
negative and summarised in (A). (C) S2 order parameter prediction using 
therandom coil index method. The closer the value toward 0, the more 
mobile the residue.  
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Figure 4.14: Secondary Structure Predictions of cSH2-Shp2 using 
NMR Data. 
(A) Secondary structure via DSSP of available crystal structure (2SHP, 
chain A) and prediction using TALOS+. Structural elements are depicted 
as loops (green solid line), helices (cyan) and sheets (pink). Differences 
between the crystal and solution structure are apparent, mainly as 
shortened helices and smaller β-sheets. (B) TALOS+ secondary 
structure probability histogram, helical propensity is positive, sheet 
propensity is negative and summarised in (A). (C) S2 order parameter 
prediction using the random coil index method. The closer the value 
toward 0, the more mobile the residue.  
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Figure 4.15: Shp2 SH2 Domains Adopt Alternative Conformations in 
Solution. 
Cartoon representation of Shp2 SH2 Domains. (A) nSH2-Shp2 (PDB ID: 
1AYD, gray) highlighting residues with alternative conformations in 
solution: 24Gly, 25Val, 48Asn, 49Gly, 50Ala and 51Val (magenta). The 
invariant arginine is displayed as grey sticks, while 25Val is displayed as 
magenta sticks. (B) cSH2-Shp2 (PDB ID: 4DGP, gray) is coloured 
similarly, dynamic residues span one region at the N-terminus: 102Leu, 
103Asn, 104Cys and 105Ala, which make up part of the interSH2 linker 
region.  
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 Deuteration of His-TanSH2-Shp2 Improves Spectral Quality 
Deuteration and purification of His-TanSH2-Shp2 was straightforward and yielded a 
pure sample of 2H, 15N and 13C-labelled protein at 2.2 mM concentration in 1 ml. 
Subsequent 15N-TROSY HSQC collection and analysis reveals a significant increase 
in resolution due to a decrease in linewidths as a consequence of deuteration and 
the TROSY pulse sequence; overlapped peaks were more easily distinguishable. 
218 peaks are observed (About 82% of the expected peak count if side-chain 
Asn/Gln peaks are expected, 95% if they are not included). (Figure 4.16). 
A standard set of TROSY backbone assignment spectra were collected using this 
sample.  
 
92% Sequence-Specific Assignment of the Backbone of His-TanSH2-Shp2 
For His-TanSH2-Shp2, backbone assignment spectra were processed and analysed 
to obtain sequence-specific assignments. The assignments from HSQC spectra of 
the individual Shp2 SH2 domains were utilised to speed up the TanSH2 assignment 
process and connectivities were made for CA and CB (i) and (i-1) chemical shifts 
using HNCA-HN(CO)CA and HNCACB and HNCOCACB spectra. Representative 
HNCA-HN(CO)CA connectivities between (i) and (i-1) resonances for residues 
46Arg-51Val (the same as for nSH2-Shp2) can be viewed in Figure 4.17. The HNCO 
spectrum was of high quality but the opposite was observed for the HN(CA)CO, 
precluding efficient assignment of CO chemical shifts for the sequential backbone 
assignment process. 
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Figure 4.16: 15N-1H TROSY HSQC Spectrum of 2H, 13C and 15N-Labelled 
His-TanSH2-Shp2. 
A 2D spectrum was recorded of 2 mM [U-2H,U-13C and U-15N]-His-TanSH2-
Shp2 in NMR buffer at 25°C on an 800 MHz (18.8 T) Varian Spectrometer. 
Positive peaks appear in black, negative (aliased) peaks appear in purple.  
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Figure 4.17: Sequential Backbone Assignment of TanSH2-Shp2 Using 
HNCA and HNCOCA Spectra. 
Strips of 3D NMR assignment spectra showing connectivities between 
HNCA (blue peaks) and HNCOCA (red peaks) established using a semi-
automated assignment method within CCPN Analysis 2.1.5. Black solid 
lines show sequential connectivities between HNCA and HNCOCA peaks 
corresponding to residues at (i) and (i-1) positions for residues 46-51 
inclusively for WT TanSH2-Shp2, corresponding to the protein sequence 
RRNGAV. A similar assignment approach was done for HNCO/HNCACO 
and HNCACB/HNCOCACB spectra in parallel.  
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Of 228 non-prolineresidues within His-TanSH2-Shp2, 209 have been assigned 
(Figure 4.18), the remaining 19 were unassigned due to poor spectral quality. These 
numbers reflect the extent of assignment for the entire, His-tag containing construct. 
When only WT residues are considered, ~95% of these are assigned, as 10/19 
unassigned residues are within the His-tag. These 10 residues run consecutively 
from the N-terminal methionine and incorporate the entire hexahistidine sequence 
and two linker serine residues, while the TEV cleavage sequence was assigned. His-
TanSH2-Shp2 contains eight prolines, all of which were assigned in all backbone 
atoms apart from main chain imino groups. The remaining unassigned WT residues 
are coloured on the 4DGP TanSH2 structure in Figure 4.19. These residues are: 
4Arg, 5Arg, 35Lys, 85His, 86Gly, 111Arg, 114His, 141Gln and 161Asn. Assignments 
for most of these residues were not obtained in the individual Shp2 SH2 
assignments, the exceptions being 111Arg and 114His, which are both located in the 
N-terminal loop preceding helix αA. For cSH2-Shp2, both 111Arg and 114His are 
assigned, but 115Gly was not. A change in the chemical exchange rate and/or 
dynamics within this loop region may have occurred, causing this variation. No side-
chain amide signals were assigned in this procedure due to the nature of the TROSY 
experiment. Chemical shift tables for all constructs assigned in this study can be 
found in Appendix 10. 
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Figure 4.18: Assigned 15N HSQC of 2H, 15N, 13C-labelled TanSH2-Shp2. 
92% TanSH2-Shp2 backbone amide signals were assigned using a 2.2 mM 
sample of uniformly 2H, 15N and 13C-labelled protein in NMR buffer at RT 
using a 800 MHz magnet.. The crowded region of the spectrum (boxed, near 
middle) is expanded for clarity (bottom right). “sc” denotes side-chain 
assignments. 73T is aliased and thus appears as a negative peak (magenta) 
and has been placed at its original position if unaliased.  
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Figure 4.19: Unassigned Regions of TanSH2-Shp2. 
Nine non-Pro residues remain unassigned: 4Arg, 5Arg, 35Lys, 85His, 
86Gly, 111Arg, 114His, 141Gln and 161Asn (red). Unassigned non-WT 
residues are indicated by a *. Eight proline residues (9, 33, 38, 101, 
107, 144, 201 and 215Pro) are highlighted in blue. (Homology model 
based on PDB ID: 4DGP)  
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15N-1H HSQC Spectrum of 15N-Labelled ΔHis-TanSH2-Shp2 
Similar conditions were used to acquire NMR data of ΔHis-TanSH2-Shp2 as was 
previously conducted for His-TanSH2-Shp2. ΔHis-TanSH2-Shp2 is missing the His-
tag that TanSH2-Shp2 normally contains. Inspection of the processed 15N-HSQC 
spectrum yielded similar results to before: 231 peaks are observed of an expected 
241 (~96%). Removal of the His-tag does not perturb the NMR spectrum 
dramatically, however, superimposition of  His- and ΔHis-TanSH2-Shp2 spectra 
(Figure 4.19) reveals around 20 CSPs throughout, varying in shift magnitude with 6W 
as high as 0.2 ppm in 1H. This indicates that the presence of a His-tag does have a 
structural effect on the remainder of the TanSH2-Shp2 construct.  
The  10 residues with largest CSP are (from largest to smallest): 6W, 7F, 105A, 8H, 
104C, 181V, 79Q, 75A, 11I and 32R. Mapping of the perturbed peaks onto the 
TanSH2 region of 4DGP (Figure 4.20; PTP domain omitted for clarity) localises the 
affected region to one side of the nSH2 domain, facing and making contacts with the 
interSH2 linker and cSH2domain. This is expected, as the natural N-terminus of 
Shp2 is largely buried in between both SH2 domains in the crystal structure of FL-
Shp2. 181Val is located in the EF loop of cSH2, far away from the nSH2:cSH2 
interface. This residue may form hydrophobic contacts with residues to the C-terminal 
of the pY in an interacting phosphorylated peptide. Also 32Arg, located in the βB 
sheet of nSH2, is the highly conserved Arg residue involved in forming a salt-bridge 
with the pY-phosphate group. Taken together, this suggests that some perturbation 
of non-interfacial residues is present in His-TanSH2-Shp2. This could be due to 
direct, non-specific interaction of His-tag residues with both SH2 domains or 
conformational changes occurring as a result of the His-tag being present. 
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Figure 4.20: The Presence of a His-tag Causes Perturbations to 
TanSH2-Shp2. 
(A) 15N-labelled ΔHis-TanSH2-Shp2 (orange) superimposed with 2H,13C 
and 15N-labelled His-TanSH2-Shp2 (black). Around 15 cross-peaks have 
shifted, presumably due to His-tag removal. (B) Top 10 residues coloured 
red on TanSH2 structure (gray, PDB ID: 4DGP). In order of highest to 
lowest CSP: 6Trp, 7Phe, 105Ala, 8His, 104Cys, 181Val, 79Gln, 75Ala, 
11Ile and 32Arg. The majority of CSPs are located on one face of the 
nSH2 domain or the interSH2 linker region.  
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Conclusions 
cSH2-Shp1 Yields a Well Resolved, Assignable NMR Spectrum 
The cSH2-Shp1 construct produces a high quality 15N HSQC. Structures of the 
former have already been solved by solution NMR in free (PDB ID: 1X6C) and 
complexed with peptide (PDB ID: 2YU7), though backbone assignment data has not 
been deposited in the BMRB database. 
The cSH2-Shp1, being highly related to the Shp2 SH2 domains, was used for NMR 
titration experiments. This is further discussed in Chapter 5. However, the nSH2-
Shp1 construct did not produce an adequate yield for NMR studies and so cannot be 
used for comparison in the present study. This is corroborated by another study 
which also found nSH2-Shp1 insoluble (Coxon et al., 2012). 
 
Near-complete Backbone Assignments Were Obtained For All Shp2 SH2 
Constructs 
94, 97 and 95% of the WT nSH2, cSH2 and TanSH2 domain residues of Shp2 were 
assigned in the present study. Additional aliphatic carbon assignments were obtained 
for nSH2 and cSH2-Shp2. Validation of the secondary structure elements of the 
isolated SH2 domains via TALOS+ and comparison with existing crystallographic 
data confirms the assignments.  
Published backbone assignment data of cSH2-Shp2 (Rubio et al., 2013) is consistent 
with data collected and analysed in the current study, including the non-
completeness of sequence-specific assignment. Aside from minor differences in 
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buffer composition, their study was performed in a similar manner to the present 
investigation, with additional side-chain proton assignments as well as assignments 
for a peptide-bound form of cSH2-Shp2. Secondary structure prediction performed by 
the Rubio et al. using the in-program module DANGLE within CCPN Analysis yielded 
similar results to current crystal data and TALOS+ predictions produced from the 
current study.   
 
The Individual SH2 Domains of Shp2 Show Conformational Flexibility 
A number of residues in both SH2 domains display a second, weaker peak 
corresponding to an alternate conformational state. 105A is an exception as it 
displays not only one but two additional peaks in the HSQC and 3D data. 105A is 
located in the interSH2 linker, but is found in the N-terminal loop for cSH2-Shp2. 
However, more secondary peaks were observed for nSH2-Shp2 than its C-terminal 
counterpart. This is strange as characterisation of Shp2 SH2 domains earlier in the 
study found more peaks than expected in the cSH2 than the nSH2 domain. Whether 
this is improper peak picking or a phenomenon dependent on other factors not taken 
into consideration here can be investigated further. The conformational changes 
observed here could be of biological significance, as it is hypothesised that the nSH2 
domain undergoes large scale reorientation to allow PTP activation and as such, 
conformational flexibility may facilitate this (Keilhack et al., 2005). 
Interestingly, 35K of the nSH2 domain and 141Q of the cSH2 domain are both 
located at the same position in the BC loop, 3 residues C-terminal of the invariant 
arginine residue. In the present study, both 35K and 141Q were unassigned in 
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individual and tandem SH2 domain 3D spectra. This is likely due to motional 
dynamics at an intermediate timescale causing line broadening. The BC loop is often 
highly flexible, as observed in the temperature factors of various SH2 domain crystal 
structures (Farrow et al., 1994), as well as solution NMR structures displaying little 
NOE information in these regions (Narula et al., 1995).   
5R and 111R are also in homologous positions for the n and cSH2 domain and form 
hydrogen bonds with residues adjacent in sequence as well residues within the PTP 
domain. It is possible that restoration of these hydrogen bonds may alter the 
exchange dynamics of 5 and 111R. The absence of the Shp2-PTP domain likely 
perturbs the WT structure and dynamics of these residues. 
  
Comparisons of the 2D 15N-HSQCs of nSH2 and cSH2 domains of Shp2  
Two peaks are observed furthest downfield in the  in each 15N-HSQC spectrum of the 
individual SH2 domains of Shp2. As described earlier in this chapter, at least one of 
these peaks likely belong to the Hε1 resonances of 6W and 112W (of nSH2 and cSH2 
Shp2 respectively) residues. However, it is entirely possible that both resonances in 
each spectrum correspond to main-chain amide resonances of other amino acids 
that are uniquely shifted to this region of the spectrum. That said, based on the 
current data, it is very likely these peaks correspond to Trp side-chains. Since each 
Shp-2 SH2 spectrum contains double the number of Trp side-chain peaks as 
expected, unambiguous assignment of these in the TanSH2 construct are impossible 
based on current data. Differences in the position of these resonances in the single 
and tandem SH2 also preclude Trp side-chain assignment in the latter. 
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 Collection and analysis of other NMR experiments, including 3D data, or site-
directed mutagenesis of the Trp residues and subsequent collection of 15N-HSQCs of 
said mutants can definitively assign these strange resonances.  
 
The Cysteines of All Shp2 SH2 Constructs are Reduced 
TanSH2-Shp2 contains two cysteine residues: 104C in the inter-SH2 linker and 174C 
in the C-terminus of sheet βD. Both cysteine sulphur atoms are 14.66 Å away from 
one another in full length crystal structures (PDB IDs: 4DGP, 2SHP) and thus cannot 
form intradomain disulphide bridges. However, the TanSH2-Shp2 construct, lacking 
the PTP domain, may display increased domain motions, allowing for positioning of 
both cysteines in proximity to one another. However, since Shp2 is normally found in 
the cytosol i.e. a reducing environment, it is unlikely that a 104C-174C disulphide 
bridge could be formed, especially as both cysteines are at least partially solvent 
exposed. 
An analysis of cysteine atom chemical shift data can give insight into the redox state 
of the cysteine residue(s) in question (Sharma & Rajarathnam, 2000). More 
specifically, CB shifts < 32 ppm indicate a reduced cysteine, > 35 ppm for an 
oxidised cysteine. In all SH2 constructs, CB shifts for 104C and 174C are around 28 
ppm. No marked differences are observed between single SH2 construct CA or CB 
shifts and the TanSH2 construct.  
The reduced state of 104 and 174C is in contrast to a paper outlining the crystal 
structure of TanSH2-Shp2 (Eck et al., 1996) which was found to harbour a disulphide 
bridge between both cysteines under highly reducing (10 mM DTT) conditions, 
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though the authors suggest this may not be the case in vivo. Based on 3D solution 
NMR data under reducing conditions (0.5 mM TCEP), cysteines 104 and 174 are 
both reduced and therefore unlikely to form covalent linkages between them. 
However, the TanSH2-Shp2 structure was solved in the presence of PDGFR-1009 
phosphorylated peptide. Complex formation may induce a conformational change 
bringing both cysteines closer in space for disulphide bridge formation, though a 
mechanism for oxidation under these conditions remains uninvestigated. PTP-
containing pathways can regulated by fluctuating redox potential and though current 
research implicates the conserved active site cysteine as the commonly modified 
residue, other solvent exposed cysteines may be redox regulated, perhaps to fine 
tune spatiotemporal protein-protein interactions (Karisch et al., 2011). 
 
The His-tag Perturbs the Chemical Environment of Specific Residues of 
TanSH2-Shp2 
Over 50% of the N-terminal His-tag of His-TanSH2-Shp2 remain unassigned and are 
located at the extreme N-terminus. Assignments were however, obtained for the TEV 
cleavage site. Many structural studies of proteins note that residues located at termini 
are often not observed in electron density for crystal structures and partially assigned 
in NMR studies due to differences in residue-level dynamics allowing for peaks to be 
observed in fast chemical exchange. Even still, assignment of extreme terminal 
residues is uncommon, though the C-terminal residue usually displays a strong peak 
in HSQC and some 3D spectra.  
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Removal of the His-tag by repeated TEV cleavage reactions and subsequent NMR 
15N HSQC data collection yielded a similar spectrum to His-TanSH2 Shp2, though 
chemical shift mapping revealed CSPs within the nSH2 domain with preference to 
the interfacial region between it and the interSH2-linker and cSH2 domain. The 
partial assignment of the His-tag in His-TanSH2 Shp2 could explain this 
phenomenon as the tag may have reduced mobility within its constrained 
environment, leading to fast exchange rates amenable to backbone assignment. 
The His-tag is unlikely to interfere with ligand binding as the majority of perturbed 
residues are located outside of the pTyr and +3 pockets.  
The assigned HSQCs of nSH2, cSH2 and TanSH2-Shp2 provide an avenue for 
exploring various ligand interactions by solution NMR and yielding rich, residue-
specific interaction data. In Chapter VI, the work presented here is used to 
investigate a biological problem. 
154 
 
CHAPTER V 
SAXS CHARACTERIZATION OF 
SHP2 SUB-DOMAINS AND 
MUTANTS. 
 
To date, almost all high resolution structural information regarding Shp2 has come 
from X-ray crystallography. This study combines low-resolution solution structural 
data with high resolution crystallographic data to investigate Shp2 behaviour in the 
basal and hyperactivated states. 
 A number of constructs of Shp2 were tested by SAXS at various synchrotron 
sources in Europe over the course of this project. The following sections concern the 
in-depth biophysical analysis of the domains of Shp2 as well as full-length constructs. 
Validation of available crystallographic data with SAXS data in solution will allow the 
assessment of current structural models. 
 
SAXS Analysis of the Tandem SH2 Domain of Shp2 
SAXS analyses of the His and ΔHis-TanSH2 Shp2 were performed to complement 
existing crystallographic data and recently collected NMR data. The sections below 
reveal insights into these isolated domains in their solution state. 
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His-TanSH2 Shp2 
 SAXS data of His-TanSH2 Shp2 were collected at concentrations of 2, 4 and 8 
mg/ml. A summary of the data can be found in Figure 5.1 A. Data quality at low-
angles were similar for all three concentrations and showed no signs of interparticle 
effects or aggregation. 
Inspection and analysis of the data as a Guinier plot (ln[I(q)] vs. q2) allows for 
approximation of I(0) and Rg which is calculated alongside Dmax and porod volume 
(Vp)  using AUTORG and AUTOGNOM within the ATSAS package (Petoukhov et al. 
2012) (Figure 5.1 B). Although the Guinier fit at each concentration (Figure 5.1 C) 
does not suggest any obvious aggregation or interparticle effects, the 2 mg/ml 
sample shows markedly different Dmax, I(0) and porod volume (Vp) values in 
comparison to the 4 and 8 mg/ml datasets. Closer inspection of the low-q range of 
2.2 mg/ml revealed large errors in the data and as such the 8 mg/ml data set was 
used for downstream analysis. 
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Figure 5.1: His-TanSH2 Shp2 SAXS Data. 
(A) Buffer Subtracted His-TanSH2 Shp2 SAXS Data. The low-angle data 
points are similar throughout all concentration tested; the wide-angle data 
points decrease in quality with increasing concentration. (B) Guinier plot 
and fit of all three concentrations tested. Slopes indicate all samples are 
free of interparticle interference and aggregation. Data from the 8 mg/ml 
set was used for downstream analysis. (C) Table of calculated parameters 
from SAXS data. Increases in concentration have an effect on calculated 
parameters, most markedly the I(0) and Porod volume. Data have not 
been normalized. 
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Homology modelling of His-TanSH2-Shp2 
Comparison of the experimental SAXS data of His-TanSH2-Shp2 and available 
crystal structures is hampered by the amino acid sequences of the constructs not 
matching the crystallographic data, which may affect the results of analyses. His-
TanSH2-Shp2 contains an N-terminal His-tag and TEV cleavage site, whereas the 
crystal structure does not. In addition, WT residues 1-3 inclusive are not part of His-
TanSH2-Shp2. For these reasons, a homology modelling approach was used to 
generate high resolution models using available crystal coordinates of the tandem 
SH2 domains of Shp2 (PDB IDs: 2SHP and 4DGP) as restraints. I-TASSER (Zhang, 
2008; Roy et al., 2010) returned five models; the top model having a confidence 
score of -0.23 where the range is -5 to 2. The higher the confidence score the more 
reliable the model, and this is also validated by the template modelling or ‘TM–score’ 
(Zhang & Skolnick, 2004) which was 0.68 ± 0.12 for the top model. A score of > 0.5 
indicates a model of correct topology. In addition, the model had 5107 other similar 
models within its cluster, meaning these conformations were generated more 
frequently than others (for comparison, the next best model only had 2480 similar 
models and a confidence score of -0.95). Visual inspection of the structure generated 
shows correct topology for both SH2 domains and minimal steric clash (Figure 5.2 
C). Based on this, the top scoring I-TASSER model will be used for further analyses. 
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Figure 5.2: Model Fitting of His-TanSH2 Shp2 SAXS Data.  
(A) SAXS data of His-TanSH2-Shp2 (black) and CRYSOL simulated 
curves of: I-TASSER His-TanSH2-Shp2 (χ2=1.53, green), TanSH2-Shp2 
domain of 2SHP (χ2=1.002, yellow) and 4DGP (χ2 =0.962, light blue). (B) 
Kratky plot of His-TanSH2-Shp2 SAXS Data, highlighting the presence of 
a globular domain and flexible region. (C) I-TASSER homology model of 
His-TanSH2-Shp2 (blue: His-tag, red: nSH2, grey: inter-SH2 linker, 
yellow: cSH2)  
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CRYSOL Simulation 
CRYSOL was used to generate simulated SAXS curves of three sets of coordinates 
and compare them to the experimental SAXS data acquired of His-TanSH2-Shp2. 
These are the two crystal structures of tandem SH2 domains (PDB IDs: 2SHP and 
4DGP) and the I-TASSER model of His-TanSH2-Shp2. By comparing the overall fit of 
the simulated SAXS data with the experimental data, as well as inspection of the χ2 
value, one can ascertain the extent of similarity between the two datasets and thus 
judge similarity between data collected in solution versus crystal conditions.  
When compared with the experimental SAXS curve of His-TanSH2-Shp2, a  good fit 
is observed with all three CRYSOL curves (Figure 5.2 A, 2SHP orange, 4DGP light 
blue and I-TASSER model green), especially at the low-q regions, indicating the 
overall size and shape match well. The χ2-values of 2SHP and 4DGP fitted to the 
experimental data are 1.002 and 0.962, respectively. However, the χ2-value of the I-
TASSER model, which encompasses the entire sequence used in the SAXS study, is 
1.53, a worse fit than the two models that do not take the full sequence into account. 
Visual inspection of the I-TASSER SAXS curve with that of the experimental data 
shows a slight mis-alignment in the q-range of 1-2 nm-1, and explain the mismatch in 
χ2.  
CRYSOL calculates curves from static structures and it is possible the lower fit 
observed for the homology model is due to flexibility in the system not accounted for. 
The good fit between simulated curves of TanSH2 structures lacking an N-terminal 
His-tag is surprising, but could be suggestive of His-TanSH2-Shp2 forming structures 
very similar to those in 2SHP and 4DGP despite the presence of a His-tag. It could 
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also suggest that the His-tag, being unfolded and only 10% of the entire construct 
sequence, does not contribute much to X-ray scattering processes overall and 
instead, the majority of SAXS information derives from the folded domains.  
A Kratky plot of the experimental data (Figure 5.2 B) contains a bell shaped curve 
with a tail region increasing in intensity at higher-q angles, suggesting a mixture of 
both globular and flexible character of the particle and though qualitative, warrants 
further investigation. 
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Ab initio Shape Determination 
To investigate the overall shape of His-TanSH2 in solution, ab initio shape 
reconstruction was performed using SAXS data. DAMMIF (Franke & Svergun, 
2009a) was used to generate 10 envelopes, all of which had the same overall shape, 
a rough L-shaped globular particle with a small protrusion at one end (Figure 5.3). 
Averaging and filtering of these envelopes using DAMAVER and DAMFILT (Volkov & 
Svergun, 2003) produced a single envelope which was then used in automatic fitting 
against the I-TASSER model of His-TanSH2 Shp2 via SUPCOMB (Kozin & Svergun 
2001), which superimposes any two structures. SUPCOMB gave three optimum 
orientations, all of which are shown in Figure 5.3, with their corresponding NSD 
values to the far right. NSD allows one to assess the fit between two 3D models; 0 is 
a perfect fit and > 1 means the models differ systematically from one another. B(i) is 
the best fit, with an NSD value of 1.57, though B(ii) and (iii) have comparable NSD 
values of 1.60 and 1.62. Visual inspection of the superimposed His-TanSH2-Shp2 
structure with the DAMMIF-derived envelope demonstrated all three orientations of 
the tandem SH2 domain fit within the final envelope well, though it is impossible to 
discern exactly which SH2 domain fits into which spherical portion. Taking B(i) as the 
reference, B(ii) differs in that the I-TASSER model is rotated about its vertical axis 
180°, so that the SH2 domain incorporated into one of two spherical portions is the 
obverse to the previous fit. B(iii) differs from B(ii) in that there is an 180° rotation 
about the horizontal axis. Presumably a 4th orientation may involve 180° rotation 
about the horizontal axis for B(i). Overall, all orientations fit well visually and 
corroborate the fits of the CRYSOL simulated curves. However, the χ2 and NSD 
values between the SAXS data and homology models and crystal structures suggest 
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that a single rigid model may not be adequate to describe what is happening in 
solution. 
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Figure 5.3: Ab initio Modelling of His-TanSH2-Shp2. 
Averaged and filtered ab initio bead model of His-TanSH2-Shp2 with top 
three (i.-iii.) automated fits of I-TASSER homology model (grey: surface 
representation of ab initio SAXS bead model, blue: His-tag, red: nSH2, grey 
loop: inter-SH2 linker, yellow: cSH2). Far right: NSD values of automatic fits 
generated by SUPCOMB, 0 being an ideal fit.  
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ΔHis-TanSH2 Shp2 
The N-terminus of TanSH2-Shp2 is situated in between both SH2 domains. It was 
reasoned the presence of a His-tag may interfere with the interdomain interface. To 
address this question,  TanSH2-Shp2 was TEV protease treated  and SAXS 
datawere collected at 2.2, 5.9 and 9.9 mg/ml concentrations and summarised in 
Figure 5.4 A. The difference in data quality is likely not protein specific but due to 
data collection at two different synchrotron sources.  
The Guinier plots of the various concentrations (Figure 5.4 B) in the 0.05-0.3 q2 
region indicate the absence of aggregation and any obvious interparticle interference, 
though the 9.9 mg/ml dataset slopes less than the other two concentrations tested, 
suggesting slight interparticle effects with the latter two. Inspection of the parameters 
calculated from the data using AUTORG and AUTOGNOM shows minor differences 
in Rg , I(0) and Dmax. The I(0) is proportional to the molecular weight of the scattering 
particle but requires calibration against a particle of known molecular weight. Using 
BSA as a standard the calculated MM is 20.8 kDa; an MM of 24.2 kDa is expected, a 
14% error. Owing to high data quality at low-q and the absence of obvious 
interparticle effects, the 9.9 mg/ml dataset was chosen for further analysis. 
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Figure 5.4: ΔHis-TanSH2 Shp2 SAXS Data. 
(A) Buffer Subtracted ΔHis-TanSH2-Shp2 SAXS Data. The low-angle 
data points are similar throughout all concentration tested, whereas the 
wide-angle data points increase in quality with concentration. (B) Guinier 
plot and fit of all three concentrations tested. Slopes indicate all three 
samples are free of interparticle interference and aggregation, and data 
from 4 and 8 mg/ml are of high quality. These two data sets were merged 
for downstream analysis. (C) Table of calculated parameters. Porod 
volume and I(0) estimates display concentration dependence, suggestive 
of interparticle effects.  
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As stated in the previous section, comparison of the experimental curve with 
simulated curves from available crystal structures can give insights into the 
differences in shape and overall fold between the two states. The same crystal 
structure coordinates for the tandem SH2 domain of Shp2 that were used in the 
analysis of His-TanSH2-Shp2 SAXS data were used here and were derived from 
PDB IDs 2SHP and 4DGP. In addition, a homology model best representing the TEV 
protease cleaved primary sequence of this TanSH2-Shp2 was generated with I-
TASSER. The main difference between the homology model and the crystal structure 
of TanSH2-Shp2 is in the N-terminal region, where the N-terminal 3S (according to 
WT sequence) in the latter is removed and residues S and M are modelled (coloured 
blue in Figure 5.5 C). Comparisons of the CRYSOL simulated curves for these 
structures and the experimental SAXS data of ΔHis-TanSH2-Shp2 are presented in 
Figure 5.5 A. Visual inspection of the curves show very good fitting in the low-q 
region with deviations appearing from q=1.5 nm-1 onward for all three simulated 
curves. χ2 fits suggest 2SHP has the best fit (χ2=2.071), then 4DGP (χ2=2.297) and 
the I-TASSER model (χ2=2.611). The simulated curve of 4DGP has the worst fit at 
the q region of 2.5 nm-1, whereas the I-TASSER model has the worst fit at the high-q 
region (3 nm-1onwards).  
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Figure 5.5: Model Fitting of ΔHis-TanSH2 Shp2 SAXS Data.  
(A) SAXS data of ΔHis-TanSH2-Shp2 (black) and CRYSOL simulated curves 
of: I-TASSER His-TanSH2-Shp2 (χ2=2.969, blue), TanSH2-Shp2 domain of 
2SHP (χ2=2.071, yellow) and 4DGP (χ2 =2.297, red). (B) Kratky plot of ΔHis-
TanSH2-Shp2 SAXS Data, highlighting the presence of a globular domain 
and flexible region. (C) I-TASSER model of ΔHis-TanSH2-Shp2. Domains are 
coloured as follows: Non-wild type residues: blue, nSH2: red, inter-SH2 linker: 
grey, cSH2: yellow. N and C represent n-terminus and C-terminus.  
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Ab initio shape determination for the ΔHis-TanSH2 Shp2 
In order to determine the ab initio shapes of ΔHis-TanSH2-Shp2 based on the SAXS 
data, DAMMIF was utilised. 10 models were generated, the superimposition of which 
reveals a high similarity. These envelopes were averaged and filtered as previously 
described, producing a single dumbbell-shaped envelope. Figure 5.6 shows the final 
envelope automatically fitted against the ΔHis-TanSH2 Shp2 I-TASSER model, 
displaying the three orientations with the lowest NSD values. The best fit, with an 
NSD-value of 1.36, seems to be the optimum superimposition by visual inspection. In 
comparison, the other two orientations produced NSD-values of 1.46 and 1.60, 
rotated in the same fashion as the models in Figure 5.6.  
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Figure 5.6: Ab initio Modelling of ΔHis-TanSH2-Shp2. 
Averaged and filtered ab initio bead model of His-TanSH2-Shp2 with top 
three automated fits of I-TASSER homology model (grey: surface 
representation of ab initio SAXS bead model, blue: His-tag, red: nSH2, 
grey loop: inter-SH2 linker, yellow: cSH2). Far right: NSD values of 
automatic fits generated by SUPCOMB, 0 being an ideal fit. 
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Hints at TanSH2 Flexibility in Solution  
Qualitative assessment of a Kratky plot of the experimental data (Figure 5.5 B) 
suggests the presence of both globular and flexible domains as there is a bell shaped 
curve at the beginning corresponding to the former and a rising tail at higher q that 
eventually plateaus corresponding to the latter (Doniach, 2001). Given the poor fits 
between crystal structures, homology models and the SAXS data for ΔHis-TanSH2-
Shp2 and the Kratky plot suggest flexible regions, it is possible  that a single rigid 
model cannot fully explain the SAXS data, which gives rise to the poor model fitting 
observed. In order to full explain the SAXS data for ΔHis-TanSH2-Shp2, flexibility 
must be accounted for. 
 
EOM Analysis of ΔHis-TanSH2-Shp2 
 
EOM analysis of ΔHis-TanSH2-Shp2 was performed, allowing flexibility in the 8 
residue interSH2-linker region, N-terminal S-M residues left over post-TEV protease 
cleavage and the CD loop of cSH2-Shp2. Results are presented in Figure 5.7. The fit 
is excellent, with a chi-squared value of 1.102, better than the values obtained for 
CRYSOL back calculated curves. Inspection of the distributions of Rg and Dmax reveal 
that, based on EOM, ΔHis-TanSH2-Shp2 takes on a broad range of states spanning 
extended and compact. Flexibility of the CD loop and interSH2 linker yielded an 
excellent fit. 
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Figure 5.7: EOM Analysis of ΔHis-TanSH2-Shp2. 
Fit of ΔHis-TanSH2-Shp2 SAXS data (black) against averaged curve 
of flexible ensemble selected by EOM (red). Χ²=1.102. (B) and (C) 
Rg and Dmax distributions respectively, of optimized ensemble from 
EOM. Both indicate ΔHis-TanSH2-Shp2 samples a range of compact 
and extended states in solution.  
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SAXS Analysis of the Catalytic domain of Shp2 
SAXS of PTP-Shp2 was performed at ESRF at 2.5, 5.3 and 10.4 mg/ml 
concentrations. (Figure 5.8) The individual buffer subtracted scattering curves are 
shown in Figure 5.8. Inspection of the Guinier plots show a downward-turn of the 
linear fit at 10.4 mg/ml, with respect to other concentrations. This indicates 
aggregation of the sample and should not be used for subsequent analyses, further 
validated by inspection of the invariant parameters which all increase with 
concentration.  
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Figure 5.8: PTP-Shp2 SAXS Data. 
(A) Buffer Subtracted PTP-Shp2 SAXS Data. The low-angle data points are 
similar throughout all concentration tested, whereas the wide-angle data points 
increase in quality with concentration. (B) Guinier plot and fit of all three 
concentrations tested. Slopes seem to indicate highest concentration is 
aggregated, therefore data derived from low-q unreliable for further analysis. 
Data from 5.3 and 2.5 mg/ml are of high quality. These two data sets were 
merged. (C) Table of calculated parameters, in which concentration-dependent 
increases are observed with increasing concentration.  
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Merging of the 2.5 and 5.3 mg/ml datasets generated a SAXS curve free from the 
effects of aggregation (Figure 5.9 A) and similar Rg, Dmax and Porod volume values to 
the lowest concentration, assumed to be the least susceptible to aggregation. 
Interestingly, qualitative inspection of the q2 > 3 region of the Kratky plot of the 
merged SAXS data (Figure 5.9 B) suggests a degree of flexibility within the PTP-
Shp2 particle. 
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Figure 5.9: Merged SAXS Data of PTP-Shp2. 
(A) Merged SAXS data of PTP-Shp2 used for further analyses. (B) Kratky plot of 
merged SAXS data of PTP-Shp2, indicating a globular particle with a degree of 
flexibility.  
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Comparison of the merged SAXS data with existing structural models may yield 
insights into the solution state of the catalytic domain. CRYSOL was used to 
generate simulated curves of the catalytic domain of Shp2 with an accessible active 
site (PDB ID: 3B7O), as well as a simulated curve of full length Shp2 (PDB ID: 
4DGP) lacking N-terminal residues 3-258 (hereby referred to as 4DGP-PTP) (Figure 
5.10). Superimposition and visual inspection of the simulated curves with the merged 
SAXS data reveals a good fit at the low q region (0.06-1 nm) but gradually worsening 
from q=1.5 nm onwards. Also, the χ2 values between 4DGP-PTP or 3B7O and the 
SAXS data are 3.503 and 3.373 respectively. This suggests that there are 
differences in the global shape of PTP-Shp2 in the solution state compared to the 
crystal structures. Indeed, the theoretical Rg values calculated from 3B7O and 4DGP-
PTP are 2.11 and 2.12 nm respectively, with the experimental Rg being 2.401 ± 0.009 
nm suggesting that in solution PTP-Shp2 is less compact than the available crystal 
structures tested.  
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Figure 5.10: Model Fitting PTP-Shp2 SAXS Data.  
Merged SAXS curve of PTP-Shp2 (black) was fitted against CRYSOL 
simulated curves of the catalytic domain of Shp2 with accessible active site 
(Yellow, χ2 =3.503, PDB ID: 3B7O) and catalytic domain of Shp2 lacking 
crystal coordinates between residues 3-258, dubbed 4DGP-PTP in main 
text (Blue, χ2 =3.373, PDB ID: 4DGP).  
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Differences between the simulated intensities and Rg values derived from the 
experimental and 3B7O simulated curves may be attributed to the complete absence 
of crystal coordinates for three regions: the 11 N-terminal residues (SMAETTDKVKQ; 
underlined are non-WT residues), a loop region on the opposite side of the catalytic 
site separating two beta-sheets (314-324, FETKCNNSKPK) and the extreme C-
terminal residue, an isoleucine. Since these regions absent, they are not simulated 
by CRYSOL and therefore do not contribute to the final simulated curve, a 
discrepancy should be expected. The 4DGP-PTP crystal structure, though missing 
the C-terminal isoleucine, encompasses the loop regions from 314-324 as well as the 
aforementioned N-terminal residues (apart from the non-WT SM residues). One 
major structural difference between 3B7O and 4DGP-PTP concerns the N-terminal 
helix of the PTP domain, which is shifted around 50° away  (Figure 5.11) from the 
rest of the domain in the former, but is packed close in the latter, likely due to the 
presence of the SH2 domains during crystallisation. The resultant simulated curve fits 
the experimental data in a similar manner to 3B7O, though there is a better fit at the 
higher q-region (2 nm-1 onwards). χ2-values for both 3B7O and 4DGP-PTP are 3.50 
and 3.37, indicating the latter structure fits better. However, a χ2-value of 3.37 is a 
relatively poor fit and demonstrates that the back-calculated envelopes produced by 
CRYSOL do not fit the experimental data and thus current structural models cannot 
explain the SAXS data well, suggesting that in solution PTP-Shp2 adopts a structure 
somewhat different to that observed in the crystal structures. 
One method that could resolve the missing loop regions of 3B7O is rigid body 
modelling, where available atomic models and experimental SAXS data are provided 
to the program BUNCH, part of the ATSAS package (Petoukhov & Svergun, 2005).  
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Figure 5.11: Superimposition of Shp2 PTP Domain Crystal Structures. 
(A) Superimposition of crystal structures of the PTP domain ONLY (lilac, PDB 
ID: 3B7O) and PTP domain crystallised as part of a near full-length protein 
(yellow, PDB ID: 4DGP). The WT N-terminal unstructured loop of 4DGP 
(green) was included in the 3B7O construct during crystallisation but was not 
modelled in the final structure of the latter. N: N-terminus, C: C-terminus. (B) 
Zoomed and reoriented region of (A) highlighting the stark differences in N-
terminal helix position in both crystal structures.  
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When provided with these data, BUNCH models missing residues of the model to be 
fitted in as ‘dummy residues’ which act as a placeholder for the amino acid residue. 
Steric clashes and improper arrangements are penalized, as would occur in a 
structure calculation. Placement of the dummy residues and comparison of simulated 
curves of the resultant model against the experimental data are performed until 
convergence on a model with the least penalties and lowest χ2 is created.  
BUNCH was run with 3B7O as the starting model, the merged SAXS curve as the 
experimental data and the missing loop regions defined beforehand. The atomic 
model was kept rigid throughout each successive BUNCH run, which yielded several 
models with loops varying in their relative positions to one another but with the rest of 
the PTP domain holding the same structure. Figure 5.12 A shows a representative 
BUNCH model with a χ2-value of 2.470; the corresponding fit is shown in Figure 5.12 
B. Seven independent BUNCH models were generated, with an average χ2-value of 
2.433, all of which are superimposed in Figure 5.13, highlighting the relatively high 
mobility of the loops in question. The mobility of the BUNCH-derived dummy residues 
is corroborated by the B-factors observed in the crystal structure of the residues 
adjacent to them, highlighted by the red regions on 3B7O in Figure 5.12 C. Though 
this is not definitive, this does explain the multiple loop conformations calculated by 
BUNCH, as well as the absence of definitive density of these regions in the 3B7O 
crystal structure, which is usually assumed to be due to high degrees of disorder.  
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Figure 5.12: Modelling of Missing Loops into PTP-Shp2 structure using 
BUNCH. 
(A) Ribbon diagram of PTP-Shp2 crystal structure (PDB ID: 3B7O). Each 
sphere represents a missing residue modelled using experimental SAXS data 
and BUNCH. Red areas indicate residues important for catalysis. (B) Merged 
SAXS data of PTP-Shp2 (black) were fitted against CRYSOL simulated curve 
of representative BUNCH model (red) in (A) yielding Χ2  =2.470. (C) 
Crystallographic temperature factors for 3B7O coloured on cartoon putty 
diagram of structure for low (dark blue-cyan), medium (green-yellow) and high 
(orange-red) areas of disorder for PTP-Shp2. Structure oriented as in (A).  
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Figure 5.13: The Missing Loops of PTP-Shp2 May Be Flexible.  
PTP-Shp2 cartoon diagram of multiple aligned BUNCH models. The two 
modelled loop regions are indicated by asterisks and are depicted in 
various colours to highlight flexible nature.  
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Interestingly, two BUNCH simulations where domains either side of the modelled 
loop were allowed to freely rotate and move with the loop yielded models with χ2-
values of 1.119 and 1.046 (Figure 5.14). Though the structures generated differ 
substantially from the original crystal structure, an excellent fit between the 
experimental and simulated data curve (Figure 5.14 A)   are observed between q-
regions 0.05-1.5 nm, with a reasonable fit thereafter in the high-q regions. The 
flexible models generated by BUNCH (Figure B and C) show a disrupted active site 
in that the KNRY-loop containing region is now positioned far from the catalytic site. 
The flexible models are not accurate representatives of the solution state since 
activity would be severely impaired, which is not the case when PTP-Shp2 is 
assayed for enzyme activity. However, the fits between the highly flexible model and 
the experimental data are much better than CRYSOL fits of the crystallographic data 
and SAXS data, suggesting that there may be flexibility elsewhere in PTP-Shp2 that 
has not been accounted for. 
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Figure 5.14: Flexible Models of PTP-Shp2 Fit the SAXS Data. 
(A) Overlay of merged SAXS data of PTP-Shp2 with CRYSOL simulated 
curve of best-fitting model generated by BUNCH (red, χ²= 1.046). (B) and 
(C): Cartoon representations of flexible models generated by BUNCH with 
original 3B7O PTP-Shp2 structure aligned (grey). Spheres represent 
modelled residue missing from 3B7O crystal structure. χ² values for (B) 
and (C) are 1.119 and 1.046 respectively. Red region indicates PTP 
signature motif involved in catalysis. 
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Ab initio shape determination of PTP-Shp2 
DAMMIF was used to generate 10 envelopes (Figure 5.15). Visual inspection of the 
envelopes indicates two populations. Seven have the general architecture of an 
oblate ellipsoid with a 42 Å extension protruding almost perpendicular from the 
surface, hereby referred to as DAM-env-1. The other three resemble an oblate 
ellipsoid of similar dimensions as the previous seven models but with an extension of 
25 Å protruding from one end of the major axis, hereby referred to as DAM-env-2. 
Interestingly, this extension is globular in nature but with an apparent centre of 
decreased bead density. Averaging and dummy atom outlier removal of the 10 
envelopes using the programs DAMAVER and DAMFILT (Volkov and Svergun, 
2003) yields an ellipsoid measuring 70 Å on it’s major axis and between 35- 40 Å on 
its minor axis.  Automatic superimposition of the DAMMIF envelope with the original 
3B7O crystal structure using SUPCOMB yields an NSD value of 1.718, which 
suggests a reasonable similarity between the two. However, automatic 
superimposition of the rigid BUNCH model of PTP-Shp2 with the same DAMMIF 
envelope leads to a higher NSD value of 2.027, suggesting the addition of the 
missing loop regions (and flexibility) leads to a worse fit.  
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Figure 5.15: Ab Initio Models of PTP-Shp2 generated by DAMMIF.  
Bead model representation of PTP-Shp2 envelopes generated by 
DAMMIN. Each colour represents one model. (A) contains 1st pool of 
superimposed models (seven total). (B) contains 2nd pool of superimposed 
models (three total). (C) Models averaged and filtered using DAMAVER 
and DAMFILT respectively to yield final envelope. PTP-Shp2 crystal 
structure (Green cartoon, PDB ID: 3B7O) automatically fitted with envelope 
using SUPCOMB; NSD= 1.718. 
187 
 
Fitting of the BUNCH model with DAM-env-1 and 2 leads to NSD values of 2.20 and 
2.08 respectively, both of which are reasonable fits, comparable to the averaged 
DAMMIF envelope fitted against the BUNCH model. Both DAM-env models 
superimposed with the BUNCH model can be seen in Figure 5.16 and demonstrate 
that both envelopes can accommodate the BUNCH model well, with no secondary 
structure elements wildly misplaced outside of the envelope. The distance between 
the tip of DAM-env-1 and the surface of the ellipsoid is about 44 Å. When this 
distance is taken from the N-terminal dummy residue in the BUNCH model (Ser), the 
residues between 42-45 Å away along the polypeptide chain are Tyr263 and Ser264. 
These two loop regions reside within the loop connecting the N-terminal helix to the 
next kinked helix; the possibility arises that this region could be responsible for the 
proposed dynamic nature of the SAXS data. B-factor values for Tyr263 and Ser264 
are 23.59 and 22.43 Å2 respectively, which are 17.4 and 11.6% higher than the 
average across all protein atoms in the structure, 20.09 Å2. It is possible that these 
residues, or indeed the entire loop, may be flexible in solution in the absence of the 
tandem SH2 domain and contribute significantly to the flexible nature of PTP-Shp2. 
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Figure 5.16: BUNCH Model-fitting of PTP-Shp2 to Ab Initio 
Envelopes.  
The two distinct species of unaveraged DAMMIN models for PTP-Shp2 
were fitted with the previously generated BUNCH rigid body model. (A) 
BUNCH model fit with DAM-env-1 envelope, yielding an NSD of 2.20. (B) 
BUNCH model fit with DAM-env-2 envelope, yielding an NSD of 2.08.  
189 
 
Ensemble Optimisation Method – Analysis of PTP-Shp2 
To further assess the flexibility of PTP-Shp2 in solution, the Ensemble Optimization 
Method (Bernadó et al. 2007)was employed via ATSAS online (Petoukhov et al. 
2007). First, 10,000 rigid structures were generated with flexibility allowed at the N-
terminal residues (SMAETTDKVKQ; underlined are non-WT residues) and residues 
314-324 using the program RANCH. The merged buffer-subtracted SAXS curve was 
then used to select a subset of the pool of 10,000 structures that best fit the 
experimental data, and then calculate Rg and Dmax distributions for the pool and 
ensemble. Comparisons of the averaged ensemble fit, Rg and Dmax distributions may 
yield more insights into the dynamic behaviour of PTP-Shp2 in solution. 
The fit of the averaged curves (Figure 5.17) for the ensemble against the 
experimental data is poor in the low-q region (<0.6 nm-1), indicating the rigid 
ensemble yields particles of a smaller Rg than the experimental data suggests. A 
better fit of the curves is seen thereafter, gradually getting worse in the high-q region. 
The χ2 between experimental data and the EOM fit is 2.489, in agreement with the 
average BUNCH model χ2 of 2.433. Based on the EOM calculations, a rigid model of 
PTP-Shp2 in solution does not fit the experimental data, suggesting a more 
extended, rather than compact set of conformations being taken by the catalytic 
subunit.  
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The PTP-Shp2 Domain is Flexible in Solution 
A rigid model of PTP-Shp2 did not fit the experimental data in EOM simulations, nor 
for BUNCH rigid-body modelling. In addition, CRYSOL back-calculated curves of 
4DGP-PTP and 3B7O both yielded poor χ2 values toward the experimental data, and 
inspection of the theoretical Rg values between the crystallographic data and the 
experimentally determined Rg found that the latter is larger. Lastly, the Kratky plot of 
PTP-Shp2 experimental data is suggestive of a partially flexible particle. When taken 
together, the current evidence point toward PTP-Shp2 being flexible in solution. 
Flexibility is likely contributed from the N-terminal helix and disordered loop region, as 
well as highly mobile loop regions nearer the catalytic site of PTP-Shp2. Further 
optimization of EOM simulations is required for a more accurate understanding of the 
location(s) of PTP-Shp2 flexibility in solution.  
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SAXS Analysis of Full length Shp2 
Wild-type Shp2 
SAXS data of FL-Shp2 WT were collected at 1, 5 and 10 mg/ml and are summarised 
in Figure 5.18. All three buffer subtracted curves in Figure 5.18 A, when scaled, are 
near-identical in shape, particularly from the low to mid q-region (0.142-2 nm-1) 
though slight deviations in intensity are noticed thereafter presumably due to 
increased signal to noise in the low concentration samples. Calculation and plotting 
of all three datasets into a Guinier plot (Figure 5.18 B) demonstrate good linearity at 
q2 values 0.1-0.25 nm-2 but either side of this range the linear fit worsens; this is 
Figure 5.17: Initial EOM Analysis of PTP-Shp2 as a Rigid Model. 
Superimposition of PTP-Shp2 SAXS data (black) with ensemble-averaged 
simulated curve (blue) generated by EOM assuming a rigid structure, 
χ²=2.489, comparable to BUNCH fit (χ²=2.470). A rigid EOM model does 
not fit the experimental data well.  
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dubbed the ‘smiling’ Guinier but is very minute and can suggest aggregation. 
However, the extremely low q-region in the Log[I(q)] vs. q plot (Figure 5.18 A) (q< 
0.14 nm-1) does not reflect this conclusion, no differences were observed between all 
three concentrations, suggesting no repulsion or aggregation effects were present in 
the sample. AUTORG and AUTOGNOM did not detect aggregation during parameter 
calculations. However, some differences in parameters were observed and are 
summarised in Figure 5.18 C. Extrapolation of the data to infinite dilution generates a 
curve with comparable Rg and Dmax values (3.297 ± 0.028 and 10.3 nm respectively) 
to the 1 mg/ml dataset. The I(0) value is comparable to the 10 mg/ml dataset (71.329 
± 0.265), and the calculated Porod volume is lower than all three datasets, at 105.73 
nm3, approximately 3.2% lower than the 10 mg/ml dataset. This dataset was used for 
downstream analysis and is summarized in Figure 5.19. For individual SAXS curves 
of FL-Shp2 WT at all concentrations tested see Appendix figure 6.  
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Figure 5.18: SAXS Data of Full-length wild-type Shp2. 
(A) Buffer Subtracted Full-length wild-type Shp2 SAXS Data. The low-angle 
data points are similar throughout all concentration tested, whereas the wide-
angle data points decrease in quality with increasing concentration. (B) 
Guinier plot and fit of all three concentrations tested. Slopes seem to indicate 
all three samples are exhibiting a slight ‘smiling Guinier’, indicative of 
aggregation. (C) Table of calculated parameters from SAXS data. Note that 
although the Guinier plot in (B) demonstrates non-linear behaviour indicating 
aggregation, all calculated parameters decrease as concentration increases, 
suggesting interparticle interference.  
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Figure 5.19: Merged and Extrapolated SAXS Data of FL-Shp2 WT. 
(A) Merged and extrapolated to zero concentration SAXS data of FL-Shp2 
WT used for further analyses. (B) Kratky plot of SAXS data of FL-Shp2 WT 
from (A), indicating a globular particle with a degree of flexibility. (C) Table 
of parameters calculated with data from A; also see main text.  
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Ab initio Modelling of WT Shp2 
Information from AUTOGNOM was input into DAMMIF to produce 10 ab initio models 
of FL-Shp2 WT using default parameters. The simulated curves of each model were 
automatically fit against the experimental curve, allowing for initial visual inspection of 
the model quality. Fits were deemed satisfactory and inspection of the ab initio 
envelopes reveals a set of related solutions that superimpose well with one another . 
DAMCLUST, a program that aligns and clusters related shape/atomic models found 
a mean NSD value of 0.5, indicating a high similarity between all envelopes tested. 
Averaging and filtering of these models using DAMAVER and DAMFILT led to the 
envelope used in the next section. 
Automatic fitting of this envelope with a Shp-2 crystal structure (PDB ID: 4DGP) 
encompassing the nSH2, cSH2 and PTP domains using SUPCOMB results in an 
NSD value of 2.042 for the best solution. Two additional solutions to automatic fitting 
result in NSD values of 2.095 and 2.142 for solution 2 and 3. All three solutions from 
SUPCOMB fit the envelope with minimal areas of the Shp-2 structure residing 
outside this region, as seen in Figure 5.20. As the NSD values are similar for all 
SUPCOMB solutions and the envelope demonstrates a degree of rotational 
symmetry, it is impossible to elucidate the orientation of FL-Shp2 subdomains with 
confidence.  
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Figure 5.20: Automatic Fitting of FL-Shp2 WT SAXS Envelope with 
Shp-2 Crystal Structure. 
(i-iii) Three automatic fits of Shp-2 crystal structure, in descending order 
of NSD (PDB ID: 4DGP, grey: surface representation of ab initio SAXS 
bead model, Red: nSH2, Yellow: cSH2, Blue: PTP. Far left: NSD values of 
fits generated by SUPCOMB, 0 being an ideal fit.  
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I-TASSER was utilised to generate a homology model of the FL-Shp2 WT construct 
used in this study and is depicted in Figure 5.21 This was performed to model the 
missing C-terminal residues absent in the crystal structure. The top model has a C-
score of -0.95 and a TM-score of 0.59±0.14, the latter score indicating the correct 
topology of the model. Structural alignment of the model with crystal coordinates of 
WT Shp2 residues 1-532 (PDB ID: 4DGP) yields an RMSD of 1.511. The N-terminal 
hexahistidine tag and TEV protease cleavage site contain a nine residue α-helix, 
spanning His3-Val11. For the purpose of this study, the model of FL-Shp2 WT 
generated by I-TASSER is sufficient for further analysis. 
Automatic fitting of the I-TASSER FL-Shp2 WT homology model with the DAMMIF-
derived SAXS envelope yielded three solutions with NSD values of 1.984, 1.995 and 
2.029 for solution 1, 2 and 3 respectively (Figure 5.21). Like the automatic fitting of 
the Shp-2 crystal structure previously, the solutions differed in their orientation on 
both axes. The modelled N- and C-terminal residues do not fit well into the envelope 
in all three solutions generated, though the NSD values suggest a slightly better fit 
than the experimentally determined Shp-2 structure. In particular, solution 1 for the 
FL-Shp2 WT homology model is 0.058 lower in NSD than the Shp-2 crystal structure. 
The improvement is <3% and could be due to more of the DAMMIF envelope being 
filled by structural elements, regardless of their location within it. As the difference is 
minor, the orientation and location of the Shp-2 terminal portions require refitting 
against experimental data for a better fit. 
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Figure 5.21: Homology Model Fitting Against FL-Shp2 WT SAXS 
Envelope. 
(A) I-TASSER model of FL-Shp2 WT. Domains are coloured as follows: nSH2: 
red, inter-SH2 linker: grey, cSH2: yellow, PTP: blue, CTE: beige. (B i-iii) 
Automatic fits of the I-TASSER homology model against the DAMMIN-
generated SAXS envelope. Values underneath each fit indicate NSD value 
generated by SUPCOMB, 0 being an ideal fit.  
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Using a data-driven modelling approach, a more reliable structure may be generated. 
For this we employed SAXSTER, which utilises P(R) data from SAXS and the protein 
primary sequence to model the best solution. The top-ranking model from SAXSTER 
for FL-Shp2 WT aligns with the experimental Shp-2 crystal structure (PDB ID: 4DGP) 
with an RMSD of 2.317. Comparison of the predicted and experimental P(R) curve 
shows a reasonable fit of the parabola up to 7 nm, the main deviation being the “tail” 
region from 8 nm onwards (Figure 5.22). The SAXSTER model overestimates this 
region, resulting in a Dmax above 13 nm, contrasting the AUTOGNOM-calculated Dmax 
of 10.3 nm.  
CRYSOL back-calculation of the SAXSTER model and subsequent comparison with 
the merged FL-Shp2 WT SAXS data gave rise to an agreeable χ² value of 1.073. 
Visual inspection of the curves shows a misfit at low-q (<0.3 nm-1) but a very good fit 
thereafter until q>1.5 nm-1, from which point the curves deviate from one another 
substantially. Taken together the folds of the modelled termini are probably incorrect, 
whereas the overall shape information of the SAXSTER model is reasonable. This is 
corroborated by the theoretical and experimental Rg values of 30.99 and 31.89 Å 
respectively, which differ by <3% to one another. Since the P(r) curves indicate a 
poor Dmax prediction and the intensities at low-q do not match well, this is expected. 
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Figure 5.22: Data-driven Modelling of FL-Shp2 WT using SAXSTER. 
(A) Overlay of CRYSOL simulated curve of model (blue) against 
experimental SAXS data (black). (B) P(r) curve of experimental and data-
driven model. The experimental and model Dmax values are 10.3 and 13.1 nm 
respectively. (C) Cartoon diagram of SAXSTER-generated model. 
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SUPCOMB-based superimposition of the SAXSTER model with the DAMMIF-derived 
envelope yielded three solutions with NSD values 1.876, 1.937 and 2.025 for 
solutions 1, 2 and 3 respectively (Figure 5.23). These values are slightly better than 
those of the previous model fits. Interestingly, the C-terminal disordered loop of the 
SAXSTER model protruding outside the envelope measures around 35 Å in total; 
when subtracted from the SAXSTER Dmax prediction of 13.1 nm, a new Dmax of 9.58 
nm is created, which is within ~7% of the AUTOGNOM-calculated Dmax of 10.3 nm. 
The data suggests that the C-terminal tail is not as extended as predicted by the 
SAXSTER model and likely folds back closer to the catalytic subunit. 
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Figure 5.23: Automatic Fitting of FL-Shp2 WT SAXS Envelope with Data-
Driven SAXSTER Model. 
Three automatic fits (i-iii) of SAXSTER-generated model with DAMMIF-
generated envelope (grey: surface representation of ab initio SAXS bead 
model, protein domains coloured as in (B). Far right: NSD values of fits 
generated by SUPCOMB, 0 being an ideal fit.  
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E76K FL-Shp2 
SAXS data of E76K FL-Shp2 were collected at the same X-ray source and 
concentrations series as WT and displays similar attributes, merged SAXS data are 
shown in Figure 5.24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24: Extrapolated SAXS Data of FL-Shp2 E76K. 
(A) Merged and extrapolated to zero concentration SAXS data of FL-Shp2 
E76K used for further analyses. (B) Kratky plot of SAXS data of FL-Shp2 
E76K from (A), indicating a globular particle with a degree of flexibility. (C) 
Table of parameters calculated with data from (A).  
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Extrapolation of the data to zero concentration using PRIMUS results in a very similar 
curve to the original datasets (Figure 5.24). The Rg value is 3.588 nm, 0.002 nm less 
than the 1 mg/ml dataset Rg. For individual SAXS curves of FL-Shp2 E76K at all 
concentrations tested see Appendix figure 7.  
Comparisons of FL-Shp2 WT and E76K SAXS Data Reveal Distinct Differences 
Superimposition of both WT and E76K scatter profiles is shown in Figure 5.25. Initial 
fitting of the Shp-2 WT crystal structure (PDB ID: 4DGP) with the extrapolated SAXS 
datasets for both WT and E76K was performed as a fast quantitative measure of 
similarity between the two datasets and a reference model. χ²-values of the WT and 
E76K SAXS data against 4DGP were 1.388 and 2.410 respectively. A better fit 
between 4DGP simulated curve and the WT SAXS data is observed than with E76K 
SAXS data (Figure 5.25. The CRYSOL-derived theoretical Rg for the Shp-2 crystal 
structure is 27.78 Å; the experimental Rg values for WT and E76K are 30.56 and 
32.87 Å respectively. This explains the generally poor fit at low-q for both datasets as 
size information resides in this region and also explains why E76K has a worse fit 
than WT. However, it does not explain the poor fit at q>1 nm-1 for E76K. From this 
analysis one can conclude that the WT SAXS data fits the most recent Shp-2 crystal 
structure better than the E76K SAXS data, further suggesting the structure of FL-
Shp2 E76K deviates from WT in size, shape and fold. Differences are observed in 
envelope shape between WT and E76K (automatic fitting between WT and mutant. 
Solution of E76K envelope does not match well, suggesting a global conformational 
change between the two constructs in solution. 
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Figure 5.25: Comparison of WT and E76K FL-Shp2 SAXS Data. 
(A) Superimposition of final WT (black) and E76K (red) SAXS curves used in 
all analyses. Differences in intensity and curve shape between both datasets 
are apparent at 0.5<q<1.6 nm-1, indicating a change in size and/or shape.(B) 
and (C) WT and E76K SAXS profiles fitted to CRYSOL simulated curves of a 
current Shp-2 crystal structure (PDB ID: 4DGP, blue), yielding χ² values of 
1.388 and 2.410 respectively.  
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EOM Analysis of FL-Shp2 
As the WT and E76K SAXS data were not yielding good fits against current crystal 
structures and homology models tested, EOM was employed to investigate the 
possibility of FL-Shp2 containing regions of flexibility. Since the WT and E76K 
constructs contain terminal residues that may be unstructured (Poole & Jones 2005), 
EOM can take this into account to yield an ensemble of structures that best fit the 
data as opposed to one rigid model.  
 In the first instance, all structural domains were kept rigid, with residues 1-22 (His-
tag) and 552-615 (C-terminal extension, CTE) remaining flexible. This was performed 
to assess the contribution of the termini to the experimental data and is summarised 
in Figure 5.26. The fit between the ensemble and experimental curve is shown in 
Figure 5.26 A and demonstrates a good superimposition, with χ²=1.146, better than 
that of 4DGP (χ²=1.388. Inspection of the models shows a rigid TanSH2+PTP 
domain with a large flexible CTE. The His-tag region tends to adopt a fully extended 
conformation localised around the same region of space between the TanSH2 
domain on the opposite face to the catalytic site. The Rg and Dmax distribution plots in 
Figures 5.26 B and C indicate that in a 3-domain rigid model, FL-Shp2 WT tends to 
adopt more extended conformations, with average Rg and Dmax values of 31.6 and 
125.4 Å. 
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Figure 5.26: EOM 
Analysis of FL-Shp2 WT 
Assuming a Rigid 
Model. 
(A) Fit of WT SAXS data 
(black) against averaged 
curve of rigid ensemble 
selected by EOM (yellow). 
Χ²=0.996.  (B) 
Superimposition of 5 
models from the EOM 
ensemble. Rigid 3 
domains of Shp-2 are 
coloured as previous;  
His-tag (denoted as N-
term) and CTE are 
represented as beads, 
each colour representing 
a different model. (C) and 
(D) Rg and Dmax 
distributions respectively. 
Both indicate the 
preference for an 
extended conformation, 
on average.  
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Next, EOM was performed with the linker between the two SH2 domains (also called 
the interSH2-linker here, residues 103-110 of WT sequence inclusively; residues 
125-132 of FL construct) kept flexible. This region may behave like a hinge region 
and thus be involved in the domain reorientation of Shp2 during activation. Results of 
the analysis are summarised in Figure 5.27 and demonstrate a similar pattern to the 
rigid model of FL-Shp2. The EOM ensemble fits well to the experimental data (Figure 
5.27 A) at all q-values, with a χ²=0.999, better than the rigid model which gave a 
value of 1.146. The average Rg and Dmax values are slightly higher than the rigid 
model, at 32.9 and 132.7 Å, respectively, and the distribution plots demonstrate that 
in a flexible interSH2 linker model, the ensemble is more extended on average 
compared to the pool (Figure 5.26 C and D), consistent with the nSH2 domain being 
released and allowed to move in space. Models from the ensemble were 
superimposed and revealed two main populations, four representative models are 
shown in Figure 5.27 B. In general, the nSH2 domain either remained relatively close 
to the PTP domain active site or undergoes major domain reorganisation to 
effectively “peel” away from the PTP domain entirely and reside on the opposite face 
of the catalytic residues. Of the 15 returned models, 4 were in the latter, peeled 
configuration, roughly 26% of the ensemble. 
Similar results were obtained for the same nSH2-mobile model (where the interSH2 
linker was kept flexible) when using E76K SAXS data (Figure 5.27), with a χ² 
between the averaged EOM ensemble and experimental data of 1.106. Comparisons 
of the Rg and Dmax distribution plots between WT and E76K (Figure 5.29) reveal that 
the mutant FL-Shp2 ensemble has higher Rg values than the WT, suggesting that the 
mutant takes on more extended conformations. However, the Dmax distribution plot 
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suggests the opposite, that E76K takes on more compact conformations than the 
WT. Although these two results seem contradictory, it could point to mutant Shp2 
adopting a range of conformations that are lower in maximum particle dimensions to 
the WT but still undergoing a global reorganisation to yield a higher Rg, though more 
experiments will be required to substantiate this. 
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Figure 5.27: EOM 
Analysis of FL-Shp2 
WT Assuming an 
nSH2-mobile Model. 
(A) Fit of WT SAXS 
data (black) against 
averaged curve of 
ensemble selected by 
EOM (green). 
Χ²=0.999. (B) 
Superimposition of 4 
models from the EOM 
ensemble. His-tag and 
CTE are omitted for 
clarity. Grey cartoon: 
cSH2 and PTP 
domain, Red sticks: 
Catalytic residues, 
Cyan sticks: 32Arg of 
nSH2 domain, 
Spheres: interSH2 
linker. nSH2 domains 
and interSH2 spheres 
are coloured in 
magenta, yellow, 
green and orange. (C) 
and (D) Distribution 
plots for Rg and Dmax of 
pool (blue) and 
selected ensemble 
(red). Both suggest 
that WT FL-Shp2 
adopts, on average, an 
extended 
conformation.  
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Figure 5.28: EOM Analysis of FL-Shp2 E76K. 
(A) Fit of E76K SAXS data (black) against averaged curve of ensemble selected 
by EOM (yellow). Χ²=1.106. (B) and (C) Distribution plots for Rg and Dmax of pool 
(blue) and selected ensemble (red). Both suggest that WT FL-Shp2 adopts, on 
average, an extended conformation.  
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Figure 5.29: Comparison of WT and E76K EOM Fits. 
(A) and (B) Rg and Dmax distribution plots for WT and E76K FL-Shp2. The E76K 
ensemble has a larger mean Rg distribution than the WT, whereas the opposite is 
true for the Dmax  distribution. (Light blue: WT pool, Black: WT ensemble, Dark 
blue: E76K pool, Red: E76K ensemble. (C) Boxplot Diagram demonstrating 
differences in EOM Ensemble Cα distances between D61 and C459 for WT and 
E76K FL-Shp2. The WT takes on a broad distribution of D61-C459 distances, 
whereas E76K takes on a narrower range of distance distributions that are in 
general higher than the WT. 
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It is well known that the active site of Shp2 is occluded by nSH2 domain residues 
residing in the DE loop (Hof et al., 1998). It is thought that the interaction of the DE 
loop residues with the active site is disrupted upon nSH2 ligand binding, allowing the 
bound-state nSH2 to reveal the catalytic residues of the PTP domain. Therefore it is 
reasonable to assume that the distance between the DE loop and catalytic residues 
could correlate with activation status of the enzyme. 
With this in mind, Cα distances were calculated between D61 within the DE loop and 
the catalytic cysteine C459 for the EOM selected ensembles. This was performed for 
both WT and E76K, the results of which are summarised in Figure 5.30 . The 
boxplots clearly reveal a difference between the Cα distances calculated between 
WT and E76K. The selected ensemble of the mutant contains models with, on 
average, larger distances than the WT and an overall broader range. The larger 
distance could be enough to fully activate or prolong FL-Shp2 activation, though 
more structural studies of the mechanistic consequences of Shp2 mutation are 
required.  
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Figure 5.30: Comparison of C-alpha Distances between D61 and C459. 
Boxplot showing the distribution of C-alpha distances between C459 and 
D61 (Catalytic motif and inhibitory loop). The data suggest E76K, on 
average, takes on a more open form than the WT form. Based on EOM-
generated models.  
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Conclusions 
Through SAXS analysis of constructs spanning various Shp2 domains as well as the 
full-length form itself, a number of insights have been made regarding the structural 
states of Shp2 in solution. In addition, study of SAXS data of a Noonan 
Syndrome/leukaemia mutant, E76K FL-Shp2, was performed and also provides 
insight into Shp2 behaviour in the mutated state. These conclusions are summarised 
below and discussed further. 
 
Global Envelopes of Shp2 Agree with Published Data 
All domains tested yielded high quality models and their shapes largely resemble the 
crystal state, though the discrepancy in the fits suggests a degree of flexibility in the 
solution state. In particular, ΔHis-TanSH2 produced an envelope with an asymmetric 
dumbbell shape, consistent with the fact the cSH2 domain of Shp2 is larger and 
contains freely mobile loops. While SAXS is unable to definitely resolve which SH2 
domain belongs to which spherical portion in the global TanSH2 envelope, it is likely 
that the cSH2 domain fits the larger sphere. In general the crystallographic and 
solution data fit well, increasing the confidence of both datasets. 
Domain dynamics may play a significant role in Shp1/Shp2 function as no other 
PTPs have been observed to contain autoinhibitory activity reliant on catalytic cleft 
occlusion. The dynamic states of Shp2 are expanded on below. 
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Shp2 and Isolated Domains are Flexible in Solution 
The TanSH2 domain was found to be partially flexible in solution. When comparing 
various flexible models, the best fits were obtained when flexibility in the N-terminus, 
interSH2 linker and CD loop of cSH2 were introduced. A functional role of the latter is 
unlikely as the CD loop is non-overlapping to canonical cSH2 pY and +3 pocket 
residues, however there may be an as of yet unassigned function to the CD loop in 
Shp2 biology. The relatively long CD loop insertion is atypical of SH2 domains which 
contain small (3-4 residue) CD loops that play a largely structural role, and thus may 
confer some function as it is highly conserved throughout vertebrate PTPN11 
sequences. 
 
The PTP domain of Shp2 has been studied structurally both free and in complex with 
small-molecule inhibitors, though no research has investigated the structure and 
dynamics of Shp PTP domains in solution as all solved structures were determined 
by X-ray crystallography. In this present study PTP-Shp2 is observed through ab 
initio modelling to adopt a globular shape that fits reasonably well to the DAMMIF-
derived envelope. However, rigid body modelling and existing crystal structures were 
unable to fit the experimental data, leading to analysis of multiple, flexible ensembles 
in an attempt to decrease the model:experimental discrepancy.  
The results show some preference for flexibility in the structure (in the Flex-N-PTP 
model), most likely localising to the N-terminal 70 residues. Flexibility can be a 
means to perform a biological function and is the case for PTP function via switching 
of the WPD loop between open and closed states (Hu & Stebbins, 2006). With Shp2 
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in the full-length, PTP domain flexibility could be a means to facilitate nSH2 release 
from the autoinhibited form into the active state. The flexibility of the PTP domain 
could also explain why Shp2 in the SH2-ligand free state still displays low basal 
phosphatase activity; intrinsic motions within the PTP domain may cause 
spontaneous nSH2 release in the absence of phosphopeptide to bind nSH2. The 
released nSH2 domain then undergoes conformational changes to optimize 
phosphopeptide binding and when bound to a ligand, remain in the released state. 
 
Presence of a His-tag alters Global TanSH2 Structure 
The DAMMIF envelopes between His and ΔHis TanSH2-Shp2 differ greatly from one 
another, suggesting the presence of a tag alters the global structure and thus may 
affect functional aspects of Shp2 function. For ΔHis-TanSH2-Shp2, the crystal 
coordinates of Shp2’s TanSH2 domain fit well within the envelope and yield low χ²-
values, indicating the solution structure is compatible with the solved crystal 
structure. For His-TanSH2, good fits were observed for atomic models with averaged 
envelopes (Figure 5.3). The fact a discrepancy between SAXS data and 
crystallographic data exists suggests that conformational and domain orientation 
reordering in solution occur. 
 
Wild-type and Mutant Shp2 Differ Structurally in Solution 
FL-Shp2 SAXS data revealed some insights into full length structural features, such 
as the good fit between current crystallographic data (Peter Hof et al. 1998) and 
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DAMMIF envelopes. Flexibility in solution could be due to the His-tag and CTE, which 
are predicted to be mostly disordered, as well as the CD loop within the cSH2 
domain. Additional flexibility may be attributed to the various functional loops within 
the PTP domain, however this was not tested during modelling. 
The C-terminal tail has not been characterized structurally up until now. SAXS has 
provided a glimpse of this region and it is most likely completely unstructured. 
Crucially however, the clear differences in the SAXS data between WT and E76K 
suggest a definite structural reorganisation, indicated by calculation of invariant 
parameters. E76K FL-Shp2 may sample more extended conformations compared to 
the WT and this is consistent with current biochemical evidence (Keilhack et al., 
2005) and molecular dynamics (MD) studies (Darian et al., 2011). This is the first 
instance of a solution technique probing mutant Shp2 structure, as discussed 
previously in Chapter I. 
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Chapter VI 
Biophysical Analysis of Shp2 and 
G6b-B Interactions 
 
G6b-B and Shp2 are known to be binding partners from co-immunoprecipitation (de 
Vet et al. 2001a), SPR and transgenic mouse knockout experiments (Mazharian et 
al. 2012). As a novel membrane receptor with little known of its biological structure 
and function, the molecular mechanisms behind G6b-B:protein interactions may 
provide key insights into its role in signalling.  With this in mind, experiments were 
performed in order to shed light on the binding mode of these biomolecules.   
 
Circular Dichroism of the dITIM of G6B-b 
Far UV CD was used to characterize the secondary structure of the doubly 
phosphorylated dITIM of G6B-b prior to high resolution analyses. The dITIM peptide 
was predicted by the secondary structure prediction program JPred (Cole et al., 
2008) to be a mixture of unstructured loops and β-strands (See Appendix 5 and 
figure). Two dITIM concentrations were tested to rule out concentration effects and to 
select for the concentration that will yield the highest quality data at lower 
wavelengths. For the present study 1 and 10 mg/ml dITIM was tested by CD. After 
solvent subtraction and inspection of the high tension values at wavelengths below 
200 nm for both concentrations tested, 10 mg/ml was chosen for further analysis 
using the online CD analysis server DICHROWEB (Whitmore & Wallace, 2004). 
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Visual inspection of the spectrum revealed that dITIM was unfolded in solution 
(Figure 6.1, top): the presence of a negative band around 200 nm with no other 
characteristics suggests little to no secondary structural elements exist. However, 
estimation of the secondary structure content based on the CD data suggested that 
whilst dITIM is primarily unfolded, there may be some transient helical and strand 
content (Figure 6.1, top, inset).  
 
Analytical Ultracentrifugation of the His-TanSH2-Shp2:dITIM Complex 
AUC experiments were conducted to investigate His-TanSH2-Shp2 (hereby called 
His-TanSH2) in the unbound and 1:1 dITIM-bound states. A protein:protein 
interaction between His-TanSH2 and dITIM should cause changes in the 
sedimentation profile of the former (Schuck, 2000). Both high (20 µM 0.5 AU A280) 
and low (6 µM; 0.15 AU A280) concentrations of unbound and dITIM-bound His-
TanSH2 were used in sedimentation velocity experiments to rule out concentration 
effects. The His-TanSH2:dITIM complex was purified by gel filtration (Chapter II and 
III) to ensure a homogenous solution of d-ITIM bound His-TanSH2 only, excess 
dITIM peptide eluting last due to its low molecular weight. 
Data obtained from sedimentation velocity experiments were processed with Sedfit 
12.1b and revealed unbound TanSH2 to have a peak sedimentation coefficient of 
2.46 S. The peak sedimentation coefficient for dITIM-bound TanSH2 is 2.77 S 
(Figure 6.1 B), a clear increase, suggesting complex formation. Interestingly, dITIM-
bound TanSH2 displays a much broader sedimentation profile than unbound 
TanSH2, which may indicate multiple species of varying hydrodynamic properties. 
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This in turn might be caused by dITIM-bound TanSH2 adopting multiple extended 
and compact conformation states in solution. 
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Figure 6.1: CD Data of dITIM of G6B-b and AUC Analysis of Unbound and 
dITIM-bound Forms of His-TanSH2-Shp2.  
(A) CD Spectrum was recorded at RT in 50 mM sodium phosphate buffer. dITIM 
concentration was 1 mg/ml. Black solid line: experimental data, Red dashed line: 
Simulated data fit. This CD spectrum is indicative of an unfolded polypeptide. 
Data were analysed using DICHROWEB. (B) Sedimentation analysis (Velocity 
experiment) of TanSH2-Shp2 both free and in complex with dITIM. The 
difference in S value is indicative of complex formation as the hydrodynamic 
radius of TanSH2-Shp2 increases. Black: Unbound TanSH2-Shp2, Red: dITIM-
bound TanSH2-Shp2. Data were analysed with SEDFIT 12.1b.  
 
A 
B 
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NMR of nSH2:ITIM1s Complex 
The 15N HSQC spectrum of nSH2 in the presence of ITIM1s (10 amino acid length, 
1:1 ratio) phosphopeptide, like that of the unbound nSH2-Shp2, is well dispersed and 
indicates the presence of folded protein. A total of 146 peaks are present, out of a 
possible 133, almost 10% more peaks than would be expected. This could suggest 
the complex is more flexible, sampling two or more structural states, or, exhibiting 
slow-intermediate exchange phenomena due to the presence of sub-stoichiometric 
concentrations of ITIM1s peptide. The peaks are near-uniform in intensity, with a few 
possessing stronger and weaker intensities, suggesting variable exchange rates and 
therefore variable timescale motions present in the complex, much like the unbound 
form which also had peaks of varying intensity. Two peaks between 10.1 and 10.6 
ppm in the 1H dimension are present in the bound state, both of which may 
correspond to the 6W Hε1 resonance. Interestingly, the unbound nSH2-Shp2 NMR 
spectrum contains two peaks in this region, both likely to belong to 6W Hε1 in two 
conformations as no correlated carbon resonances were observed in 3D assignment 
spectra in this region. Superimposition of unbound and ITIM1s-bound nSH2-Shp2 
HSQCs reveal both 6W Hε1 peaks have undergone CSPs. The Hε1 peak at 10.5 ppm 
has shifted 0.4 ppm upfield, while the Hε1 peak at 10.6 ppm has shifted 0.01 ppm 
upfield. The intensities remain relatively constant for the 10.6 ppm peak whereas the 
10.5 ppm peak volume has decreased 4-fold. This suggests the conformation(s) 
corresponding to the latter peak are decreasing in relative populations between the 
unbound and bound states, with intermediate exchange timescale dynamics being 
suggested by broadening of resonances. 
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Based on the results from the nSH2:ITIM1s NMR peptide titration experiments, it was 
clear that assignment of the bound state would be challenging due to the slow-
intermediate exchange regime observed. It was decided to collect a set of BEST 
backbone assignment spectra to aid the assignment process. Data were obtained on 
a 900 MHz Varian spectrometer and analysed using a semi-automated assignment 
method on CCPN Analysis 2.1.5. The results of this assignment are presented 
below. 
 
Backbone Assignment of nSH2:ITIM1s Complex 
Unambiguous assignment of the nSH2:ITIM1s complex backbone was 
straightforward due to the increased peak resolution observed in the spectra from 
acquiring data on a high-field magnet. A representative HNCA-HN(CO)CA sequential 
walk through the sequence is presented in (Figure 6.2 A), showing (i) and (i-1) 
connectivities for residues 46R-51V, as was the case for nSH2 and TanSH2-Shp2 
apo-state assignments. Four prolines (9P in the initial N-terminal loop, 33P at βB6 – 
immediately C-terminal to the conserved Arg at position βB5, 38P at position BC4 
and 101P in the final C-terminal loop) are unassignable using currently collected 
spectra, leaving 110 assignable residues, of which 100 were assigned in the 15N-
HSQC spectrum (Figure 6.2 B). This is an assignment coverage of 90%, unassigned 
residues are as follows: 3S, 4R, 35K, 54I, 65L, 66Y, 67G, 85H, 86G and 90E. Apart 
from 54I which resides in sheet βD, all unassigned residues are located in loop 
regions and is summarised in (Figure 6.3). 65L, 66Y and 67G form part of the EF 
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loop and were assigned in the unbound state, meaning the SH2:peptide interaction 
affects the exchange rates of this region such that peaks are no longer observable. 
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Figure 6.2: Sequential Backbone Assignment of nSH2:ITIM1s  
(A) HNCA and HNCOCA Spectra. Strips of 3D NMR assignment spectra showing 
connectivities between HNCA (blue peaks) and HNCOCA (red peaks) established using a 
semi-automated assignment method within CCPN Analysis 2.1.5. Black solid lines show 
sequential connectivities between HNCA and HNCOCA peaks corresponding to residues at 
(i) and (i-1) positions for residues 46-51 inclusively for WT nSH2-Shp2, corresponding to the 
protein sequence RRNGAV. A similar assignment approach was done for HNCO/HNCACO 
and HNCACB/HNCOCACB spectra in parallel. (B): Assigned 15N HSQC of 15N, 13C-labelled 
nSH2-Shp2 in Complex with ITIM1s . nSH2-Shp2 backbone amide signals were assigned 
using a 2 mM sample of uniformly 15N and 13C-labelled protein. The crowded region of the 
spectrum (boxed, middle) is expanded for clarity (bottom right). “sc” denotes side-chain 
assignments. Assigned side-chain HN peaks of Asn/Gln are connected via single horizontal 
black solid lines. A larger figure can be found in Appendix figure 8. 
A 
B 
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Figure 6.3: Unassigned Residues and Conformational Flexibility in 
nSH2:ITIM1s  
(A) Assignment of eight WT residues was not possible for the nSH2:ITIM1s 
complex and are highlighted (red) in a cartoon and surface representation 
(grey, PDB ID 1AYD). 35K forms part of the BC loop, 65G, 66Y and 67G form 
portions of sheet βE and the EF loop. (B) Cartoon representation of nSH2-
Shp2 with residues of multiple peaks in ITIM1s-bound HSQC highlighted (red). 
Apart from 98L, all residues localise to one distinct patch of nSH2 with no 
overlap to the pTyr and +3 pockets. (C) B-factor putty representation of nSH2-
Shp2 indicating regions of flexibility. From right to left the red, wide regions 
correspond to the BC and BG loops respectively (PDB ID: 1AYD)  
A 
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A number of peaks in the nSH2:ITIM1s complex HSQC were found to adopt 
alternative conformations. Due to the sub-saturating concentrations of peptide, these 
alternative conformations may correspond to unbound nSH2 domain. However, 
comparison of unbound and bound nSH2 HSQC spectra reveals the peaks 
corresponding to alternative conformations are distinct to both and thus may be a 2nd 
conformation of unbound and/or bound nSH2. The residues are: 21L, 22T, 23R, 24G, 
25V, 48N, 49G, 50A, 51V and 98L. These are summarised in Figure 6.3 B and 
cluster to one affected region of nSH2-Shp2 which are distinct from pTyr and +3 
binding pockets. This area of conformational heterogeneity may represent a normal 
feature of nSH2-Shp2 regardless of binding status. Chemical shift tables for 
nSH2:ITIM1s can be found in Appendix 10. 
 
Secondary Structure Prediction of nSH2:ITIM1s 
TALOS+ was employed to predict the secondary structure of nSH2-Shp2 in the 
ITIM1s-bound state. Chemical shift values for CO, CA, CB, N and H derived from 
backbone assignment analysis of nSH2:ITIM1s were used as input. Figure 6.4 
summarises the results. Like the nSH2 and cSH2 domains of Shp2 in the unbound 
state (Chapter IV), the typical SH2 domain fold is observed: two α-helices flanking 
three β-sheets, with some additional short β-strands predicted throughout the 
sequence. Secondary structure elements between the unbound and bound forms of 
nSH2-Shp2 reveal no significant differences between the two. This suggests the 
ITIM1s binding does not perturb the secondary structure content of nSH2-Shp2. 
However, no data are available to elucidate the secondary structure of ITIM1s. Since 
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CD analysis suggests dITIM is almost completely unfolded, ITIM1s is likely to be 
unfolded too. While this may change in the bound state, most SH2 domain binding 
partners adopt an extended conformation (Pawson & Schlessinger 1993). 
 
 
 
 
 
 
Figure 6.4: nSH2-Shp2 in the ITIM1s Bound State Maintains the Same 
Secondary Structure to Unbound nSH2-Shp2.  
(A) Secondary structure via DSSP of available crystal structure (1AYD) and 
prediction using TALOS+. Structural elements are depicted as loops (green 
solid line), helices (cyan) and sheets (pink). Differences between the crystal 
and solution structure are apparent, mainly as shortened helices and more β-
sheets. (B) TALOS+ secondary structure probability histogram, helical 
propensity is positive, sheet propensity is negative and summarised in (A). (C) 
S2 order parameter prediction using RCI method. The closer the value toward 
0, the more mobile the residue. 
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NMR Titrations of Individual SH2 Domains with ITIM Peptides 
Multiple 15N-HSQC titration experiments were recorded on a 600 MHz Varian DD 
NMR spectrometer in order to identify ligand binding sites. Unlabelled single ITIM 
peptide was added in 100 µM increments to 2.5-fold excess (unless specified) into an 
NMR tube containing 400 µM [U-15N] cSH2-Shp1 as well as nSH2 and cSH2-Shp2. 
All experiments were performed in NMR buffer. In-depth analysis of ITIM interactions 
with various Shp SH2 domains is described further below. 
 
nSH2-Shp2 Binds the ITIM1 in Slow Exchange 
More than 30 peaks undergo CSPs upon addition of ITIM1 peptide to 0.25 molar 
equivalence.  All CSPs display slow exchange, indicating a slow on/off rate. By 0.75 
molar equivalence most CSPs do not change intensity further (Figure 6.5). CSP 
analysis reveals that over 40 CSPs above the mean are present, the strongest of 
which are 54I and 59T. Four peaks corresponding to residues 65L and 66Y (EF loop) 
as well as 89K and 90E (BG loop), which are known to interact with phosphopeptide 
residues C-terminal to pY, completely broaden. Figure 6.6  depicts the nSH2-
Shp2:ITIM1 interaction and shows many significant perturbations on one face of the 
SH2 domain, mainly localised to the +3 binding pocket, though CSPs above the 
mean are noted in C-terminal residues of sheet βB and the BC loop. For the latter, 
binding information is sparse due to the presence of two proline residues and an 
unassigned 35K presumably in intermediate exchange in the unbound state. Five 
new peaks appear throughout the HSQC. Notably, one of these new peaks is located 
far downfield in the 15N dimension (105.3 ppm) and appears at 0.25 molar 
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equivalence. Given its location in the HSQC spectrum, this peak could correspond to 
the previously unassigned 86G residue, though further spectra would need to be 
recorded to confirm this. ITIM1s and ITIM1 CSPs share similarity, though ITIM1 
CSPs undergo slow exchange and stronger shifts. 
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Figure 6.5: NMR Titrations of nSH2-Shp2 with ITIM1 Peptide. 
Superimposition of multiple 15N-SOFAST HMQC spectra of 400 µM 15N-labelled 
nSH2-Shp2 with ITIM1 peptide in 0.25 eq increments. Data were collected on a 
Varian 600DD NMR Spectrometer at 25 °C in NMR buffer. (A) Addition of ITIM1 
peptide causes multiple CSPs in nSH2-Shp2.  (B) Zoomed region of black box in 
(A) highlighting strongly perturbed residues in slow exchange. Black arrows 
indicate CSPs as well as relative shift distance.  
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Figure 6.6: nSH2-Shp2 CSPs Induced by ITIM1 Titration. 
(A) Histogram (bottom panel) displaying CSPs induced by ITIM1 titration as a 
function of residue number for 400µM 15N-labelled nSH2-Shp2. Peptide was 
added to 2.5-fold excess. Dashed lines indicate CSPs ≥ mean + 2 S.D (red), 
mean + 1 S.D (orange) and mean (0.11± 0.10, grey), highlighting strongly 
perturbed residues. 54I and 59T CSPs are displayed on a separate chart (top 
panel). (B) Surface Representation of nSH2-Shp2 (PDB ID: 1AYD) with ITIM1-
induced CSPs mapped on. CSPs ≥ mean + 2 S.D (red), mean + 1 S.D (orange) 
and completely broadened resonances (dark gray) are shown here. Residues 
43L and 44S are buried and thus not observed here. 
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nSH2-Shp2 Binds ITIM2 in Fast Exchange 
Upon addition of ITIM2 peptide to 0.25 equivalence to nSH2-Shp2, ≈25 peaks 
undergo CSPs, with the majority in fast exchange. 43L, 46R, 54I, 68G and 88L shift 
in intermediate exchange, while 65L and 66Y completely broaden (Figure 6.7). Aside 
from two new peaks that appear at 2-fold molar excess of ITIM2 peptide, no further 
CSPs were noted. CSP analysis reveals ITIM2 causes broadening of most assigned 
signals corresponding to BC loop residues, apart from 34S which undergoes minimal 
perturbation (Figure 6.8). The largest shifts were noted in sheets βC and βD and the 
EF loop and show that ITIM2 engages nSH2 in on one face, in the canonical pY- and 
+3 binding pockets.  
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Figure 6.7: NMR Titrations of nSH2-Shp2 with ITIM2 Peptide. 
Superimposed 15N-SOFAST HMQC titration series of 400µM 15N-labelled 
nSH2-Shp2 with unlabelled ITIM2 peptide collected on a Varian 600DD NMR 
Spectrometer at 25 °C in NMR buffer. (A) 0-1.50 eq titration points. Multiple 
CSPs of different magnitudes and exchange rates are observed, some of which 
are highlighted with black arrows. CSPs halt after 1.50 eq, Grey and red 
spectra represent start and end (1.5 eq) points for the titration. (B) Zoomed 
region of black box in (A), highlighting CSPs in intermediate-fast exchange.  
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Figure 6.8: Histogram and Binding Surface of nSH2-Shp2 CSPs Induced 
by ITIM2.  
(A) The histogram displays CSPs induced by ITIM2 titration as a function of 
residue number for 400 µM 15N-labelled nSH2-Shp2. Peptide was added to 
2.5-fold excess. Dashed lines indicate ≥ mean + 2 S.D (red), ≥ mean+ 1 S.D 
(orange) and mean (0.071± 0.09, grey) CSPs, highlighting strongly perturbed 
residues. 54I displayed a CSP of 0.64 ppm and is shown on a separate chart. 
(B) Cartoon and transparent surface representation of nSH2-Shp2 (PDB ID: 
1AYD) with ITIM2-induced CSPs mapped on. CSPs ≥ mean + 2 S.D (red), 
mean + 1 S.D (orange) and completely broadened resonances (gray) are 
shown here.  
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nSH2-Shp2 Binds ITIM1s in Intermediate-Slow Exchange 
The truncated ITIM1 peptide ITIM1s was titrated to 2.5 fold molar excess, although 
the concentration of [U-15N]-nSH2-Shp2 was lower in this experiment (125 µM) than 
previously. At 0.25 molar equivalence of ITIM1s peptide, ≈20 peaks experience 
intensity reduction, with minor perturbations in ppm values. 66Y and 67G broaden 
significantly (Figure 6.9). Further addition of ITIM1s peptide led to CSPs in a mixture 
of chemical exchange states. Residues 43L and 54I are in slow exchange, whilst 41F 
is in intermediate exchange, with many other peaks in fast exchange. Negligible 
CSPs are noted after 1.5-fold molar excess of ITIM2 peptide. CSP analysis reveals 
that residues within helix αA, sheets βC and βD undergo significant CSPs, with 
broadening of BC and EF loop signals too (Figure 6.10). Mapping of perturbed 
residues onto the nSH2 structure (PDB ID: 1AYD) reveals a significant binding patch 
in residues forming and surrounding the pY-pocket with other perturbations in the BG 
loop. Interestingly, two residues outside of the aforementioned patches also display 
binding phenomena. Residue 59T broadens whilst 61D shifts in slow exchange. Both 
residues are located in the DE loop. Specifically, the main chain amide of D61 shifts 
upfield and thus becomes shielded in the bound state.   
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Figure 6.9: nSH2-Shp2 CSPs Induced by ITIM1s Titration.  
Superimposed 15N-HSQC spectra of unbound (grey), 0.5 eq (green) and 2.5 
eq (purple) 125 µM 15N-nSH2-Shp2 titration experiments with ITIM1s peptide 
performed at 25 °C on a Varian 600DD NMR spectrometer in NMR buffer. 
Arrows (red: slow exchange, black: fast exchange) indicate CSPs and 
direction.  
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Figure 6.10: Histogram and Binding Surface of nSH2-Shp2 CSPs Induced 
by ITIM1s.  
(A) The histogram displays CSPs induced by ITIM1s titration as a function of 
residue number for 125 µM 15N-labelled nSH2-Shp2. Peptide was added to 2.5-
fold excess. Dashed lines indicate ≥ mean + 2 S.D (red), ≥ mean+ 1 S.D 
(orange) and mean (0.083± 0.077, grey) CSPs, highlighting strongly perturbed 
residues. (B) Surface Representation of nSH2-Shp2 (PDB ID: 1AYD) with 
ITIM1s-induced CSPs mapped on. CSPs ≥ mean + 2 S.D (red), mean + 1 S.D 
(orange) and completely broadened resonances (gray) are shown here.  
A 
B 
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cSH2-Shp2 Binds ITIM1 in Multiple Exchange Timescales 
ITIM1 peptide titration causes ≈20 CSPs across all observable NMR timescales, with 
no further shift changes around 1.75-fold molar excess (Figure 6.11). The majority of 
CSPs shift in fast exchange; peaks in slow exchange include 119G, 154G, 170V and 
183G. These residues are located in helix αA, CD loop, sheet βD and EF loop 
respectively and apart from 154G, are conserved regions of direct interaction with 
phosphopeptides. It is therefore likely that conformational changes during ITIM1 
binding cause line broadening of 154G. CSP analysis reveals perturbations across 
most structural elements of cSH2-Shp2, such as helix αA, sheets βC and βD and the 
BG loop (Figure 6.12). Mapping of significant residues onto the crystal structure (PDB 
ID: 4DGP) reveals residues perturbed on both faces of the SH2 domain (On the side 
containing both pY and +3 pockets, perturbed residues populate both regions, though 
more are observed in the latter). However, perturbations are also observed along BG 
loop residues which reach behind the SH2 domain and back toward the extreme N-
terminal part of the cSH2 sequence. 
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Figure 6.11: NMR Titrations of cSH2-Shp2 with ITIM1 Peptide. 
Superimposed 15N-SOFAST HMQC titration series of 400µM 15N-labelled cSH2-
Shp2 with unlabelled ITIM1 peptide up to 2.5-fold molar excess. Data were 
collected on a Varian 600DD NMR Spectrometer at 25 °C in NMR buffer. (A) 0-
1.75 eq titration points. Multiple CSPs of different magnitudes and exchange rates 
are observed, some of which are highlighted with black arrows. CSPs halt after 
1.75 eq, though 2.50 eq is also shown. Grey and pink spectra represent start and 
end (2.5 eq) points for the titration. (B) Control and 0.25 eq titration points show 
initial CSPs changes upon ITIM1 binding.  
242 
 
 
 
 
 
 
 
Figure 6.12: Histogram of cSH2-Shp2 CSPs Induced by ITIM1.  
(A) The histogram displays CSPs induced by ITIM1 titration as a function of 
residue number for 400µM 15N-labelled cSH2-Shp2. Peptide was added to 2.5-
fold excess. Dashed lines indicate ≥ mean+ 2 S.D (red), ≥ mean + 1 S.D 
(orange) and mean (0.04± 0.06, grey) CSPs, highlighting strongly perturbed 
residues. (B) Surface Representation of cSH2-Shp2 (PDB ID: 4DGP) with 
ITIM1-induced CSPs mapped on. CSPs ≥ mean + 2 S.D (red), ≥ mean + 1 S.D 
(orange) and completely broadened resonances (gray) are shown here.  
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cSH2-Shp2 Binds ITIM2 in Slow Exchange 
Initial addition of ITIM2 peptide to 0.25 molar equivalence causes ≈six intermediate-
slow exchange CSPs and complete broadening of signals for residues 119G, 135F, 
154G, 170V, 182G, 197Y and 213K (Figure 6.13). Further titration causes multiple 
peaks to undergo CSPs in slow exchange, with no additional shifts after equimolar 
concentrations are achieved. Assignment of peaks in slow exchange was performed 
using data from ITIM1 titration, since it was found that many common residues 
between both titration series undergo CSPs in the same general direction. CSP 
analysis thereafter reveals strong perturbations from residues 170V and 210L, the 
latter of which broadened early in the titration only to reappear in intermediate 
exchange at 0.75 molar equivalence. ≈25 CSPs are above the mean, with many 
broadened completely, such as those in BC and BG loops (Figure 6.14). Mapping of 
significant CSPs onto the cSH2-Shp2 structure reveals a similar pattern as observed 
for the cSH2-Shp2:ITIM1 interaction. Both pY and +3 pocket residues are perturbed 
as well as residues on the opposite face, found within the C-terminal of the BG loop. 
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Figure 6.13: NMR Titrations of cSH2-Shp2 with ITIM2 Peptide. 
Superimposed 15N-SOFAST HMQC titration series of 400µM 15N-labelled cSH2-
Shp2 with unlabelled ITIM2 peptide up to 2.5-fold molar excess. Data were 
collected on a Varian 600DD NMR Spectrometer at 25 °C in NMR buffer. (A) 0-
1.00 eq titration points in 0.25 eq increments. Multiple CSPs of different 
magnitudes and exchange rates are observed, some of which are highlighted 
with black arrows. CSPs halt by 1 eq. Grey and red spectra represent start and 
end points. (B) Zoomed region from orange box in (A) show CSPs upon ITIM2 
binding in more detail.  
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Figure 6.14: Histogram of cSH2-Shp2 CSPs Induced by ITIM2.  
(A) The histogram displays CSPs induced by ITIM2 titration as a function of 
residue number for 400µM 15N-labelled cSH2-Shp2. Peptide was added to 2.5-
fold excess. Dashed lines indicate CSPs ≥ mean + 2 S.D (red), mean + 1 S.D 
(orange) and mean (0.06± 0.08, grey), highlighting strongly perturbed residues. 
170V and 210L displayed CSPs of 0.54 and 0.44 ppm respectively and are 
displayed on a separate chart. (B)  Surface Representation of cSH2-Shp2 
(PDB ID: 4DGP) with ITIM2-induced CSPs mapped on. CSPs ≥ mean + 2 S.D 
(red), mean + 1 S.D (orange) and completely broadened resonances (gray) are 
shown here.  
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Interestingly, 195E in position αB7 broadens although the side-chain faces away from 
the SH2 core and is in the middle of a helix. 194V and 197Y are also perturbed 
above the mean and are also located in helix αB. While the side-chain of 197Y forms 
part of the +3 pocket, 194V and 195E do not and instead may undergo CSPs due to 
helix repositioning in the bound state. Since the residues C-terminal to pY in ITIM2 
are very hydrophobic (three consecutive valine residues), packing of their side-chains 
into the +3 pocket may induce such changes. 
 
cSH2-Shp2 Binds ITIM1s in Fast Exchange 
cSH2-Shp2 titration with ITIM1s was performed in the same manner as with nSH2-
Shp2 insofar as 125 µM [U-15N]-protein was titrated step-wise with ITIM1s peptide 
until no further shifts were observed. ≈20 peaks experienced CSPs on the fast 
exchange timescale, with 170V the only residue to shift in intermediate-slow 
exchange (Figure 6.15). No significant shifts were noted up to 3.5-fold molar excess 
(437.5 µM) of ITIM1s peptide. 
CSP analysis reveals 31 CSPs above the mean, mainly localising to sheet βD and 
the BC and BG loops (Figure 6.16). Interestingly, only two residues from the EF loop 
region undergo significant CSPs: 181V and 182G. Additionally, 179Y in the 
preceding short β sheet (βE) is perturbed just above the mean. Mapping of strong 
perturbations onto the cSH2-Shp2 structure (PDB ID: 4DGP) reveals a binding patch 
perpendicular to the central three large β-sheets, in both pY and +3 pockets. 
Additional shifts are displayed on the opposite face to the canonical pockets; these 
are mainly BG loop residues. 
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Figure 6.15: cSH2-Shp2 Titration with ITIM1s Peptide by NMR. 
Superimposed 15N-SOFAST HMQC titration series of 400µM 15N-labelled 
cSH2-Shp2 with unlabelled ITIM1s peptide up to 2.5-fold molar excess. Data 
were collected on a Varian 600DD NMR Spectrometer at 25 °C in NMR buffer. 
Multiple CSPs of different magnitudes and exchange rates are observed, 
some of which are highlighted with black arrows. Blue and red spectra 
represent start and end (2.5 eq) points for the titration.  
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Figure 6.16: cSH2-Shp2 CSPs Induced by ITIM1s Titration. 
(A) Histogram displaying CSPs induced by ITIM1s titration as a function of 
residue number. Dashed lines indicate CSPs ≥ mean + 2 S.D (red), mean + 1 
S.D (orange) and mean (0.05± 0.07, grey), highlighting strongly perturbed 
residues. (B) Surface representation of cSH2-Shp2 (PDB ID: 4DGP) with 
ITIM1s-induced CSPs mapped on. CSPs ≥ mean + 2 S.D (red), mean + 1 S.D 
(orange) and completely broadened resonances (gray) are shown here.  
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cSH2-Shp1 Interactions with ITIM Peptides 
For cSH2-Shp1 titrations, 100 µM [U-15N]-protein in NMR buffer was titrated with 
unlabelled ITIM1 or ITIM peptides, as performed in previous experiments. Residue 
specific assignments were not available for TanSH2-Shp1 due to its poor 
expression/solubility so only general comments on binding phenomena are described 
here. 
 
cSH2-Shp1 Binds ITIM1 in Fast Exchange 
Addition of ITIM1 peptide to 0.25 molar equivalence results in around 17 weak CSPs 
in a fast exchange regime (Figure 6.17 A). These peaks continue to be perturbed up 
until the end of the titration series where 1.5-fold molar excess of ITIM1 peptide had 
been added. At this point ≈20 peaks displayed significant perturbations. Very weak 
perturbations were observed for the peak around 11 ppm which likely corresponds to 
Hε1 of either 110W or 131W. In addition, two side-chain resonances belonging to 
either Asn or Gln undergo CSPs. It is likely that titration up to saturation was not 
performed as the experimental end point still showed CSPs; in general titrations are 
continued until two identical HSQC spectra are observed at the endpoint. 
   
cSH2-Shp1 Binds ITIM2 in Fast-Intermediate Exchange 
Initial titration of cSH2-Shp1 with ITIM2 peptide to 0.25 molar equivalence causes 
≈35 CSPs, including possible Trp and Asn/Gln side-chain amide resonances (Figure 
6.17 B). CSPs continue to shift until equimolar concentrations of ITIM2 are present. 
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Comparison of ITIM1 and ITIM2 CSPs with cSH2-Shp1 reveal that similar peaks are 
perturbed by addition of peptide. The majority of peaks move in the same direction 
regardless of which ITIM peptide is added and in general, ITIM2 causes larger shifts 
than ITIM1. Although the NMR solution structure of cSH2-Shp1 has been elucidated, 
assignment data are not yet available on BMRB, PDB or any associated repositories, 
hindering further analysis. 
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Figure 6.17: cSH2-Shp1 Titrations with ITIM Peptides. 
ITIM1 (A) and ITIM2 (B) peptide were titrated into 100 µM [U-15N]-cSH2-Shp1 in 
25 µM increments with 15N-HSQC spectra recorded at each point until no further 
CSPs were observed. Spectra were then superimposed. Black arrows indicate 
CSPs. Data were collected on a Varian 600DD NMR Spectrometer at 25 °C in 
NMR buffer.  
A 
B 
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NMR Titrations of TanSH2 with ITIM Peptides 
Multiple 15N-HSQC titration experiments were recorded on an 800 MHz Varian NMR 
spectrometer. Unlabelled single ITIM or dITIM peptide was added in 100 µM 
increments to 2.5 and 1.5-fold molar excess respectively into an NMR tube 
containing 400 µM [U-15N] His-TanSH2-Shp2 in NMR buffer. Due to issues with 
peptide solubility, some precipitation was observed during the titration series, 
especially with dITIM. In-depth analysis of ITIM interactions with TanSH2:Shp2 is 
described further below. 
 
TanSH2:ITIM1  
Titration of TanSH2-Shp2 with ITIM1 causes around 20 CSPs. Crucially, some of 
these peaks display CSPs in slow exchange, such as 22T, 48N, 49G and 73T, whilst 
others show relatively minute CSPs in fast exchange (Figure 6.18), this is particular 
evident below equimolar concentrations of TanSH2 and ITIM1. A number of peaks 
also broaden completely such as 7F, 8H, 13G, 31A and 58N. At this point in the 
titration, CSPs and broadened peaks localise to the nSH2 domain. When molar 
equivalence is reached, peaks undergoing shifts in slow exchange no longer display 
intensity changes. Above molar equivalence and up to the end of ITIM1 titration, a 
number of peaks undergo CSPs in fast exchange (Figure 6.19). 
CSP analysis reveals that addition of ITIM1 peptide to equimolar concentration 
results in perturbations localised to nSH2 domain residues (Figure 6.20). However 
cSH2 domain CSPs occur above equimolar concentration (1 eq and above) (Figure 
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6.20). Mapping of residues above mean + 1 and 2 S.Ds reveals  around 26 assigned 
peaks undergo CSPs with Δδ values between the mean and mean + 1 S.D, just over 
25% of residues, while 28 peaks completely broadened, including residues between 
positions 58-61 (DE loop; 59T did not broaden but was unassignable in the bound 
state), 65-67 (EF loop) and 88-91(BG loop), inclusively. A number of assigned, 
overlapped peaks could not be assigned in the bound state since there is no way to 
discriminate which peak shifted, these were: 17E, 21L, 34S, 59T, 74L, 76E, 81Y, 
92N, 106D, 109S, 127T, 191T, 197Y and 208T.   
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Figure 6.18: TanSH2-Shp2 Interacts with ITIM1 Peptide. 
Superimposed 15N-HSQC Spectra of 400 µM 15N-labelled His-TanSH2-Shp2 
titrated with varying amounts of ITIM1 peptide. Data were collected on a Varian 
800 NMR Spectrometer at 25 °C in NMR buffer. (A) Control and ITIM1-bound 
(1:1 ratio/molar equivalence) His-TanSH2-Shp2. (B) Zoomed region of (A), 
purple box. 67G of the EF loop shifts in slow exchange, whilst cSH2 residues 
(183G and 207G) do not undergo CSPs. (C) Zoomed region of (A), orange box. 
48N and 72A of the nSH2 undergo CSPs in slow exchange whilst cSH2 residue 
peaks such as 138R and 150S do not. Arrows indicate direction of CSPs and 
asterisks show areas of peak broadening.  
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Figure 6.19: Addition of ITIM1 Peptide to Excess Causes Further CSPs in 
His-TanSH2-Shp2. 
400 µM 15N-labelled His-TanSH2-Shp2 (blue) was titrated to 2.5-fold molar 
excess with ITIM1 peptide (pink), causing many peaks to undergo CSPs in slow 
and fast exchange regimes. Data were collected on a Varian 800 NMR 
Spectrometer at 25 °C in NMR buffer.  
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Figure 6.20: TanSH2-Shp2 CSPs Induced by ITIM1 Titration. 
(A, C, E) Histograms of CSPs induced by ITIM1 titration as a function of residue 
number for 400µM 15N-labelled TanSH2-Shp2. Dashed lines indicate CSPs ≥ 
mean + 2 S.D (red), mean + 1 S.D (orange) and mean (grey), highlighting 
strongly perturbed residues (B, D, F) Cartoon and transparent surface 
representations of TanSH2-Shp2 (PDB ID: 4DGP) with ITIM1-induced CSPs 
calculated from (A), (C) and (E) mapped on. CSPs ≥ mean + 2 S.D (red) and 
mean + 1 S.D (orange) are shown, with CSPs ≥ highlighted in yellow for (F). 
Mean values for (B) (D) and (F) are 0.028± 0.068, 0.017± 0.025 and 0.048± 
0.071 respectively.  
1eq 
2.5-
1eq 
Overall 
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TanSH2:ITIM2 
A similar phenomenon is observed when titrating TanSH2-Shp2 with ITIM2. Around 
13 peaks undergo CSPs at 0.25 molar equivalence in a slow exchange regime, 
including residues 123E, 131K, 152R, 174C and 180D (Figure 6.21 A). A similar 
number of peaks completely broaden, including 117L, 119G, 143H, 148V, 154G, 
171M, 199K, 182G, 203V and 204E (Figure 6.21 B). All the aforementioned residues 
are located within the cSH2 domain. Slow exchange peaks display no further 
intensity changes at equimolar concentrations of ITIM2 peptide. At higher 
concentrations of ITIM2, a number of peaks undergo fast exchange CSPs until the 
end of the titration course (Figure 6.22). CSP analysis reveals that the cSH2 domain 
preferentially binds ITIM2 peptide at 1 eq (Figure 6.23 A), though significant CSPs 
seem to be located throughout the SH2 domain rather than on one face as seen for 
the ITIM titrations with individual cSH2-Shp2 (Figure 6.14). At 2.5 eq, ITIM2 has 
caused CSPs in both SH2 domains (Figure 6.23 E and F). Observation of CSPs that 
occur between 1 and 2.5 eq demonstrate that the nSH2 domain undergoes the most 
shifts at these concentrations (Figure 6.23 C and D). It is worth noting that CSPs 
caused by ITIM2 are not as pronounced as those caused by ITIM1 toward TanSH2 
(Figure 6.23). However, significant CSPs in the cSH2 domain are located in the EF 
loop, known to be involved in pY-peptide binding, as well as residues 154G and 
199K, located in the CD loop and αB helix. These residues are in regions not 
normally involved in direct pY-peptide interaction. Binding of ITIM2 likely induces 
conformational changes throughout cSH2 which could alter relative structural 
element orientation and dynamics, which may explain the large CSPs observed for 
these residues.  
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Figure 6.21: TanSH2-Shp2 Titrations with ITIM2 Peptide. 
(A) Superimposition of unbound (light blue) and ITIM2-bound (1.0 eq, pink) and 
(B) unbound (light blue), 0.5 eq (brown) and 1.0 eq (pink) TanSH2-Shp2 15N-
HSQC spectra. Arrows highlight CSPs and direction whilst asterisks highlight 
broadened peaks. For (B), note cSH2 peaks 166K and 174C perturbing in slow 
exchange, whilst nSH2 residues such as 26D and 45V undergoing no CSPs. 
98L is a known nSH2 high affinity site for ITIM peptide interaction and shifts in 
fast exchange. Residues in italic are part of non-WT His-tag sequence and 
undergo no CSPs. Data were collected on a Varian 800 NMR Spectrometer at 
25 °C in NMR buffer.  
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Figure 6.22: TanSH2-Shp2 Interacts with ITIM2 Peptide. 
Superimposition of unbound (light blue) and ITIM2-bound (2.5 eq, pink) 
TanSH2-Shp2 15N-HSQC spectra, highlighting CSPS throughout the 
spectrum. Data were collected on a Varian 800 NMR Spectrometer at 25 
°C in NMR buffer.  
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Figure 6.23: TanSH2-Shp2 CSPs Induced by ITIM2 Titration. 
(A, C, E) Histograms of CSPs induced by ITIM2 titration as a function of 
residue number for 400µM 15N-labelled TanSH2-Shp2 at 1 eq, 2.5 eq 
minus 1 eq and 2.5 eq respectively. Dashed lines indicate CSPs ≥ mean 
+ 2 S.D (red), mean + 1 S.D (orange) and mean (grey), highlighting 
strongly perturbed residues.  (B, D, F) Cartoon and transparent surface 
representations of TanSH2-Shp2 (PDB ID: 4DGP) with ITIM2-induced 
CSPs calculated from (A), (C) and (E) mapped on. CSPs ≥ mean + 2 S.D 
(red) and mean + 1 S.D (orange) are shown, with CSPs ≥ highlighted in 
yellow for (F). Mean values for (B) (D) and (F) are 0.016± 0.021, 0.021± 
0.022 and 0.046± 0.040 respectively.  
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nSH2 residues significantly perturbed by saturating concentrations of ITIM2 peptide 
are located in canonical pY-peptide binding regions: Both BC and EF loop residues 
and 43L within the βC sheet. However, additional residues outside of these regions, 
such as 16A and 46R within the αA helix and middle of the CD loop are significantly 
perturbed too. Minor helical rearrangements in order to accommodate ITIM2 binding 
could be the cause of this. For 46R, although it is located far from the canonical pY-
peptide pockets, the side-chain forms multiple H-bonds with residues nearby: 20L, 
21L, 24G, 26D and 28S. It is therefore likely that 46R plays a structure-stabilising role 
in the nSH2 domain. It was also noted earlier in this chapter that a portion of the 
aforementioned residues were found to have secondary peaks in both 2D and 3D 
NMR data, suggesting they were sampling alternative chemical environments. Taken 
together, it is likely that ITIM2 peptide binding causes reorganization of residues in 
and around the CD loop, in turn causing 46R to adopt a conformation in a different 
chemical environment to the unbound state.  
 
TanSH2:dITIM  
At 0.25 molar equivalence CSPs are observed in the slow exchange regime (Figure 
6.24 B). These correspond to residues 10N, 22T, 49G, 73T, 93G, 152R, 171M, 
180D, 181V and 183G. Those CSPs in the nSH2 domain do not localise to a 
distinctive patch but to loop regions throughout the chain However, early CSPs in the 
cSH2 domain seem to localise at the +3 pocket.  
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Figure 6.24: TanSH2-Shp2 Titrations with dITIM Peptide. 
TanSH2-Shp2 15N-HSQC spectra of (A) Superimposition of unbound (teal) 
and dITIM-bound (1.5 eq, red) and (B) zoomed region of spectrum of 
unbound (teal), 0.25 eq (purple), 0.5 eq (orange) and 1.5 eq (red). Arrows 
highlight CSPs and direction whilst asterisks highlight broadened peaks. Data 
were collected on a Varian 800 NMR Spectrometer at 25 °C in NMR buffer.  
A 
B 
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At 0.5 molar equivalence peak intensities between the unbound and bound states are 
roughly equal. Although dITIM peptide was added to 1.5-fold molar excess, no 
significant shifts were observed after molar equivalence was reached. Multiple peaks 
underwent CSPs (~60) varying in magnitude. Most CSPs were occurring in slow 
exchange, making assignment of TanSH2-Shp2 in the bound state difficult. 
Assignment of the TanSH2:dITIM complex was performed using titration data from 
previous experiments. A combination of peak overlap and broadening hampered 
efforts, leading to incomplete assignment of the dITIM-bound state. However, some 
general features of the interaction can be observed and concluded from the current 
experiments. 
CSPs caused by the dITIM binding TanSH2-Shp2 are larger in comparison to binding 
single ITIMs (Figure 6.25 A). However, due to dITIM interaction with TanSH2-Shp2 in 
the slow exchange regime, it was difficult to unambiguously assign peaks in the 
bound state, even with previously collected NMR titration data. As such, only CSPs 
for peaks certain to belong to the predicted residue were assigned. In this manner, 
differentiation between broadened and unassignable peaks was difficult and as a 
result, peaks in the control spectrum that were no longer present in dITIM-bound 
spectra were assumed to interact with TanSH2-Shp2. The extent of residue 
interaction was undeterminable based on current data. The dITIM peptide seems to 
engage with residues seen in previous titrations (Figure 6.25 B).  
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Figure 6.25: TanSH2-Shp2 CSPs Induced by ITIM2 Titration. 
(A) Histogram displaying CSPs induced by dITIM titration as a function of residue 
number for 400µM 15N-labelled TanSH2-Shp2. Peptide was added to 1.5-fold 
excess. Dashed lines indicate CSPs ≥ mean + 2 S.D (red), mean + 1 S.D 
(orange) and mean (0.075± 0.087, grey), highlighting strongly perturbed residues. 
54I and 154G CSPs (bars next to asterisks) were truncated for clarity, ppm values 
are 0.56 and 0.36 respectively. (B) Surface Representation of TanSH2-Shp2 
(PDB ID: 4DGP) with dITIM-induced CSPs mapped on. CSPs ≥ mean + 2 S.D 
(red) and mean + 1 S.D (orange) are shown here. Mean= 0.08± 0.09.  
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SAXS Analysis of the Shp2 Tandem SH2:G6b-B dITIM Complex 
SAXS data of the tandem SH2 domain of Shp2 (ΔHis-TanSH2 Shp2, hereby referred 
to as TanSH2) both free and in complex with the dITIM of G6b-B were collected at 
2.3, 4.6 and 9.3 mg/ml at the new P12 beamline utilising X-rays produced by the 
PETRA III storage ring in Hamburg, Germany.  
After initial inspection of the data for signs of radiation damage, buffer subtraction 
and curve plotting as Log[I(q)] vs q (Figure 6.26) were performed. SAXS intensity 
plots of unbound TanSH2 at all concentrations tested were nearly identical in shape 
throughout the entire q-range. dITIM-bound TanSH2 SAXS data displayed similar 
properties. As such the highest concentrations were chosen were further analysis for 
their high quality at the higher q-angles.  
Superimposition of unbound and dITIM-bound SAXS intensity plots reveals 
differences at the low and high q-range, suggesting a change in particle size upon 
complex formation. Rg values further indicate this: 2.26 and 2.56 nm for free and 
dITIM-bound TanSH2, respectively. Invariant parameters are available for bound and 
unbound TanSH2 (Appendix 9). 
Inspection and comparison of the the P(r) curves for unbound and dITIM-bound 
TanSH2 revealed differences between the two. In particular, TanSH2:dITIM displays 
a maximum particle dimension of 8.38 nm, 1.15 nm larger than free TanSH2 (7.23 
nm). No other significant changes in the P(r) curves are observed. In addition, 
superimposition of normalised Kratky plots of unbound and dITIM-bound TanSH2 
reveal no significant changes in curve shape.  
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Figure 6.26: SAXS Data of TanSH2-Shp2:dITIM. 
Data were collected at beamline P12 within PETRA III storage ring, DESY, 
Hamburg on a Dectris Pilatus 2M pixel X-ray detector. (A) SAXS intensity 
plot of unbound (black) and dITIM-bound (red) TanSH2-Shp2. Differences 
between both curves are observed, suggesting a change in global shape 
and size upon complex formation. (B) P(r) curves of unbound and dITIM-
bound TanSH2-Shp2, highlighting differences in pair-wise atomic 
distribution. (C) Normalised Kratky plots  show no significant changes in 
unbound and dITIM-bound forms of TanSH2-Shp2.   
A 
B C 
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Taken together, SAXS data of free and dITIM-bound forms of TanSH2 indicate 
binding of dITIM leads to: 1) An increase in particle size, 2) a change in particle 
shape, likely due to domain rearrangements and 3) no change in the degree of 
disorder as qualitatively judged by Kratky plots.   
 
Ab initio Modelling of TanSH2:dITIM Complex 
DAMMIF was used to generate 10 ab initio models of free and complexed TanSH2 
based on SAXS data analysed with GNOM. Averaging and filtering of models with 
the DAMAVER suite of programs produced rigid-body envelopes for further 
inspection and analysis.  
Unbound TanSH2 adopts a dumbbell-shaped envelope containing two distinct 
roughly spheroid regions of different dimensions: 34 x 23 x 16 Å and 37 x 33 x 31 Å 
for the smaller and larger spheroid, respectively (Figure 6.27 A). The larger spheroid 
has an 18 Å protrusion on the face opposite from its junction with the smaller 
spheroid. SUPCOMB was utilised to superimpose the envelope with a homology 
model based on the crystal structure of TanSH2-Shp2 (PDB: 4DGP). The resultant fit 
has a χ2 of 1.46, indicating the SAXS-derived envelope and homology model adopt 
similar global shapes. The larger cSH2 domain fits best in the larger spheroid and 
vice versa for the nSH2 domain. The CD loop within the cSH2 domain fits within the 
18 Å protrusion well. 
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dITIM-bound TanSH2 adopts a similarly shaped dumbbell as in the unbound form, 
however, both spheroids are of similar dimensions: 33 x 27 x 37 Å and 33 x 26 x 34 
Å respectively. In addition, the protrusion has increased in length to 28 Å.  
 
 
 
 
 
 
 
Figure 6.27: Ab initio Models of TanSH2-Shp2:dITIM Complex. 
DAMMIF-derived envelopes of unbound (A) and dITIM-bound (B) TanSH2-
Shp2 superimposed with homology model of TanSH2 domain (based on PDB 
ID: 4DGP, cartoon representation) using SUPCOMB (χ2= 1.46, unbound and 
2.14, bound). nSH2, red; interSH2 linker, grey; cSH2, yellow; SAXS envelope, 
grey transparent surface. Two views are shown.  
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SUPCOMB was again utilised to fit the TanSH2-Shp2 homology model, yielding a 
superimposition with χ2= 2.14 (Figure 6.27 B). This is a worse fit than unbound 
TanSH2 and indicates that the global shape of the TanSH2:dITIM complex is 
significantly different from that of the unbound TanSH2 model. The similar 
dimensions of both spheroids making up the dITIM-bound TanSH2 envelope also 
make unambiguous assignment of n and cSH2 domains to either one difficult. It is 
also not known whether the 28 Å protrusion belongs to the CD loop of the cSH2 
domain or forms part of the dITIM peptide.  
One possible reason for the poor fit between the TanSH2 homology model and the 
dITIM-bound SAXS envelope is that the former was based on the inhibited state of 
Shp2 as part of the near-full length protein, which could differ in structure to the 
ΔPTP domain construct used in this study. To account for this, a second model was 
generated by reorienting the n and cSH2 domains to resemble the structure 
published by Eck. et al, where the pY binding pockets are on the same face and 
antiparallel to one another (Eck et al., 1996). Automatic fitting yielded a χ2 of 2.15, 
slightly worse than the inhibited orientation of TanSH2. Manual fitting of the individual 
SH2 domains into the dITIM-bound TanSH2 envelope led to a χ2 of 1.81. While this is 
better than previous models, the current model does not fully explain the SAXS data.  
The fact the dITIM peptide, a 36-mer, has not been explicitly accounted for in rigid 
body modelling could explain the poor fits produced for dITIM-bound TanSH2.  
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ITIM Peptides Fail to Activate WT FL-Shp2 Catalytic Activity 
Previous studies have investigated the effect of both single and dual-pY containing 
phosphopeptides on the rate of dephosphorylation of various Shp2 constructs. These 
have shown a high increase in Shp2 catalytic activity with the addition of 
phosphopeptide (Eck et al., 1996; Gavrieli et al., 2003). The tight binding of various 
ITIM peptides to Shp2 SH2 domains observed in previous studies as well as the 
current investigation suggests G6b-B ITIM peptides should activate Shp2 and 
thereby increase catalytic activity (Pumphrey et al., 1999; Famiglietti et al., 1999; 
Gavrieli et al., 2003). 
PNPP activity assays were performed to investigate whether the presence of ITIM 
peptides could increase the catalytic activity of WT FL-Shp2 in vitro. Experiments 
were carried out at RT and as described in Chapter II. Increasing concentrations of 
dITIM seemed to decrease the extent of PNPP dephosphorylation, contrary to 
previous research on the effect of pY-peptides on Shp2 activation state (Figure 6.28). 
However, the high standard deviation for 0.3 and 0.75 µM dITIM concentration 
obscures effective interpretation of the data. Further activity assays with single ITIM 
peptides were partially carried out; ITIM1 peptide added to saturating concentrations 
also failed to increase Shp2 activity as observed by PNPP activity assay (data not 
shown). The results seem to suggest that dITIM addition leads to minimal increases 
in activity. 
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Figure 6.28: PNPP Activity Assays of WT FL-Shp2. 
FL-Shp2 (concentration: 3 µM) catalytic activity was assessed with PNPP 
activity assay. Activity was assessed either in the presence of either 
increasing amounts of sodium phosphate buffer only or sodium phosphate 
buffer + dITIM. Each point is an average of 3 repeats within the same 
experiment, initiated at RT with 10 µl 150 mM PNPP (final concentration of 
15 mM), run for 10 minutes and terminated upon addition of 25 µl 5 M NaOH. 
Data collected using iMark Microplate reader (BioRad) at 415 nm 
wavelength. Assay buffer: 50 mM HEPES pH 7.5, 2 mM EDTA, 5 mM DTT, 
2% glycerol, 0.01% Triton X-100. dITIM stock: 244 µM dITIM in 50mM Na 
Phosphate pH 7.4. 
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Chapter Conclusions 
Phosphorylated dITIM is Primarily Unfolded 
Secondary structure predictions of dITIM suggested a portion of ITIM2 could form a 
β-strand or extended structure. CD analysis of phosphorylated dITIM indicates a 
predominantly random coil structure with possible minor secondary structural 
elements. Since the secondary structure prediction program does not take into 
account PTMs, prediction of dually-phosphorylated dITIM secondary structure could 
not be made. This may explain the difference between predicted and experimental 
data, as phosphorylation has been known to cause changes in secondary structure. 
However, both ITIMs are constitutively phosphorylated (Mazharian et al., 2013) and 
thus dually-phosphorylated dITIM is more biologically relevant than its 
unphosphorylated form as the latter is not known to exist at significant levels within 
cells. 
  
TanSH2-Shp2 Binds dITIM in 1:1 Stoichiometry 
As dITIM contains two points of contact for SH2 domain binding, and since TanSH2-
Shp2 contains two binding sites for phosphorylated peptides, it was presumed the 
pair would bind with 1:1 stoichiometry. To validate this hypothesis and to rule out 
other binding stoichiometries, a solution-based sedimentation technique was 
employed.  
Velocity AUC experiments comparing unbound and dITIM-bound TanSH2-Shp2 
reveal an increase in the hydrodynamic radius upon complex formation. The shift in 
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cS is also consistent with 1:1 binding stoichiometry and such an increase may be 
indicative of reorientation of SH2 domains to accommodate dITIM. 
 
Shp2 SH2 Domains Display Binding Preferences toward ITIM Peptides 
Solution NMR binding experiments showed that the individual SH2 domains of Shp2 
are capable of binding ITIM peptides derived from G6b-B. ITIM1 binds the nSH2 
domain in slow exchange while binding the cSH2 domain in slow exchange. For 
ITIM2, the opposite is true: the nSH2 domain binds ITIM2 in fast exchange and binds 
the cSH2 domain in slow exchange. This indicates that the nSH2 domain has a 
higher affinity toward ITIM1 than ITIM2 and the cSH2 domain has a higher affinity 
toward ITIM2 than ITIM1. The ITIM specificity for either SH2 domain thereby 
suggests that in a cellular environment, there is a preferred domain orientation 
present in the Shp2:G6b-B interaction. Whether this phenomenon is of functional 
relevance to Shp2 and indeed the Shp phosphatases in general remains to be 
elucidated. 
 
ITIM1 Truncation Results in Weaker SH2 Binding 
ITIM1s, where ITIM1 was truncated by two C-terminal residues (+5 and +6 positions 
of phosphopeptide) showed diminished (that is, reduced CSP magnitude) binding to 
both nSH2 and cSH2 domains, although differential exchange phenomena were still 
present between the two domains. Peaks of both SH2 domains also underwent 
smaller CSPs with ITIM1s than with ITIM1. This suggests ITIM1 residues at the +5 
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and +6 positions i.e. 216H and 217L of WT G6b-B respectively, are important in 
contributing binding affinity to the Shp2 SH2 domain interaction.  A combinatorial 
screening approach used to study the SH2 domains of Shp1 and Shp2 found they 
were able to bind phosphopeptide residues beyond the +3 position, up to +6, and 
each SH2 domain showed preferences for certain amino acids at these positions. For 
example, nSH2-Shp2 was observed to prefer bulky residues such as F, H and W (in 
order of highest to lowest preference) at the +5 position (Imhof et al., 2006). 
Interestingly, the cSH2 domains of Shp1 show narrower amino acid binding 
preferences at the +4, +5 and +6 positions which could confer additional specificity 
for the tandem SH2 domains when binding peptides. 
 
SH2:ITIM Specificity is Maintained in TanSH2-Shp2 
NMR titration experiments of His-TanSH2-Shp2 with single ITIM1 and ITIM2 peptides 
as well as dITIM demonstrated that TanSH2-Shp2 was capable of binding ligands 
and was thus functionally active. Closer inspection of CSPs revealed that TanSH2-
Shp2 was able to bind ITIM peptides with the same differential exchange rates 
observed for the individual SH2 domains binding single ITIM peptides. ITIM1 
preferentially bound the nSH2 in a slow exchange regime and after 1:1 molar 
equivalence, presumably when the nSH2 binding site was completely bound, were 
CSPs observed for the cSH2 domain in a fast exchange regime. In a similar manner, 
TanSH2-Shp2 titration with ITIM2 causes CSPs in residues within cSH2-Shp2 in a 
slow exchange regime, albeit these CSPs were markedly reduced compared to ITIM2 
binding cSH2-Shp2 alone. In the current experiment, ITIM2-induced CSPs in the 
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cSH2 domain of TanSH2-Shp2 were weaker in general than for ITIM1 binding the 
nSH2 domain in TanSH2-Shp2. However, after 1:1 molar equivalence of TanSH2-
Shp2 and ITIM2 is reached, fast exchange CSPs are observed for residues within 
nSH2-Shp2.  This clearly demonstrates that peptide specificity is maintained between 
either SH2 domain within the TanSH2-Shp2 construct. 
 
Differences in SH2:ITIM Peptide Interactions 
Whilst both ITIM1 and ITIM2 peptide bind the SH2 domains of Shp2, different 
subsets of residues underwent CSPs in NMR titration experiments. In particular, the 
interaction of either ITIM with nSH2-Shp2 caused CSPs in residues within or at the 
beginning of the DE loop, specifically 59T, 60G and 61D. In WT FL-Shp2, these 
residues make numerous contacts with the PTP catalytic cleft, particularly 61D which 
acts as a phosphate group mimic ( Hof et al., 1998). ITIM1 binding causes significant 
CSPs or broadening here, although these residues are distinct from the pY and +3 
pockets in nSH2-Shp2. It cannot be proven without uncertainty that ITIM1 residues 
do not make direct contacts with DE loop residues, based on current NMR data. 
However, taken together with previous phosphopeptide bound nSH2-Shp2 
structures, ITIM1-binding likely causes conformational changes in the DE loop. Like 
ITIM1, ITIM2 binding causes 60G to undergo significant CSPs, though to a lesser 
extent. Surrounding residues also undergo CSPs above the mean, again to a lesser 
extent than those seen when ITIM1 peptide had been added. Therefore, ITIM2-
induced perturbations is DE loop residue signals could be affinity dependent, only 
changing conformation once bound to its cognate ligand. Interestingly, cSH2-Shp2 
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DE loop residue undergo minimal CSPs upon ITIM peptide binding, suggesting DE 
loop conformational changes are restricted to nSH2-Shp2. nSH2-Shp1 contains a 
homologous DE loop sequence, suggesting the mechanisms of peptide binding 
causing DE loop conformational changes is conserved. This has also been proposed 
in previous studies ( Hof et al., 1998) 
Crystal structures of phosphopeptide-bound nSH2 in isolation (Lee et al., 1994) or as 
part of the tandem SH2 domain (Eck et al., 1996) showed differences in DE and EF 
loop conformation when compared with unbound nSH2 in isolation and as part of WT 
FL-Shp2. These conformational changes in the bound state would cause steric clash 
with PTP domain residues and could disrupt the H-bonding network enough to cause 
nSH2 domain removal from the active site. This mechanism has been suggested and 
based on crystallographic data and modelling (Hof et al., 1998) and is corroborated 
by the current study of phosphopeptide:Shp2 interactions by solution NMR. Also, 
molecular modelling suggests Y66 within the EF loop acts as a conformational switch 
for nSH2-Shp2 (Guvench et al., 2007), influencing DE loop residues to undergo local 
changes and thus could form part of the overall Shp2 activation mechanism. Y66 was 
consistently found to undergo either significant CSPs or broaden altogether in ITIM 
titration experiments. While this is not definitive in confirming Y66 acts as a 
conformational switch in Shp2 activation, these results are promising and warrant 
further investigation.  
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dITIM-Binding Causes Domain Rearrangements in TanSH2-Shp2 
NMR titration data of the TanSH2:dITIM interaction provided some insights into the 
binding mode in that the affinity is likely below the micromolar range based on the 
presence of slow exchange phenomena present during the course of the experiment, 
implying a slow off rate of dITIM peptide from the TanSH2 domain.  Further 
information obtained from SAXS characterisation of the complex revealed a larger Rg 
value than for the TanSH2 domain alone, meaning the relative size of the protein has 
increased and this is likely attributed to complex formation with dITIM. Additionally, 
the SAXS envelope of dITIM-bound TanSH2 has become more extended, suggesting 
dITIM terminal residues extending parallel and away from TanSH2 or, more likely, 
extension of TanSH2 on its major axis caused by  large scale domain reorientation of 
one or both SH2 domains. 
The orientation of the Shp2 SH2 domains as part of the full length protein does not 
appear optimal for binding dually phosphorylated peptide motifs due to both 
phosphopeptide pockets facing different directions. Initial engagement of one SH2 
domain with its cognate ITIM ligand increases the effective local concentration of the 
second ITIM ligand, increasing the likelihood of an interaction with the remaining 
unbound SH2 domain. Furthermore, the initial ITIM interaction with its SH2 domain 
could cause a conformational change in the latter, allowing it to sample more areas 
of space. An increase in the relative mobility of the interSH2-linker might play a role 
in facilitating this domain reorientation. An optimal tandem SH2 orientation could 
form, allowing the remaining SH2 domain to bind the remaining ITIM. 
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The current understanding of Shp2 structural biology posits that PTP domain-bound 
nSH2 adopts a distorted conformation unable to effectively bind phosphopeptides. 
Residues within the DE and EF loops of nSH2 as part of FL-Shp2 show marked 
differences in Cα positions compared to nSH2 in isolation (Hof et al,. 1998). cSH2 
however, adopts a conformation more readily able to bind phosphopeptide, and has 
been hypothesised to be the first point of interaction for peptide ligands (Pao et al., 
2007). Aside from circumstantial data from crystal coordinates however, no 
experimental data is available to lend weight to this hypothesis. The AUC and SAXS 
experiments from the current study demonstrate that TanSH2 in isolation increases 
in hydrodynamic radius and radius of gyration upon binding dITIM peptide. 
Qualitative analysis of the intrinsic flexibility of TanSH2:dITIM using Kratky plots 
reveal that differential mobility may exist between it and unbound TanSH2. It is 
possible that stable binding of dITIM causes certain mobile elements to rigidify (BC, 
CD and EF loops of both SH2 domains) whilst causing a large scale domain 
reorientation to produce an optimal conformation for favourable dITIM binding, the 
bound state being more extended as a result of interSH2-linker relocation. 
 
nSH2:ITIM1s Complex Formation 
The interaction of nSH2-Shp2 with the ITIM1 sequence was judged by SPR (Coxon 
et al., 2012) to be stronger than ITIM2. Slow exchange peaks were difficult to 
unambiguously assign, leading to use of 3D NMR spectra to assign the backbone to 
over 90% for nSH2:ITIM1s. Residues involved in ITIM1s high affinity binding were 
unassignable, such as the EF loop, as well as 35K within the BC loop and 85H and 
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86G within the BG loop, which were also unassigned in uncomplexed nSH2-Shp2. It 
is interesting to note that these residues were unassignable in both peptide-bound 
and unbound forms. For 85H and 86G, neither of which form H-bonds with residues 
within the nSH2 domain or contacts with phosphopeptides, intermediate exchange 
processes independent of ligand binding could explain their complete lack of 
assignments. However, 35K, situated in the highly mobile BC loop, does not appear 
during ITIM1s interaction. This is consistent with other studies of peptide-bound SH2 
domains investigated by NMR which show the BC loop as being highly flexible. While 
it is thought the BC loop may stabilise in a narrower set of conformations during 
peptide interaction, the failure to obtain backbone information may suggest no 
significant change in the dynamic state of 35K upon ligand binding. From NMR 
titration analysis, both flanking serine residues (34S and 36S) either undergo 
significant CSPs or broaden completely. This suggests at least part of the BC loop is 
capable of directly binding and/or changing conformation during phosphopeptide 
docking, consistent with previous reports of SH2:phosphopeptide interactions 
(Bradshaw & Waksman, 2002; Frese et al., 2006). 
Backbone assignment and secondary structure prediction of nSH2:ITIM1s using 
chemical shift data yielded a typical SH2 domain topology that does not deviate from 
the unbound nSH2 domain secondary structure predictions made in Chapter IV as 
well as available crystallographic data (Lee et al., 1994).  
The EF Loop of nSH2:ITIM1s complex is in intermediate exchange as observed by 
peak broadening of residues 65L, 66Y and 67G. The EF loop forms portions of the 
SH2 specificity pocket and is critical in binding hydrophobic residues at the +3 
position of phosphopeptides (Songyang et al., 1993). ITIM1s residues C-terminal to 
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pY are Ala-Asp-Leu-Asp. The conserved Leu or other hydrophobic residue of binding 
phosphopeptides has been shown in previous SH2 domain ligand-bound structures 
to bind deep into the hydrophobic specificity pocket, contributing entropy-driven 
binding energy to the interaction (De Fabritiis et al., 2008; Ladbury et al., 1995). A 
canonical SH2:peptide interaction is most likely occurring. Interestingly, both ITIM1 
and ITIM1s peptide titration series to 2.5-fold molar excess do not cause EF loop 
residue peaks to return once nSH2-Shp2 is fully saturated. As the ITIM1s peptide 
has a slightly lower affinity for nSH2-Shp2, a 1:1 ratio of peptide:SH2 may not have 
been sufficient for saturating nSH2-Shp2 peptide binding sites, which may explain 
why EF loop residues were in intermediate exchange in nSH2:ITIM1s backbone 
assignment spectra.  
 
dITIM and Role of Shp2 Interaction 
PNPP activity assays were used to test the hypothesis that dITIM peptide interaction 
with WT FL-Shp2 should increase the enzymatic rate of dephosphorylation caused 
by release of the autoinhibitory contacts from the nSH2 DE loop with the catalytic 
cleft. However, little to no activation was noted and instead, a slight inhibitory dITIM 
concentration-dependent effect was observed. There could be a number of reasons 
for this result. Firstly, the SH2 domains could be tightly bound to the catalytic domain, 
exhibiting a very slow off-rate that effectively prevents dITIM binding to the 
overlapping site.  Secondly, the presence of the His-tag could disrupt efficient dITIM 
binding and PTP activation. Although NMR titration experiments clearly 
demonstrated His-TanSH2 could bind dITIM, which is corroborated by sedimentation 
281 
 
velocity AUC experiments, in the full-length protein there could be additional points of 
contact and interaction with the PTP domain and/or C-terminal tail that could prevent 
domain reorientation for efficient activation.  
Thirdly, dITIM could activate WT FL-Shp2 regardless of the presence of an N-
terminal His-tag, only to bind and dephosphorylate dITIM peptide not bound to the 
TanSH2 domain. This is a possibility as saturating concentrations of dITIM peptide 
were reached after 3 µM, though an inhibitory effect was already observed by this 
point. Experiments have not been performed to investigate whether the Shp2 PTP 
domain can indeed bind and dephosphorylate dITIM. Finally, independent repetitions 
were not performed for this experiment using different batches of WT FL-Shp2, 
buffers and new stocks of dITIM, limiting the reliability of these initial results. While no 
positive control was used to assess Shp2 activity during the course of the assay, 
qualitative PNPP assays (i.e. to observe any colour change after 1h when compared 
to controls) are performed for each FL-Shp2 batch produced to ensure active protein 
is present, though a reliable positive control would strengthen the experiment. It is 
also unclear whether phosphate buffer may inhibit PTP activity and this warrants 
further investigation. 
Additionally, the PNPP assay may not be appropriate to investigate the role of dITIM 
on FL-Shp2 and instead, the malachite green phosphate detection assay or DiFMUP 
assay could be utilised (Montalibet et al., 2005).  
For the reasons outlined above, the activity assay performed is deemed inconclusive 
and warrants further investigation by way of different assay methods with WT and 
mutant forms, technical repetitions and His-tag removal. 
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Chapter VII 
Discussion and Conclusions 
 
This project has investigated various questions put forth at the beginning of this work 
regarding aspects of Shp2 structural biology that were yet to be answered. Through 
experimentation and modelling, a number of novel discoveries have been made 
which can now be utilised in building a better understanding of this fascinating 
molecule in the solution state. In addition, like all research projects, many new 
questions have arisen and will need to be investigated in the future. The following 
chapter will attempt to summarise what has been learnt about Shp2 and contemplate 
the wider implications of the present study. 
 
Shp2 in the Solution State 
All solved structures of Shp2 SH2 domains were done so by X-ray crystallography. 
Such a "rigid snapshot" may not be enough to describe the native state of proteins in 
solution, especially those with numerous mobile elements, some of which are 
important for protein function. For SH2 domains in general, mobile loops govern 
stabilisation and specificity of phosphopeptide interactions. For such a highly 
conserved protein of potential therapeutic value, increased knowledge of Shp2 in the 
solution state may be important to consider when designing experiments and 
inhibitors.  
283 
 
NMR studies of nSH2, cSH2 and tandem SH2 domains of Shp2 reveal the secondary 
structure of these proteins is consistent with previously published structures of Shp2 
as well as other SH2 domain structures solved by both X-ray crystallography and 
solution NMR. In addition, SAXS analysis of the unbound tandem SH2 domain show 
that while there is some resemblance to a rigid structure, a flexible model best 
represents the available data. Dynamic regions of the tandem SH2 domain lie at the 
termini, interSH2-linker and CD loop of the cSH2 domain. Interestingly, the interSH2-
linker has been shown to form numerous contacts between itself and both adjacent 
SH2 domains and thus was assumed to be fair rigid, also being under 10 residues in 
length it was thought unlikely to be mobile.  
Shp2 exhibits flexibility in solution that would not be detected well by X-ray 
crystallography. Domains in isolation fit crystallographic data well but with 
discrepancies that suggest conformational flexibility and loop mobility contribute to 
the SAXS data. 
The C-terminal tail, which has not been structurally characterised up until the present 
study, is likely to be highly mobile in solution as judged by the SAXS data. Sharp 
peaks from FL-Shp2 observed in NMR experiments could correspond to the C-
terminal tail, though this is somewhat speculative. Given that none of the assigned 
peaks in either individual SH2 domain and tandem SH2 domain do not overlay with 
the peaks in the FL-Shp2 spectrum, the peaks in the latter must originate from either 
the catalytic domain or C-terminal tail, and, more unlikely, the His-tag.  
The SH2 Domains of Shp2 exhibit conformational changes in discrete patches, 
particular for the nSH2 domain where such states were observed outside of the 
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canonical pockets. This could be due to minor sequence-specific structural 
rearrangements, explaining why little secondary conformational changes are present 
in the cSH2 domain. 
The interSH2 linker was found to be mobile as part of a TanSH2-only construct. This 
mobility likely arises due to free movement of the nSH2 in the absence of PTP 
domain to form an interface with, and thus could correspond to the TanSH2 in the 
active FL-Shp2 structure.  
Conformational flexibility observed in the CD loop by NMR of cSH2 might be of 
functional relevance, but as of yet no function has been assigned to them. Using the 
Crk SH2 domain as an example, it was observed that the wild-type structure contains 
a long polyproline motif–containing insertion within the DE loop that was found to 
bind the c-Abl SH3 domain (Anafi et al., 1996; Donaldson et al., 2002). Such a 
phenomenon in the context of Shp2 is certainly possible due to the solvent 
accessibility of the CD loop, though it is not rich is proline residues, instead 
harbouring a number of lysine residues which could form electrostatic interactions 
with other biological molecules. 
 
Structural Differences between WT and Mutant Shp2 are Present 
The first experimental evidence of FL-Shp2 E76K mutation causing structural 
perturbation has been presented in this study. The likely scenario is the equilibrium 
between closed and open form could be disrupted allowing FL-Shp2 to take on an 
extended structure for longer residence times.  
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A crystal structure does not yet exist for E76K Shp2, though studies have looked at 
other disease relevant mutants (Yu et al., 2013; Qiu et al., 2014) but given the 
importance of understanding highly-activating Shp2 mutants, it was surprising E76K 
was not structurally characterized and this could be due to the increased mobility 
caused by E76K mutation. 
 
The Case of the Two-Faced Tryptophans 
Current evidence taken from NMR experiments indicates the presence of at least two 
equally populated conformations of the tryptophan side-chain indole system. It is 
possible other conformations exist but are not visible at the time-scales mentioned.  
Various crystal structures of the SH2 domains of Shp2 show that both 6W and 112W 
reside in the first N-terminal loop of each individual SH2 domain. Trp residues at this 
position are highly conserved, suggesting they have a role.  
The flanking residues of each Trp are identical, suggesting that this N-terminal 
portion may be evolutionarily conserved and thus likely serve a function. Since this 
region is located on the opposite face to the phosphopeptide binding cleft, it is 
improbable that the role of these Trp residues and indeed the N-terminal loop as a 
whole are functional in some form. It is therefore likely the loop could play a structural 
role. The indole ring could engage in multiple hydrophobic interactions and stabilise 
the SH2 domain core. Both 6W and 112W engage in H-bonding with the main-chain 
amide groups of 31A and 137V respectively. There could be potential for the indole 
side chain amide to form H-bonds half of the time in solution. This may be caused by 
286 
 
the rest of the N-terminal loop peeling on and off the back side of the SH2 domains. 
However, while this could hold true in the individual SH2 domains, the presence of 
double the expected Trp resonances in the tandem SH2 suggests this phenomenon 
could still occur as part of a WT protein. The Trp residues within the SH2 domains 
are both in the same relative position in both SH2 domains (βB4) and are located one 
residue N-terminal to the highly conserved Arg residues involved in pY engagement. 
As such, conformational changes in ArgβB5 and any other residue in the conserved 
FLVR motif could induce CSPs in surrounding residues not directly involved in 
phosphopeptide binding. This may explain why CSPs are observed in both 6W and 
112W main-chain and side-chain amide groups upon ITIM peptide engagement.  
 
Functional Significance of dual ITIM Specificity and Phosphopeptide 
Engagement 
The preferential binding of SH2 domains to specific peptide sequences is well 
studied and multiple studies have also observed peptide specificity across SH2 
domains within the same polypeptide chain (See introduction). The individual Shp2 
SH2 domains have been observed to bind ITIM1 and ITIM2 peptides with varying 
affinities, as well as showing both ITIMs in tandem (dITIM) can bind the tandem SH2 
domain with even higher affinity (Coxon et al., 2012). 
In the present study, the molecular interactions of G6b-B ITIM peptides have been 
assessed by a variety of biophysical methods. Differential exchange phenomena 
were observed for both nSH2 and cSH2 domains of Shp2 as well as the cSH2 
domain of Shp1 and this was ITIM peptide dependent. This partly corroborates data 
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from Coxon et al. in that differences in relative affinity for n and cSH2-Shp2 existed 
when studied by SPR and direct-binding assays. However, their study also showed 
cSH2-Shp2 displayed negligible binding to ITIM1, ITIM2 and dITIM peptides. cSH2-
Shp1 was also shown to weakly bind ITIM peptides. By solution NMR experiments, 
cSH2-Shp2 was found to bind both ITIM1 and ITIM2, the latter with higher affinity. In 
addition, cSH2 residues from TanSH2-Shp2 bound ITIM2 in slow exchange and 
ITIM1 in fast exchange, as well as binding dITIM in slow exchange. Taken together, 
cSH2-Shp2 does in fact bind both ITIM peptides, with a clear preference for ITIM2. 
cSH2-Shp1 was also found to bind both ITIM1 and ITIM2, also displaying a 
preference for ITIM2. Coxon et al. also observed that nSH2-Shp2 binds dually 
phosphorylated dITIM with a KD value of 130 nM. However, TanSH2-Shp2 bound 
dually-phosphorylated dITIM with a KD value of 0.48± 0.09 nM i.e almost 271-fold 
higher in the presence of the cSH2 domain. Given the NMR titration data showing 
binding and preference for cSH2-Shp2 and ITIM2, the additional binding affinity seen 
by SPR likely arises from cSH2 binding ITIM2. 
The TanSH2 in complex with dually phosphorylated peptide takes on and extended 
“open” structure and this is the first instance of such an interaction being structurally 
characterised for Shp family PTPs. Single phosphorylated peptides binding into each 
SH2 pocket may not induce the same rearrangements caused by dually 
phosphorylated peptides and thus make the solution characterisation of the 
TanSH2:dITIM novel. A model for immunoreceptors activation is summarised in 
Figure 7.0. 
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Figure 7.0: Model for Shp2:G6B-b Interaction 
(A) Sub-optimal SH2 domain orientation during Shp2:G6B-b docking leads to 
ineffective signalling. The interaction between the ITIMs and TanSH2-Shp2 is 
too weak to activate dephosphorylation. The CTE is likely still functional and 
may become phosphorylated by nearby PTKs, causing Y542 and Y580 to act 
as binding sites for other proteins. 
(B) When the TanSH2 of Shp2 binds G6B-b in its preferred orientation, a 
stabilized complex can form and lead to a marked increase in PTP activity, 
affecting downstream signalling cascades.  
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Limitations 
There were a number of limitations of the present studies and these are outlined 
below. 
Although Shp2 was the main focus in this research project, parallel collection and 
analysis of data from the closely related homologue Shp1 may have proved useful for 
comparing ITIM peptide binding and mechanisms of activation. More specifically, the 
nSH2 domain of Shp1 was insoluble post-overexpression in E. coli, preventing a 
direct comparison between it and nSH2-Shp2. Whilst attempts were made to refold 
nSH2-Shp1 from solubilised inclusion bodies, this was ultimately unsuccessful, 
though it is well documented for other SH2 domains (Babon et al., 2006; Haan et al., 
1999). These results were corroborated by a recent publication during this study that 
had similar difficulties with nSH2-Shp1 (Coxon et al., 2012). Consequently, low 
expression yields of TanSH2-Shp1 are likely due to presence of the nSH2-Shp1 and 
as a consequence this construct was not pursued for further study. 
The use of N-terminal His-tagged TanSH2 and various FL-Shp2 constructs resulted 
in pure and reasonable to high amounts of protein for biophysical studies. However, 
validation that the His-tag does not interfere with Shp2 ligand binding was not 
performed. Data suggest that there is a definite structural perturbation caused by the 
presence of an N-terminal His-tag and this could potentially affect normal ITIM 
peptide binding. This is an important question that needs to be addressed prior to 
further studies involving SH2-domain containing phosphatases. 
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Future Work 
Although a myriad of experiments were performed in order to develop an 
understanding of Shp2 interactions with various biomolecules, many more research 
questions have been asked and as a result, description of further experimentation is 
described below to strengthen or otherwise test multiple hypotheses. 
Further biophysical characterisation of full length Shp2 WT and mutant via AUC or 
dynamic light scattering (DLS) will further aid the investigation of structural 
reorganisation of the sub-domains in disease states. The information derived from 
these methods, primarily the hydrodynamic radius, may explain available SAXS data 
as well as provide a basis for further hypothesis testing. In the former scenario, the 
radius of gyration/hydrodynamic radius (Rg/Rh) ratio can provide information of the 
flexibility of Shp2 in solution (Bielnicki et al., 2011), where ratios close to 1 point 
toward compact molecules and ratios above 1.5 suggest flexibility (Rubinstein & 
Colby, 2003). In the latter scenario, hydrodynamic radii of various Shp2 mutants 
could provide information on the extent of conformational change, measured as a 
deviation from the WT Rh value. 
From this research project, assignment data now exist for the nSH2 and cSH2 
domains of Shp2. Introducing disease mutant substitutions into either of these 
individual domains, as well as the TanSH2 domain, and acquiring 15N-HSQC spectra 
could yield insights into the extent of conformation change in solution. Deviation from 
WT can potentially be measured as CSPs depending on how close WT and mutant 
peaks are. This would yield residue level information concerning the nature of 
conformational change in various disease mutation contexts. In addition, CD 
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experiments can yield complementary secondary structure information so as to 
further investigate structural perturbations.  
Following on from the ‘HSQC mutation screen’, one could select promising mutants 
for further characterisation by way of 3D backbone assignment spectra data 
collection and analysis. Taken together with side-chain proton assignments and NOE 
distance restraints a solution structure of a Shp2 SH2 domain can be solved. This is 
of particular importance as whilst various crystal structures of Shp2 mutants do exist 
(see Introduction), only two such structures have investigated SH2 domain mutations 
(Qiu et al., 2014)  
In addition to NMR studies of unliganded mutant SH2 domains, peptide titration 
experiments similar to those carried out in this study could be performed for disease-
relevant mutants, E76K being a leading choice as it is the most abundant mutation 
observed in Noonan syndrome and cancer settings (Tartaglia et al., 2003). 
As described in the previous section, the presence of an N-terminal His-tag may 
cause aberrant ligand binding. Testing this hypothesis by efficient removal of the His-
tag or production of a construct with a C-terminal tag instead would assist validation 
of efficient construct design. 
SH2 domain residues critical in Shp2:G6b-B interactions can be delineated through 
site-directed mutagenesis of strongly perturbed residues identified by solution NMR 
binding studies. This may yield further information as to the residue-level 
determinants of Shp2 specificity for ITIM peptides as well as explain in part the 
differential affinity of Shp1 and Shp2 toward various biologically relevant peptide 
motifs. However, with the currently available data from the present and previous 
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studies, data-driven docking of TanSH2-Shp2 with dITIM may be possible. Using 
CSP data from solution NMR titration experiments and SAXS data of the 
TanSH2:dITIM complex, SAXS-assisted docking via HADDOCK could produce a 
reasonable model (Schmitz et al., 2012). However, since no dITIM-residue specific 
information of the TanSH2:dITIM interaction exists, further experiments such as 
filtered NOESY experiments may need to be performed in ordered to provide 
additional NOE restraints. The dITIM peptide is disordered in solution so flexible 
docking will have to be used to yield a better model (Bonvin, 2006). 
Cell-based studies would bolster hypotheses regarding the functional relevance of 
Shp2 domain orientation within ITIM/ITAM/ITSM interactions. For example, switching 
of ITIM1 and ITIM2 sequences with one another so that ITIM1 is C-terminal to ITIM2 
and observing changes in Shp1/Shp2 binding as well as consequences of 
downstream signalling pathways could potentially explain the need for peptide motif 
specificities of SH2 domains within the same polypeptide chain. 
SAXS studies of various Shp2 constructs and mutants identified regions of flexibility. 
However, further validation with complimentary techniques may strengthen these 
hypotheses. Specifically, the dynamics of TanSH2-Shp2 can be investigated utilising 
NMR relaxation experiments collecting T1, T2 and Heteronuclear NOE data in both 
unbound and ligand-bound forms (Kay, 2005). A simpler approach employing limited 
proteolysis and peptide sequencing/mass spectrometry to identify surface exposed 
regions might also assist in confirming the dynamic nature of Shp2 in solution. 
294 
 
Final Remarks 
Whilst X-ray crystallography and MD studies of Shp2 are numerous, little structural 
research has been performed in the solution state. This project has investigated the 
behaviour of Shp2 in solution using a variety of biophysical methods. Information has 
been obtained at the structural level both free and in complex with cognate ligands, 
further confirming the validity of crystallographic data and discovering the intrinsic 
flexible nature of Shp2 in wild-type and mutant forms. The knowledge gained from 
this study will be fed into further biophysical research as well as drug discovery 
efforts. 
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Appendix 
1. Human PTPN11 cDNA gene sequence (synthesised by Genscript) 
ATGACCAGCCGTCGCTGGTTTCATCCGAATATTACGGGTGTTGAAGCGGAAAACCTGCT
GCTGACCCGTGGTGTGGATGGCAGTTTTCTGGCGCGTCCGAGCAAATCTAATCCGGGT
GATTTCACCCTGAGCGTGCGTCGCAATGGCGCAGTTACCCACATTAAAATCCAGAACAC
GGGCGATTATTACGATCTGTACGGCGGTGAAAAATTTGCCACCCTGGCAGAACTGGTTC
AGTATTACATGGAACATCACGGTCAGCTGAAAGAGAAAAACGGCGATGTGATCGAACTG
AAATATCCGCTGAACTGCGCAGATCCGACGAGTGAACGTTGGTTCCATGGTCACCTGAG
CGGCAAAGAAGCGGAAAAACTGCTGACCGAAAAAGGTAAACATGGCTCTTTTCTGGTGC
GTGAAAGTCAGAGCCACCCGGGTGATTTCGTTCTGAGTGTGCGCACGGGTGATGATAA
AGGCGAAAGTAATGATGGCAAAAGCAAAGTTACCCATGTGATGATTCGTTGTCAGGAAC
TGAAATACGATGTTGGCGGTGGCGAACGCTTTGATAGCCTGACCGATCTGGTGGAACA
CTATAAGAAAAACCCGATGGTGGAAACCCTGGGCACGGTTCTGCAGCTGAAACAGCCG
CTGAATACCACGCGCATTAACGCGGCCGAAATCGAAAGCCGTGTTCGCGAACTGTCTAA
ACTGGCGGAAACCACGGATAAAGTGAAACAGGGTTTTTGGGAAGAATTTGAAACCCTGC
AGCAGCAGGAATGCAAACTGCTGTACAGCCGTAAAGAAGGCCAGCGCCAGGAAAACAA
AAACAAAAACCGTTACAAAAACATCCTGCCGTTCGATCATACCCGCGTGGTTCTGCACG
ATGGTGATCCGAACGAACCGGTGTCTGATTACATCAATGCCAACATTATCATGCCGGAA
TTTGAAACCAAATGCAACAACTCTAAACCGAAAAAATCTTACATCGCAACCCAGGGCTGT
CTGCAGAATACGGTGAACGATTTTTGGCGTATGGTTTTCCAGGAAAACTCTCGCGTTATT
GTGATGACCACGAAAGAAGTTGAACGTGGTAAAAGTAAATGTGTGAAATACTGGCCGGA
TGAATACGCCCTGAAAGAATATGGCGTTATGCGTGTGCGCAATGTTAAAGAAAGCGCAG
CGCATGATTACACGCTGCGCGAACTGAAACTGTCTAAAGTTGGTCAGGGCAACACCGAA
CGTACGGTGTGGCAGTATCATTTTCGTACCTGGCCGGATCATGGTGTGCCGAGCGATC
CGGGTGGCGTTCTGGATTTCCTGGAAGAAGTGCATCACAAACAGGAATCTATTATGGAT
GCCGGTCCGGTGGTTGTGCATTGCAGTGCAGGTATCGGCCGTACCGGCACGTTCATCG
TTATCGATATCCTGATCGATATCATCCGCGAAAAGGGTGTGGATTGTGATATTGATGTTC
CGAAAACGATCCAGATGGTTCGTTCTCAGCGCAGTGGCATGGTGCAGACCGAAGCACA
GTATCGTTTCATCTACATGGCGGTGCAGCATTATATTGAAACCCTGCAGCGTCGCATCG
AAGAAGAACAGAAAAGTAAACGCAAAGGTCACGAATACACGAACATCAAATACAGCCTG
GCCGATCAGACCAGCGGCGATCAGTCTCCGCTGCCGCCGTGTACCCCGACGCCGCCG
TGTGCCGAAATGCGTGAAGATAGCGCCCGCGTGTATGAAAACGTTGGCCTGATGCAGC
AGCAGAAATCTTTTCGTTAA  
Shp2 protein sequence: 
>sp|Q06124-2|PTN11_HUMAN Isoform 2 of Tyrosine-protein phosphatase non-
receptor type 11 OS=Homo sapiens GN=PTPN11 
MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTG 
DYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGK 
EAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYD 
VGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETT 
DKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEP 
VSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEV 
ERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHF 
RTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIR 
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EKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGH 
EYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR 
 
WT FL-Shp2 Sequence: 
MHHHHHHSSGVDLGTENLYFQSMTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAV
THIKIQNTG 
DYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGK 
EAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYD 
VGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETT 
DKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEP 
VSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEV 
ERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHF 
RTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIR 
EKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGH 
EYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR 
E76K FL-Shp2 Sequence: 
MHHHHHHSSGVDLGTENLYFQSMTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAV
THIKIQNTG 
DYYDLYGGEKFATLAKLVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGK 
EAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYD 
VGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETT 
DKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEP 
VSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEV 
ERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHF 
RTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIR 
EKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGH 
EYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR 
His-TanSH2-Shp2 
MHHHHHHSSGVDLGTENLYFQSM R R W F H P N I T G V E A E N L L L T R G V 
D G S F L A R P S K S N P G D F T L S V R R N G A V T H I K I Q N T 
G D Y Y D L Y G G E K F A T L A E L V Q Y Y M E H H G Q L K E K N G 
D V I E L K Y P L N C A D P T S E R W F H G H L S G K E A E K L L T 
E K G K H G S F L V R E S Q S H P G D F V L S V R T G D D K G E S N 
D G K S K V T H V M I R C Q E L K Y D V G G G E R F D S L T D L V E 
H Y K K N P M V E T L G T V L Q L K Q P L 
 
ΔHis-TanSH2-Shp2 
SM R R W F H P N I T G V E A E N L L L T R G V D G S F L A R P S K S 
N P G D F T L S V R R N G A V T H I K I Q N T G D Y Y D L Y G G E K 
F A T L A E L V Q Y Y M E H H G Q L K E K N G D V I E L K Y P L N C 
A D P T S E R W F H G H L S G K E A E K L L T E K G K H G S F L V R 
E S Q S H P G D F V L S V R T G D D K G E S N D G K S K V T H V M I 
R C Q E L K Y D V G G G E R F D S L T D L V E H Y K K N P M V E T L 
G T V L Q L K Q P L 
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nSH2-Shp2 
GSGRAMTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTG 
DYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCLINEF 
 
cSH2-Shp2 
GSGRAMPLNCADPTSERWFHGHLSGK 
EAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYD 
VGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINLINEF 
 
Legend: 
Red single amino acid: E76K mutation in E76K FL-Shp2 
Red in ΔHis and His-TanSH2-Shp2 indicates nSH2 domain 
Orange in ΔHis and His-TanSH2-Shp2 indicates cSH2 domain 
Purple within nSH2 and cSH2-Shp2 represent terminal non-WT sequences. 
Underlined sequences represent N-terminal His-tag and TEV cleavage site (if “SM”, 
remaining TEV site residues post-cleavage. 
NB: A similar colour coding system is used in appendix figure 4. 
 
 
2. Full length G6B-b Amino acid Sequence 
>sp|O95866|G6B_HUMAN Protein G6b OS=Homo sapiens GN=G6B PE=1 SV=1 
MAVFLQLLPLLLSRAQGNPGASLDGRPGDRVNLSCGGVSHPIRWVWAPSFPACKGLSKGR 
RPILWASSSGTPTVPPLQPFVGRLRSLDSGIRRLELLLSAGDSGTFFCKGRHEDESRTVL 
HVLGDRTYCKAPGPTHGSVYPQLLIPLLGAGLVLGLGALGLVWWLHRRLPPQPIRPLPRF 
APLVKTEPQRPVKEEEPKIPGDLDQEPSLLYADLDHLALSRPRRLSTADPADASTIYAVV 
V 
 
dITIM sequence used in study is indicated in red. 
 
 
 
3. Chapter VI: Secondary Structure Prediction of G6b-B dITIM. 
Jpred was used to predict the presence of helical and sheet character within human G6b-B 
unphosphorylated dITIM. B= beta sheet, conf= confidence score (0-9). Yellow arrows 
indicate beta sheet location in relation to sequence.  
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4. Summary of Constructs used in study: 
 
 
 
 
 
 
Appendix Figure 4: Summary of Constructs used in study: 
Full-length Shp2 is drawn at the top for reference (Shp2). All schematic drawings below 
dashed line are constructs used in this study, with names to the left of them. Black lines 
represent wild-type linkers between domains or unstructured elements. Orange lines 
represent His-tags left on after purification, while purple lines represent non-wild type 
residues either side of individual SH2 constructs nSH2 and cSH2-Shp2. Red box: nSH2 
domain, Yellow box: cSH2 domain, Blue box: PTP domain. Numbers represent amino 
acid number; those in italics represent wild-type residue numbers, the rest are non-wild-
type as part of a stability sequence or hangover post-cleavage. 
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5. Mass Spectrometry of Selected Constructs: 
 
Appendix Figure 5: MALDI-TOF MS 
of TanSH2, WT FL and E76K FL-Shp2 
i. His-TanSH2-Shp2: Expected size is 
26.2 kDa 
ii. WT FL-Shp2: Expected size is 70.5 
kDa. 
iii. E76K FL-Shp2: Expected size: 
70.5 kDa. 
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Appendix Figure 6: Chapter V WT FL-Shp2 SAXS Curves 
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Appendix Figure 7: Chapter V; E76K FL-Shp2 SAXS Data 
Appendix Figure 6: Chapter V; WT FL-Shp2 SAXS Data 
Shp2wt_139, 141 and 143 are 10, 5 and 1 mg/ml respectively. 
(A) Unscaled 
(B) Scaled 
Manipulations were done in Primus Qt. 
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Appendix Figure 7: Chapter V; E76K FL-Shp2 SAXS Data 
Shp2e76k_146, 148 and 150 are 10, 5 and 1 mg/ml respectively. 
(A) Unscaled 
(B) Scaled 
Manipulations were done in Primus Qt 
332 
 
Appendix figure 8: Chapter VI; Sequential backbone assignment of 
nSH2:ITIM1s: Inset figure. 
 
9. Chapter VI SAXS invariant parameters for unbound and dITIM-bound TanSH2 
Shp2. 
 
 
 
State 
Conc 
(mg/ml) 
Avg Rg 
nm) Avg I(0) 
Dmax 
(nm) 
Unbound 9.26 2.25 1213.43 7.23 
Unbound 4.63 2.33 1000.16 8.08 
Unbound 2.32 2.43 1158.43 7.86 
Bound 9.26 2.54 1324.36 8.38 
Bound 4.63 2.39 1318.95 7.37 
Bound 2.32 2.57 1322.50 7.68 
      
 
10. Chemical Shift Lists of Assigned Proteins 
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nSH2-Shp2 Apo 
!                   H      N      C     CA     CB 
     -2    Gly      -      -      -  45.46      - 
     -1    Arg   8.28 120.98 176.19  56.21  30.93 
      0    Ala   8.38 124.76 177.83  52.74  19.25 
      1    Met   8.36 119.20 176.33  55.82  32.49 
      2    Thr   7.85 112.45 173.86  61.67  69.82 
      5    Arg      -      - 175.10  58.07  30.07 
      5    Arg      -      -      -      -      - 
      6    Trp   6.31 109.50 175.00  54.76  30.02 
      7    Phe   7.77 123.86 173.49  57.30  39.73 
      8    His   8.63 129.37 173.09  52.35  33.81 
      9    Pro      -      - 178.09  63.49  32.86 
     10    Asn      -      -      -      -      - 
     10    Asn   8.34 113.31 174.77  54.02  39.32 
     11    Ile   6.83 113.21 175.50  60.55  41.48 
     12    Thr   8.42 112.90 175.87  60.15  71.99 
     13    Gly   9.65 110.08 176.01  47.80      - 
     14    Val   7.78 120.30 178.81  65.74  32.00 
     15    Glu   7.40 121.02 179.56  59.17  30.01 
     16    Ala   8.72 121.57 178.83  55.17  18.89 
     17    Glu   8.35 116.93 177.18  60.20  28.75 
     18    Asn   7.77 116.09 178.74  56.99  38.72 
     18    Asn      -      -      -      -      - 
     19    Leu   8.51 121.78 179.03  58.42  42.67 
     20    Leu   8.28 118.62 179.37  58.05  42.47 
     21    Leu   8.32 116.89 177.79  56.76  41.38 
     22    Thr   7.74 109.22 176.16  63.56  70.59 
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     23    Arg   8.42 119.28 176.57  55.72  31.95 
     24    Gly   6.99 106.72 170.99  43.87      - 
     25    Val   8.94 109.67 176.24  59.12  36.12 
     26    Asp   8.93 122.90 177.00  57.84  38.99 
     27    Gly   8.66 112.92 175.91  44.84      - 
     28    Ser   9.31 122.26 172.80  60.62  64.39 
     29    Phe   8.00 116.31 170.52  55.74  44.37 
     30    Leu   9.23 115.07 174.49  54.24  45.00 
     31    Ala   9.65 121.82 174.27  50.06  23.51 
     32    Arg   9.00 116.80 172.38  53.89  30.19 
     33    Pro      -      - 176.55  63.11  32.28 
     34    Ser   7.76 116.97      -  57.19  63.98 
     35    Lys      -      - 178.36  56.51  32.42 
     36    Ser   8.75 115.43 175.06  60.61  63.16 
     37    Asn      -      -      -      -      - 
     37    Asn   7.81 121.06 170.55  50.83  39.63 
     38    Pro      -      - 177.42  64.37  31.63 
     39    Gly   8.81 114.98 173.87  45.39      - 
     40    Asp   7.99 119.51 176.62  53.63  41.97 
     41    Phe   8.91 116.99 173.90  57.18  44.37 
     42    Thr   9.59 117.79 172.92  62.35  72.41 
     43    Leu   9.50 127.76 175.45  53.39  44.69 
     44    Ser   9.28 123.78 172.46  58.90  64.75 
     45    Val   8.94 123.42 173.89  60.12  35.75 
     46    Arg   9.11 126.97 175.41  54.54  32.11 
     47    Arg   9.44 130.91 174.83  55.58  32.33 
     48    Asn      -      -      -      -      - 
     48    Asn   9.29 125.25 175.43  54.41  37.52 
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     49    Gly   9.61 105.94 172.20  46.03      - 
     50    Ala   7.96 122.59 175.05  50.45  22.26 
     51    Val   8.68 119.94 174.76  61.13  34.11 
     52    Thr   8.86 124.26 171.07  60.08  71.27 
     53    His   8.41 125.29 175.37  54.77  32.44 
     54    Ile   9.80 127.56 174.90  60.43  40.72 
     55    Lys   8.58 128.16 175.39  57.97  33.17 
     56    Ile   8.76 122.96 175.44  60.22  39.84 
     57    Gln   8.75 128.49 174.73  55.62  29.02 
     58    Asn   8.53 122.87 176.04  51.04  40.12 
     58    Asn      -      -      -      -      - 
     59    Thr   8.18 116.01 175.08  61.38  69.83 
     60    Gly   8.17 113.63 173.82  46.00      - 
     61    Asp   7.68 118.31 174.70  54.69  42.37 
     62    Tyr   7.20 114.25 172.80  56.70  40.72 
     63    Tyr   9.58 118.51 175.51  56.42  41.78 
     64    Asp   9.05 120.69 174.44  53.66  43.65 
     65    Leu   8.07 118.65 178.26  53.40  41.03 
     66    Tyr   8.59 118.95 176.00  60.37  35.30 
     67    Gly   7.51 107.13 174.43  44.64      - 
     68    Gly   8.36 107.59 174.05  44.84      - 
     69    Glu   8.22 122.15 174.09  56.73  30.08 
     70    Lys   7.69 118.52 176.40  54.91  34.89 
     71    Phe   9.13 118.11 175.95  57.15  44.09 
     72    Ala   9.41 123.36 177.97  54.46  19.95 
     73    Thr   7.17 101.40 173.77  58.82  73.71 
     74    Leu   7.89 122.09 178.10  56.96  41.07 
     75    Ala   8.21 118.64 179.65  55.49  18.03 
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     76    Glu   7.80 117.05 177.82  59.41  31.00 
     77    Leu   6.91 122.53 177.26  58.70  41.82 
     78    Val   7.90 118.76 177.18  67.38  31.66 
     79    Gln   7.98 117.23 177.72  59.05  28.06 
     79    Gln      -      -      -      -      - 
     80    Tyr   7.82 118.31 179.63  62.23  38.91 
     81    Tyr   7.74 117.20 177.70  62.82  38.06 
     82    Met   8.27 119.89 177.45  59.35  34.00 
     83    Glu   7.40 114.85 175.99  56.78  30.57 
     84    His   7.40 118.20 173.84  54.94  27.00 
     86    Gly      -      - 174.16  45.32      - 
     87    Gln   7.94 115.96 175.39  56.24  29.65 
     87    Gln      - 113.01      -      -      - 
     88    Leu   8.49 124.23 174.34  54.69  41.59 
     89    Lys   8.06 123.74 176.91  54.34  36.88 
     90    Glu   8.73 119.85 178.56  55.45  31.41 
     91    Lys   9.01 122.96 177.28  59.32  31.99 
     92    Asn      -      -      -      -      - 
     92    Asn   7.99 114.95 176.27  52.93  37.58 
     93    Gly   8.11 108.66 173.91  44.94      - 
     94    Asp   8.07 121.99 175.74  54.88  40.51 
     95    Val   8.31 121.78 175.99  63.18  32.90 
     96    Ile   8.49 127.61 173.98  59.71  39.15 
     97    Glu   8.16 124.22 175.33  55.10  31.82 
     98    Leu   8.64 124.88 174.72  53.00  39.85 
     99    Lys   8.06 120.68 176.37  58.51  34.82 
    100    Tyr   7.80 116.33 172.37  52.89  40.66 
    101    Pro      -      - 176.26  62.68  32.14 
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    102    Leu   8.71 128.49 175.57  54.43  41.86 
    103    Asn   8.56 125.62 175.03  53.51  38.98 
    103    Asn      -      -      -      -      - 
    104    Cys   8.63 121.89 174.74  59.18  27.21 
    105    Leu   8.70 128.05 176.89  55.12  42.01 
    106    Ile   7.83 120.57 175.47  61.14  38.80 
    107    Asn   8.42 122.17 174.55  53.21  39.25 
    107    Asn      -      -      -      -      - 
    108    Glu   8.15 121.24 174.80  56.67  30.63 
    109    Phe   7.66 124.98 180.18  58.98  40.54 
 
cSH2-Shp2 Apo 
!                   H      N      C     CA     CB 
     97    Gly      -      - 173.83  45.27      - 
     98    Arg   8.19 120.83 175.84  55.85  31.10 
     99    Ala   8.41 125.99 177.28  52.37  19.14 
    100    Met   8.29 121.11 174.21  53.07  32.51 
    101    Pro      -      - 176.66  63.06  32.06 
    102    Leu   8.34 122.08 177.21  55.44  42.48 
    103    Asn   8.46 118.69 174.97  53.24      - 
    104    Cys   8.26 119.46 173.96  58.64  28.15 
    105    Ala   8.37 125.93 176.99  52.38  19.24 
    106    Asp   8.19 121.17 175.39  52.01  41.21 
    107    Pro      -      - 176.37  63.93  31.49 
    108    Thr   7.57 110.19 173.96  62.55  68.68 
    109    Ser   7.92 116.97 174.53  58.47  63.74 
    110    Glu   7.67 121.91 178.06  55.48  28.08 
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    111    Arg   8.81 120.20 174.94  57.53  29.70 
    112    Trp   6.31 109.68 176.00  54.34  29.51 
    113    Phe   7.68 123.83 175.00  57.65  39.23 
    114    His   9.15 125.85 175.20  56.49  33.76 
    115    Gly      -      - 173.75  47.64      - 
    116    His   8.77 126.82 173.01  56.46  28.12 
    117    Leu   7.78 129.85 174.89  54.68  45.15 
    118    Ser   8.85 123.05 175.47  57.45  65.63 
    119    Gly   9.87 111.52 176.46  47.76      - 
    120    Lys   8.20 120.61 180.06  58.91  32.23 
    121    Glu   7.81 120.64 179.56  59.09  29.68 
    122    Ala   8.80 122.32 178.97  55.20  18.39 
    123    Glu   8.60 116.84 178.81  60.04  28.74 
    124    Lys   7.80 122.65 178.07  60.03  32.46 
    125    Leu   7.95 118.98 179.52  58.20  43.02 
    126    Leu   8.40 116.44 179.61  57.84  42.62 
    127    Thr   8.17 115.21 175.12  66.32  68.78 
    128    Glu   8.25 119.31 178.64  58.99  30.58 
    129    Lys   8.28 113.63 177.17  55.45  34.30 
    130    Gly   7.15 106.70 170.97  43.92      - 
    131    Lys   8.48 116.05 175.34  54.01  35.61 
    132    His   9.03 121.19 177.79  60.55  30.64 
    133    Gly   8.65 116.16 175.35  45.18      - 
    134    Ser   8.75 120.67 172.95  60.27  63.28 
    135    Phe   7.53 116.46 171.08  55.05  44.47 
    136    Leu   9.04 115.23 174.47  54.11  44.83 
    137    Val   9.35 120.05 173.00  60.66  34.52 
    138    Arg   9.45 123.85 174.41  53.06  34.17 
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    139    Glu   8.67 120.73 176.35  56.97  30.70 
    140    Ser   7.88 115.41 176.51  57.53  63.45 
    141    Gln      -      -      -  57.24  28.30 
    141    Gln      -      -      -      -      - 
    142    Ser   9.05 116.33 175.01  60.40  63.36 
    143    His   8.21 123.26 170.22  53.16  28.79 
    144    Pro      -      - 177.91  64.25  31.45 
    145    Gly   8.98 115.88 173.09  45.22      - 
    146    Asp   7.96 119.17 176.10  53.44  42.05 
    147    Phe   9.14 117.62 173.28  57.02  43.61 
    148    Val   9.54 119.37 174.25  61.37  36.12 
    149    Leu   9.40 129.85 174.85  53.28  44.32 
    150    Ser   9.13 125.76 172.94  59.07  64.59 
    151    Val   8.82 122.82 174.82  59.80  36.01 
    152    Arg   9.04 128.55 175.07  55.05  31.54 
    153    Thr   8.80 122.08 174.64  60.96  70.29 
    154    Gly   9.74 112.72 173.07  45.02      - 
    155    Asp   8.39 120.65 176.11  54.00  42.26 
    156    Asp   8.54 120.60 176.46  54.91  41.07 
    157    Lys   8.34 120.30 177.10  56.30  32.66 
    158    Gly   8.27 109.26 174.33  45.53      - 
    159    Glu   8.46 120.57 176.81  56.79  30.21 
    160    Ser   8.38 115.75 174.68  58.34  63.85 
    161    Asn      -      -      -      -      - 
    161    Asn      -      -      -  53.57  38.72 
    162    Asp   8.24 119.24 176.81  54.42  40.99 
    163    Gly   8.28 108.59 174.26  45.65      - 
    164    Lys   7.98 120.39 176.61  56.04  33.20 
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    165    Ser   8.30 117.04 174.16  58.32  64.07 
    166    Lys   8.65 123.00 174.98  56.08  34.29 
    167    Val   8.13 121.45 174.33  60.54  34.75 
    168    Thr   8.80 124.49 171.64  61.54  70.68 
    169    His   8.74 126.37 174.77  54.79  31.61 
    170    Val   9.57 127.70 174.88  61.67  33.60 
    171    Met   8.72 127.22 175.43  56.06  31.54 
    172    Ile   9.03 125.63 175.52  59.90  39.59 
    173    Arg   8.79 128.00 175.55  55.48  31.56 
    174    Cys   8.82 125.13 174.56  57.10  28.15 
    175    Gln   8.66 127.79 175.05  55.01  31.50 
    175    Gln      -      -      -      -      - 
    176    Glu   9.34 125.20 174.93  57.36  27.54 
    177    Leu   8.35 109.06 175.25  56.60  39.38 
    178    Lys   7.53 117.91 175.92  53.93  36.16 
    179    Tyr   9.31 120.09 175.84  56.96  41.88 
    180    Asp   9.16 119.52 174.02  54.26  45.75 
    181    Val   8.78 114.09 177.25  60.30  31.81 
    182    Gly   9.40 113.08 174.90  45.76      - 
    183    Gly   8.20 107.88 174.39  44.91      - 
    184    Gly   8.43 108.33 173.69  45.15      - 
    185    Glu   7.99 120.73 174.28  56.43  30.28 
    186    Arg   7.88 119.64 176.01  54.37  32.86 
    187    Phe   9.42 119.88 176.18  57.57  43.69 
    188    Asp  10.00 120.72 175.29  56.08  41.75 
    189    Ser   7.57 108.60 173.86  56.42  66.55 
    190    Leu   8.73 122.12 178.20  57.11  42.15 
    191    Thr   7.94 114.76 175.29  68.73  67.16 
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    192    Asp   7.77 121.04 177.93  57.28  40.61 
    193    Leu   6.96 122.53 177.22  58.95  42.14 
    194    Val   7.98 120.13 177.23  67.20  31.47 
    195    Glu   8.26 115.82 179.69  58.99  29.05 
    196    His   7.71 118.68 178.81  60.80  31.11 
    197    Tyr   7.71 117.28 176.47  61.20  36.90 
    198    Lys   7.79 119.42 178.23  58.94  33.09 
    199    Lys   6.94 116.13 175.42  56.68  34.26 
    200    Asn      -      -      -      -      - 
    200    Asn   7.61 118.22 170.78  50.57  40.66 
    201    Pro      -      - 176.62  63.01  32.48 
    202    Met   8.67 121.36 174.67  55.29  34.91 
    202    Met      -      - 174.65      -      - 
    203    Val   8.24 123.08 176.46  61.98  32.61 
    204    Glu   8.69 126.17 177.38  56.66  30.62 
    205    Thr   8.29 115.72 175.09  64.48  69.46 
    206    Leu   8.30 120.32 178.05  55.83      - 
    207    Gly   8.26 107.83 174.30  45.52      - 
    208    Thr   7.79 115.19 172.88  62.00  69.86 
    209    Val   8.36 122.99 175.66  61.76  33.09 
    210    Leu   8.88 128.34 174.48  53.75  43.39 
    211    Gln   7.92 122.37 174.26  54.71  30.91 
    212    Leu   8.48 124.44 176.65  54.58  40.44 
    213    Lys   9.12 122.16 175.88  57.11  33.21 
    214    Gln   7.52 115.62 171.84  53.40  29.09 
    214    Gln      -      -      -      -      - 
    215    Pro      -      - 176.56  61.62  32.89 
    216    Leu   8.59 125.72 175.47  53.87  41.68 
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    217    Asn      -      -      -      -      - 
    217    Asn   8.53 125.09 176.90  52.92  39.52 
    218    Thr   8.51 114.19 174.35  61.27  69.55 
    219    Thr   8.25 115.62 174.54  61.74  69.50 
    220    Arg   8.23 124.11 175.76  56.12  30.88 
    221    Ile   8.17 122.09 175.54  61.05  38.94 
    222    Asn   8.47 122.68 174.65  53.11  38.91 
    223    Leu      -      -      -      -      - 
    223    Leu   8.24 123.09 176.99  55.21  42.35 
    224    Ile   8.05 120.85 175.68  61.13  38.69 
    225    Asn      -      -      -      -      - 
    225    Asn   8.37 122.10 174.54  53.17  39.20 
    226    Glu   8.19 121.59 174.91  56.61  30.61 
    227    Phe   7.68 125.09 180.26  58.93  40.34 
nSH2-Shp2:ITIM1s 
!                   H      N      C     CA     CB 
     -2    Gly      -      - 174.30  45.49      - 
     -1    Arg   8.28 120.98      -  56.23  30.88 
     -1    Arg      -      - 176.20      -      - 
      0    Ala   8.38 124.79 177.85  52.77  19.27 
      1    Met   8.36 119.23 179.40  55.85  32.56 
      2    Thr   7.87 112.78 175.74  61.79  69.53 
      4    Arg      -      -      -  55.55  31.36 
      5    Arg   8.34 119.16      -  58.07  29.97 
      5    Arg      -      - 175.01      -      - 
      6    Trp  10.62      -      -      -      - 
      6    Trp   6.32 109.75 175.20  54.69  29.70 
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      7    Phe   7.76 123.84 173.35  57.14  39.69 
      8    His   8.66 129.61 173.09  52.32  33.54 
      9    Pro      -      - 178.00  63.41  32.79 
     10    Asn      -      -      -      -      - 
     10    Asn   8.40 113.14 174.66  53.78  39.33 
     11    Ile   6.78 113.18 175.46  60.37  41.52 
     12    Thr   8.39 112.81 175.84  60.25  71.51 
     13    Gly   9.49 109.70 175.60  47.84      - 
     14    Val   7.93 120.60 178.74  66.18  32.06 
     15    Glu   7.49 120.82 179.60  59.19  29.98 
     16    Ala   8.63 121.19 178.82  55.13  19.13 
     17    Glu   8.20 116.69 177.24  60.93  28.39 
     18    Asn   7.66 116.07 178.65  56.99  38.82 
     18    Asn      -      -      -      -      - 
     19    Leu   8.48 121.75 179.01  58.38  42.68 
     20    Leu   8.28 118.66 179.45  58.10  42.59 
     21    Leu   8.34 116.98 177.81  56.81  41.28 
     22    Thr   7.72 109.24 176.24  63.60  70.45 
     23    Arg   8.43 119.15 176.57  55.71  32.04 
     24    Gly   7.02 106.79 171.08  43.89      - 
     25    Val   8.93 109.81 176.27  59.10  36.05 
     26    Asp   8.95 123.07 176.99  57.83  38.95 
     27    Gly   8.66 113.03 175.95  44.84      - 
     28    Ser   9.36 122.48 172.78  60.70  64.35 
     29    Phe   8.08 116.55 170.54  55.73  44.42 
     30    Leu   9.18 115.08 174.56  54.15  45.05 
     31    Ala   9.65 121.99 174.31  50.07  23.71 
     32    Arg   9.19 117.41      -  54.11  30.18 
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     33    Pro      -      -      -  63.30  32.66 
     34    Ser      -      -      -      -  63.97 
     34    Ser   7.84 117.52      -  57.82      - 
     36    Ser   8.45 114.77      -      -      - 
     36    Ser      -      - 175.25  60.67  62.61 
     37    Asn      -      -      -      -      - 
     37    Asn   7.94 121.47 170.67  50.72  39.55 
     38    Pro      -      - 177.54  64.34  31.59 
     39    Gly   8.87 115.18 174.06  45.40      - 
     40    Asp   8.07 119.84 176.61  53.56  42.04 
     41    Phe   8.91 117.50 173.37  57.14  44.25 
     42    Thr   9.59 117.72 173.92  62.12  73.15 
     43    Leu      -      -      -  53.25  45.15 
     43    Leu   9.50 126.47      -      -      - 
     44    Ser   9.27 122.38      -  58.91  65.02 
     44    Ser      -      - 172.29      -      - 
     45    Val   8.93 123.83 173.81  60.19  35.74 
     46    Arg   9.17 127.29 175.40  54.82  31.81 
     47    Arg   9.45 131.28 174.86  55.32  32.52 
     48    Asn   8.38      -      -      -      - 
     48    Asn   9.30 125.49 175.43  54.41  37.49 
     49    Gly   9.57 106.06 172.08  46.06      - 
     50    Ala   7.97 122.92 174.84  50.46  22.25 
     51    Val   8.62 119.82 174.75  61.08  33.87 
     52    Thr   8.83 124.07 170.99  60.34  70.75 
     53    His   8.28 125.53 174.43  54.54  31.86 
     54    Ile      -      - 175.27  60.28  42.13 
     54    Ile   9.77 124.84      -      -      - 
345 
 
     55    Lys   8.77 127.96 175.67  58.49  33.85 
     55    Lys      -      -      -      -      - 
     56    Ile      -      -      -  60.22      - 
     56    Ile   8.83 122.49      -      -  39.59 
     57    Gln   8.73 129.17 174.54  55.70  28.46 
     58    Asn      -      - 176.17      -      - 
     58    Asn   8.46 122.98      -  50.72  40.19 
     59    Thr   8.08 114.96      -  61.45  69.74 
     59    Thr      -      - 175.22      -      - 
     60    Gly   8.11 113.34 173.80  45.87      - 
     61    Asp   7.57 117.92 174.86  54.68  42.63 
     62    Tyr   7.18 114.19 172.53  56.74  40.34 
     63    Tyr   9.62 118.38 175.70  56.26  41.90 
     64    Asp   9.08 120.88 174.61  53.70  43.16 
     67    Gly      -      - 174.19  44.31      - 
     68    Gly      -      - 174.29  44.89      - 
     68    Gly   8.43 107.17      -      -      - 
     69    Glu   8.16 122.08 174.03  56.52  30.15 
     70    Lys   7.67 118.60 176.36  54.90  35.17 
     71    Phe   9.13 117.92 175.87  57.13  44.31 
     72    Ala   9.40 123.29 178.16  54.51  20.02 
     73    Thr      -      - 173.66  58.84  73.49 
     73    Thr   7.17 101.60      -      -      - 
     74    Leu   7.89 122.23 178.18  56.99  41.23 
     75    Ala   8.24 118.70      -  55.50  18.14 
     76    Glu   7.77 117.04 177.84  59.41  31.09 
     77    Leu   6.91 122.60 177.30  58.63  41.80 
     78    Val   7.88 118.76 177.17  67.36  31.63 
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     79    Gln   7.99 117.32 177.72  59.09  28.16 
     80    Tyr   7.80 118.31 179.63  62.18  38.99 
     81    Tyr   7.74 117.28 177.74  62.91  37.99 
     82    Met   8.26 119.96 177.48  59.20  34.11 
     83    Glu   7.42 114.93 176.06  56.87  30.62 
     84    His   7.42 118.12 173.92  54.94  27.03 
     86    Gly      -      - 174.26  45.50      - 
     87    Gln   7.94 116.17 175.29  56.32  29.71 
     88    Leu      -      -      -      -  41.66 
     88    Leu   8.38 123.58 173.96  54.35      - 
     89    Lys   8.30 123.94 175.24  54.61      - 
     89    Lys      -      -      -      -  36.14 
     90    Glu      -      - 178.51  56.75      - 
     91    Lys   8.85 123.25      -      -      - 
     91    Lys      -      -      -  59.73  32.26 
     92    Asn      -      -      -      -      - 
     92    Asn   8.09 115.24 176.15  53.20  37.55 
     93    Gly   8.11 108.76 174.02  44.93      - 
     94    Asp   8.17 122.26 175.65  54.90  40.83 
     95    Val   8.31 121.08 176.27  62.11  33.66 
     96    Ile   8.43 127.48 173.90  60.80  39.03 
     97    Glu   8.35 124.75      -  55.01  32.00 
     97    Glu      -      - 175.21      -      - 
     98    Leu   8.67 125.14 174.67  53.30  40.00 
     99    Lys   8.05 120.26 176.33  58.47  34.63 
    100    Tyr   7.79 116.54 172.34      -      - 
    100    Tyr      -      -      -  52.72  40.66 
    101    Pro      -      - 176.29  62.64  32.15 
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    102    Leu   8.74 128.54 175.66  54.41  41.97 
    103    Asn   8.57 125.69 175.20  53.51  38.95 
    104    Cys   8.63 121.81 174.63  59.15  27.32 
    105    Leu   8.67 127.92 176.91  55.16  42.02 
    106    Ile   7.85 120.65 175.49  61.15  38.85 
    107    Asn   8.42 122.17 174.55  53.24  39.21 
    107    Asn      -      -      -      -      - 
    108    Glu   8.15 121.31 174.82  56.67  30.69 
    109    Phe   7.66 125.02 180.20  58.93  40.41 
TanSH2-Shp2 
!                   H      N      C     CA     CB 
    -11    Ser      -      -      -  58.47  63.58 
    -10    Gly   8.35 111.21      -  45.02      - 
     -9    Val   7.82 119.25      -  61.59  32.19 
     -8    Asp   8.33 124.33      -  53.79  40.66 
     -7    Leu   8.29 124.26      -  55.14  41.25 
     -6    Gly   8.47 109.49      -  45.35      - 
     -5    Thr   7.91 113.72      -  62.15  68.96 
     -4    Glu   8.47 123.13      -  57.23  29.08 
     -3    Asn   8.28 119.36      -  53.49  38.36 
     -2    Leu   8.05 122.57      -  55.98  41.08 
     -1    Tyr   8.00 119.95      -  58.72  37.77 
      0    Phe   7.91 119.89      -  58.77  38.64 
      1    Gln   8.13 119.59      -  57.15  28.14 
      2    Ser   7.91 115.00      -  58.93  63.31 
      5    Arg      -      -      -  57.43  29.14 
      6    Trp   6.42 110.81      -  54.82  29.44 
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      7    Phe   7.80 124.57      -  57.11  39.24 
      8    His   8.60 130.06      -  51.91  33.09 
      9    Pro      -      -      -  63.09  31.95 
     10    Asn   8.41 113.79      -  53.24  39.04 
     11    Ile   6.72 114.22      -  60.18  40.62 
     12    Thr   8.30 113.76      -  60.00  71.38 
     13    Gly   9.49 110.52      -  47.33      - 
     14    Val   7.76 120.89      -  65.30  30.89 
     15    Glu   7.36 121.34      -  58.67  29.23 
     16    Ala   8.64 122.08      -  54.73  18.17 
     17    Glu   8.26 117.32      -  59.78  27.98 
     18    Asn   7.71 116.54      -  56.51  38.17 
     19    Leu   8.45 122.44      -  58.00  41.72 
     20    Leu   8.23 119.09      -  57.59  41.51 
     21    Leu   8.26 117.27      -  56.45  40.36 
     22    Thr   7.68 109.81      -  63.10  69.98 
     23    Arg   8.38 119.67      -  55.31  31.00 
     24    Gly   6.95 107.08      -  43.33      - 
     25    Val   8.87 110.31      -  58.74  35.27 
     26    Asp   8.86 123.35      -  57.35  38.58 
     27    Gly   8.62 113.44      -  44.42      - 
     28    Ser   9.27 122.98      -  60.16  64.02 
     29    Phe   7.97 116.95      -  55.58  43.67 
     30    Leu   9.12 115.43      -  53.89  44.15 
     31    Ala   9.53 122.36      -  49.77  23.06 
     32    Arg   8.93 117.16      -  53.35  29.35 
     33    Pro      -      -      -  62.71  31.50 
     34    Ser   7.69 117.34      -  56.93  63.71 
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     35    Lys      -      -      -  55.93  31.18 
     36    Ser   8.74 116.18      -  60.16  62.92 
     37    Asn   7.73 121.59      -  50.39  39.16 
     38    Pro      -      -      -  64.01  30.82 
     39    Gly   8.75 115.78      -  44.93      - 
     40    Asp   7.92 119.82      -  53.21  41.42 
     41    Phe   8.81 117.39      -  56.95  43.75 
     42    Thr   9.56 118.20      -  61.79  71.61 
     43    Leu   9.43 127.74      -  53.02  43.63 
     44    Ser   9.22 124.41      -  58.59  64.35 
     45    Val   8.88 123.90      -  59.73  34.99 
     46    Arg   9.07 127.61      -  54.20  31.06 
     47    Arg   9.38 131.37      -  55.18  31.42 
     48    Asn   9.22 125.80      -  54.15  37.07 
     49    Gly   9.52 106.47      -  45.60      - 
     50    Ala   7.89 123.15      -  50.08  21.65 
     51    Val   8.60 120.36      -  60.67  33.30 
     52    Thr   8.82 124.84      -  59.81  70.67 
     53    His   8.34 125.68      -  54.41  31.82 
     54    Ile   9.72 127.13      -  60.05  39.71 
     55    Lys   8.49 128.47      -  57.43  32.35 
     56    Ile   8.74 123.37      -  59.88  39.15 
     57    Gln   8.65 128.93      -  55.14  28.23 
     58    Asn   8.42 123.29      -  50.51  39.58 
     59    Thr   8.11 116.00      -  61.08  69.31 
     60    Gly   8.03 113.83      -  45.56      - 
     61    Asp   7.55 118.45      -  54.49  41.85 
     62    Tyr   7.10 114.54      -  56.31  40.16 
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     63    Tyr   9.53 118.85      -  55.90  41.21 
     64    Asp   9.00 121.29      -  53.21  43.14 
     65    Leu   7.94 119.16      -  52.98  39.98 
     66    Tyr   8.49 119.34      -  60.10  34.68 
     67    Gly   7.37 107.33      -  44.18      - 
     68    Gly   8.32 107.79      -  44.36      - 
     69    Glu   8.18 122.73      -  56.13  29.24 
     70    Lys   7.62 119.04      -  54.52  34.09 
     71    Phe   9.07 118.45      -  56.83  43.56 
     72    Ala   9.34 123.63      -  54.11  19.39 
     73    Thr   7.09 105.75      -      -      - 
     73    Thr      -      -      -  58.51  72.94 
     74    Leu   7.87 122.54      -  56.55  40.15 
     75    Ala   8.34 118.99      -  54.89  17.53 
     76    Glu   7.69 117.32      -  58.79  30.20 
     77    Leu   6.84 122.77      -  58.29  40.76 
     78    Val   7.82 119.25      -  67.09  30.78 
     79    Gln   7.94 117.80      -  58.65  27.26 
     80    Tyr   7.72 118.84      -  61.66  38.04 
     81    Tyr   7.65 117.78      -  62.32  37.29 
     82    Met   8.22 120.52      -  58.80  33.07 
     83    Glu   7.37 115.40      -  56.36  30.00 
     84    His   7.36 118.62      -  54.43  26.27 
     86    Gly      -      -      -  44.97      - 
     87    Gln   7.85 116.49      -  55.87  28.87 
     88    Leu   8.40 124.63      -  54.27  40.82 
     89    Lys   7.99 124.20      -  54.04  36.02 
     90    Glu   8.66 120.26      -  54.97  30.58 
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     91    Lys   8.96 123.44      -  58.67  31.05 
     92    Asn   7.93 115.46      -  52.81  37.18 
     93    Gly   8.03 109.14      -  44.47      - 
     94    Asp   8.00 122.46      -  54.45  39.96 
     95    Val   8.26 122.19      -  62.80  32.12 
     96    Ile   8.42 128.11      -  59.14  38.34 
     97    Glu   8.12 124.72      -  54.58  30.97 
     98    Leu   8.55 125.26      -  52.63  39.01 
     99    Lys   8.00 121.23      -  58.06  34.02 
    100    Tyr   7.72 116.92      -  52.57  39.98 
    101    Pro      -      -      -  62.19  31.34 
    102    Leu   8.61 128.95      -  54.13  41.19 
    103    Asn   8.52 126.02      -  53.13  38.67 
    104    Cys      -      -      -  58.77  27.10 
    104    Cys   8.63 122.64      -      -      - 
    105    Ala   8.75 131.07      -  51.74  18.74 
    106    Asp   7.84 122.66      -  51.67  41.05 
    107    Pro      -      -      -  63.36  30.93 
    108    Thr   7.64 110.86      -  63.72  68.48 
    109    Ser   7.75 115.74      -  58.13  63.42 
    110    Glu   7.48 121.90      -  54.61  27.35 
    111    Arg      -      -      -  57.53  29.36 
    112    Trp   6.24 109.34      -  53.30  30.45 
    113    Phe   7.53 124.39      -  58.72  38.77 
    114    His      -      -      -  55.13  31.92 
    114    His   8.82 126.97      -      -      - 
    115    Gly   5.78 105.20      -  47.41      - 
    116    His   8.59 124.42      -  55.87  28.05 
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    117    Leu   7.57 128.36      -  54.42  43.96 
    118    Ser   8.67 122.36      -  57.06  65.40 
    119    Gly   9.75 111.82      -  47.23      - 
    120    Lys   8.15 121.13      -  58.66  31.48 
    121    Glu   7.72 121.02      -  58.59  29.02 
    122    Ala   8.71 122.60      -  54.65      - 
    122    Ala      -      -      -      -  17.87 
    123    Glu   8.49 117.21      -  59.69  28.26 
    124    Lys   7.73 123.00      -  59.51  31.71 
    125    Leu   7.96 119.66      -  57.65  41.82 
    126    Leu   8.31 116.88      -  57.39  41.67 
    127    Thr   8.10 115.75      -  65.82  68.37 
    128    Glu   8.24 119.88      -  58.66  29.78 
    129    Lys   8.19 114.15      -  55.19  33.50 
    130    Gly   7.08 107.26      -  44.03      - 
    131    Lys   8.43 116.71      -  53.58  34.54 
    132    His   8.94 121.56      -  59.99  30.08 
    133    Gly   8.59 116.54      -  44.67      - 
    134    Ser   8.67 121.30      -  60.02  62.91 
    135    Phe   7.72 117.54      -  55.02  43.83 
    136    Leu   8.95 115.25      -  53.70  44.31 
    137    Val   9.50 120.82      -  60.27  33.89 
    138    Arg   9.33 124.10      -  52.34  33.40 
    139    Glu   8.68 121.30      -  56.51  29.73 
    140    Ser   7.82 116.20      -  57.23  63.25 
    141    Gln      -      -      -  56.81  27.47 
    142    Ser   8.93 116.67      -  60.06  63.24 
    143    His   8.12 123.65      -  52.96  28.36 
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    144    Pro      -      -      -  63.86  30.67 
    145    Gly   8.92 116.21      -  44.74      - 
    146    Asp   7.90 119.58      -  53.14  41.43 
    147    Phe   9.10 117.96      -  56.90  43.36 
    148    Val   9.50 120.18      -  61.19  35.01 
    149    Leu   9.31 130.19      -  53.01  43.39 
    150    Ser   9.13 125.71      -  58.64  64.36 
    151    Val   8.76 123.04      -  59.28  35.30 
    152    Arg   8.96 129.12      -  54.48  30.79 
    153    Thr   8.75 122.33      -  60.33  70.03 
    154    Gly   9.87 113.45      -  44.55      - 
    155    Asp   8.33 121.11      -  53.68  41.84 
    156    Asp   8.48 121.12      -  54.59  40.61 
    157    Lys   8.29 120.81      -  55.94  31.89 
    158    Gly   8.21 109.76      -  45.11      - 
    159    Glu   8.40 121.12      -  56.31  29.52 
    160    Ser   8.31 116.23      -  58.07  63.74 
    161    Asn      -      -      -  53.43  38.35 
    162    Asp   8.17 119.72      -  54.23  40.51 
    163    Gly   8.20 109.10      -  45.24      - 
    164    Lys   7.92 120.92      -  55.81  32.44 
    165    Ser   8.23 117.61      -  58.02  64.01 
    166    Lys   8.61 123.46      -  55.78  33.54 
    167    Val   8.06 121.79      -  60.08  34.06 
    168    Thr   8.69 124.96      -  61.29  70.05 
    169    His   8.66 126.63      -  54.35  31.32 
    170    Val   9.62 128.01      -  61.23  33.10 
    171    Met   8.65 127.54      -  55.75  30.95 
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    172    Ile   8.96 126.08      -  59.61  38.74 
    173    Arg   8.70 128.25      -  54.96  30.69 
    174    Cys   8.74 125.46      -  56.87  28.15 
    175    Gln   8.61 128.34      -  54.65  30.74 
    176    Glu   9.27 125.65      -  57.04  26.86 
    177    Leu   8.29 109.64      -  56.01  38.59 
    178    Lys   7.49 118.69      -  53.64  35.52 
    179    Tyr   9.26 120.45      -  56.60  41.38 
    180    Asp   9.07 119.96      -  53.92  45.30 
    181    Val   8.72 114.48      -  60.01  31.09 
    182    Gly   9.30 113.39      -  45.41      - 
    183    Gly   8.10 108.44      -  44.51      - 
    184    Gly   8.37 108.80      -  44.65      - 
    185    Glu   7.92 121.23      -  55.86  29.52 
    186    Arg   7.82 120.07      -  54.07  31.87 
    187    Phe   9.35 120.31      -  57.23  43.25 
    188    Asp   9.92 121.08      -  55.79  41.23 
    189    Ser   7.49 108.89      -  56.22  66.21 
    190    Leu   8.69 122.49      -  56.78  41.25 
    191    Thr   7.98 115.38      -      -      - 
    191    Thr      -      -      -  66.35  68.14 
    192    Asp   7.69 121.40      -  57.04  40.15 
    193    Leu      -      -      -  58.58  41.24 
    193    Leu   6.89 123.04      -      -      - 
    194    Val   7.99 120.70      -  66.74  30.72 
    195    Glu      -      -      -  58.62  28.56 
    195    Glu   8.18 116.02      -      -      - 
    196    His      -      -      -  60.29  30.56 
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    196    His   7.62 119.30      -      -      - 
    197    Tyr      -      -      -  60.81  36.53 
    197    Tyr   7.69 117.81      -      -      - 
    198    Lys   7.76 119.99      -      -  32.28 
    198    Lys      -      -      -  58.60      - 
    199    Lys   6.84 116.91      -  56.22  33.51 
    200    Asn   7.57 118.65      -  50.20  40.17 
    201    Pro      -      -      -  62.75  31.68 
    202    Met   8.61 121.84      -  54.93  34.22 
    203    Val   8.18 123.39      -  61.50  31.88 
    204    Glu   8.61 126.60      -  56.07  29.93 
    205    Thr   8.21 116.27      -  64.32  68.91 
    206    Leu   8.24 120.75      -  55.52  40.22 
    207    Gly   8.19 108.22      -  45.05      - 
    208    Thr   7.75 115.88      -  61.63  69.33 
    209    Val   8.30 123.61      -  61.37  32.30 
    210    Leu   8.82 128.78      -  53.13  42.06 
    211    Gln   7.82 123.06      -  54.39  30.12 
    212    Leu   8.40 124.63      -  54.06  39.25 
    213    Lys   9.04 122.38      -  57.07  32.59 
    214    Gln   7.47 115.62      -  53.04  28.75 
    215    Pro      -      -      -  61.21  31.63 
    216    Leu   8.07 129.34      -  57.13  42.14 
 
 
 
 
